

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 Email: rickjaffeesquire@gmail.com

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14 Attorneys for the Plaintiffs

15 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
16 **FOR THE COUNTY OF ALAMEDA**

17 CINDY KIEL, J.D., an Executive Associate Vice
18 Chancellor at UC Davis, MCKENNA
19 HENDRICKS, a UC Santa Barbara student,
20 EDGAR DE GRACIA, a UCLA student, and
21 LELAND VANDERPOEL, an employee at the
22 Fresno satellite extension of the UCSF Medical
23 Education Program, and FRANCES OLSEN,
24 Professor of Law at UCLA,

25 Plaintiffs,

26 vs.

27 THE REGENTS OF THE UNIVERSITY OF
28 CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG20072843

**PETER GÖTZSCHE MD'S
DECLARATION IN SUPPORT OF
PLAINTIFFS' MOTION FOR A
PRELIMINARY INJUNCTION**

BY FAX

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID- 2206283

Action Filed: August 27, 2020

Trial Date: None Set

I Peter Götzsche, MD declare as follows:

1
**PETER GÖTZSCHE MD'S DECLARATION IN SUPPORT OF PLAINTIFFS' MOTION
FOR A PRELIMINARY INJUNCTION**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1. I submit this declaration in support of Plaintiffs’ Motion for a preliminary injunction.
2. I am a medical doctor and I have been involved in medical research and the evaluation of medical research for 45 years (even before I became a doctor). I have personal knowledge of the information set forth herein, and if called to testify, I could competently testify as follows:
 3. In 1993, I co-founded the Cochrane Collaboration which is a collaborative effort by patients, scientists and researchers around the world to evaluate medical research to assist patients, health professionals and policy makers to make better decisions. During the twenty-five years I worked with the Cochrane Collaboration, the group has published about 10,000 systematic reviews or protocols for upcoming reviews on the benefits and harms of interventions used in healthcare.
 4. In 2018, I founded the Institute for Scientific Freedom where I continue with the same kind of work, I performed at the Cochrane Collaboration. (A copy of my CV with a list of books, book chapters and publications are attached as Exhibit “A.”)
 5. I am the author of seven books since 2007, the first of which is Rational Diagnosis and Treatment: Evidence-based Clinical Decision-making (4th ed.).
 6. One of my most recent books, published earlier this year, and the one which is most relevant to the issues in this case is titled “Vaccines: Truths, Lies and Controversy.” The book was published by People’s Press in Denmark; will be published by Skyhorse in New York later this year; and will appear in many languages. The book has a chapter on the flu vaccines, and specifically reviews the evidence of its benefits and harms. In this declaration, I will present some of the conclusions I reached in the chapter drawing in

1 particular on the results from the three reviews the Cochrane Collaboration published on
2 the flu vaccine to healthy adults in 2010, 2014 and 2018.

3 **The Efficacy and Public Benefit of the Flu Vaccine is so questionable that it Should**
4 **not be Given Routinely to Healthy Adults**

- 5 7. My general conclusion is that the recommendation in some countries that healthy adults
6 should take the seasonal flu vaccine is not supported by the medical literature, despite
7 American government agencies', e.g. CDC's, enthusiastic support for giving this vaccine
8 to healthy people. The 2010 Cochrane review, "Vaccines for preventing influenza in
9 healthy adults," was based on randomized clinical trials and comparative studies
10 assessing serious and rare harms.¹ It concluded: "The results of this review seem to
11 discourage the utilization of vaccination against influenza in healthy adults as a routine
12 public health measure." The researchers furthermore noted that, "We found no evidence
13 that vaccines prevent viral transmission or complications" and that: "Inactivated vaccines
14 caused local harms and an estimated 1.6 additional cases of Guillain-Barré Syndrome per
15 million vaccinations. The harms evidence base is limited."
16
17 8. Four years later, the Cochrane review was updated with 41 new trials.² This massive
18 addition of new data had no material influence on the results of the review and the
19 researchers' conclusion was similar to that in their 2010 review: "The results of this
20 review provide no evidence for the utilization of vaccination against influenza in healthy
21 adults as a routine public health measure."
22

23
24 ¹ Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza
25 in healthy adults. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD001269. DOI:
26 10.1002/14651858.CD001269.pub4.

27 ² Demicheli V, Jefferson T, Al-Ansary LA, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza
28 in healthy adults. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD001269. DOI:
10.1002/14651858.CD001269.pub5.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

9. In 2018, the Cochrane review was updated again and the review now included 52 randomized clinical trials and over 80,000 people:³ “Inactivated influenza vaccines probably reduce influenza in healthy adults from 2.3% without vaccination to 0.9% (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.36 to 0.47; 71,221 participants; moderate-certainty evidence).” This could be considered a worthwhile effect at the population level but hardly at the individual level, as “71 healthy adults need to be vaccinated to prevent one of them experiencing influenza.”
10. It can be debated, however, whether flu shots for healthy adults are worthwhile interventions at the population level. It was quite disappointing that vaccination did not decrease admissions to hospital (risk ratio 0.96; 95% CI 0.85 to 1.08) or days off work (difference -0.04 days; 95% CI -0.14 to 0.06).
11. The Executive Order mandating the flu vaccine is based on a belief that it will reduce hospital bed usage. That belief is simply wrong, which the Cochrane review showed.
12. The Executive Order from Janet A. Napolitano is a three-page document where she quotes the literature selectively to such an extent that I consider it scientific misconduct. According to the US Office of Research Integrity, research misconduct includes “changing or omitting data or results such that the research is not accurately represented in the research record.”⁴ This is exactly what Napolitano did in her document. Cochrane reviews are widely respected for their high standards but instead of quoting the relevant Cochrane review of the randomized trials, she quoted a number of deeply flawed case-

³ Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub6.
⁴ <https://ori.hhs.gov/definition-misconduct>.

1 control studies, even though case-control studies are known to be notoriously unreliable
2 for assessing the benefits of interventions in healthcare. I have criticized some of the
3 worst of these studies in my vaccine book, including two of the studies mentioned by
4 Napolitano, and shown why the benefit they claim for flu shots are simply impossible,
5 given other evidence. For one of the two studies,⁵ I wrote in my book that the CDC
6 claimed that, “In recent years, flu vaccines have reduced the risk of flu-associated
7 hospitalizations among adults on average by about 40%. How is this possible when the
8 randomized trials didn’t find anything? Oh well, it was a systematic review of case-
9 control studies. Forget it.” For the other study that Napolitano quotes,⁶ I wrote: “A 2018
10 study showed that from 2012 to 2015, flu vaccination among adults reduced the risk of
11 being admitted to an intensive care unit (ICU) with flu by 82 percent. Interesting game.
12 We are approaching 100% vaccine efficacy but are witnessing a scientific playroom,
13 totally detached from reality.”
14
15

16 **There is Convincing Evidence that Flu Shots Can Cause Harm**

17 13. Systematic reviews have noted serious deficiencies in the reporting of harms in published
18 influenza vaccine trials. But it is a fact that flu shots can cause serious harm. I mention in
19 my vaccine book that it has been firmly established that the influenza vaccine Pandemrix
20 can cause narcolepsy, a life-long, seriously debilitating condition with poor treatment
21
22

23 ⁵ Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza
24 illness among adults: a systematic review and meta-analysis of test-negative design case-control studies. *J Infect*
25 2017;75:381-94.

26 ⁶ Thompson MG, Pierse N, Sue Huang Q, et al. Influenza vaccine effectiveness in preventing influenza-associated
intensive care admissions and attenuating severe disease among adults in New Zealand 2012-2015. *Vaccine*
2018;36:5916-25.

1 options where people suddenly fall asleep, with an onset from about two months after
2 vaccination and up to at least two years later. The likely mechanism is an autoimmune
3 cross-reaction in people with a particular tissue type between the active component of the
4 vaccine and receptors on brain cells controlling the day rhythm. More than 1300 people
5 developed narcolepsy. I also mention that, in 2009, Australia suspended its universal
6 vaccination influenza program for children younger than five years because of a surge in
7 febrile convulsions following vaccination (1 in 110 children). Official inquiries
8 confirmed the vaccine's role, also in this case. These harms came to light because their
9 incidence was ten times the background rate. Influenza vaccines are biologics, and
10 biologic manufacturing is messy, with risks of contamination far in excess of that seen in
11 ordinary drug production.
12

13 14. I agree with the statement in the Complaint that the package insert of a popular flu
14 vaccine relates many local and systemic adverse events including serious adverse events.
15

16 15. I also agree with the concerns in the complaint about possible harmful virus interferences
17 between the flu vaccine and various viruses, including not only the novel pandemic
18 coronavirus but even the influenza virus itself. Studies by Canadian researchers indicated
19 that people who received a seasonal influenza vaccine in 2008 had an increased risk of
20 getting infected with another influenza strain in 2009.⁷ They replicated their findings in
21 five different studies and I find their methods and results convincing.
22

23 16. The most reliable studies and reviews we have suggest that administering the flu vaccine
24 to the 510,000 members of the University of California community might cause serious
25

26 ⁷ Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008–09 seasonal influenza vaccine and
27 pandemic H1N1 illness during spring–summer 2009: four observational studies from Canada. PLoS Med
28 2010;7:e1000258.

1 harm and will likely cause more harm than good. This is particularly because mandatory
2 flu shots are highly likely to increase vaccine hesitancy in general, including refusing
3 life-saving vaccines to people’s children like the MMR vaccine. I therefore consider it
4 likely that mandatory vaccination of 510,000 members of the University of California
5 community will increase deaths from infections because public distrust in the authorities
6 will be nourished by this ill-thought through and totally inappropriate use of force.

7
8 17. No one has any idea about what the results would be of increased vaccine coverage for
9 influenza on the risk of getting infected with coronavirus and dying from it, but I am not
10 optimistic that the results would be beneficial. For example, it has been thoroughly
11 documented in many carefully conducted studies that vaccination with non-live viruses
12 increases mortality from other infections (see my book; particularly Peter Aaby has made
13 groundbreaking research in this area).

14 18. My overall conclusion about Napolitano’s forced vaccination scheme is that it is deeply
15 unethical, violates basic human rights, and is based on no reliable evidence whatsoever.
16 In fact, the best evidence we have tells us that her forced vaccination scheme is highly
17 likely to be harmful.

18
19 19. I have a balanced view on vaccines, based on reliable science. This is the reason why my
20 new vaccine book, first published in February 2020, has already appeared in Danish,
21 Swedish and Dutch, three very small language areas, and will also appear in major
22 languages like Spanish, French and German. My evidence-based approach to vaccines is
23 apparent on the first page in my vaccine book: “Some vaccinations are so beneficial that
24 we should all get them while others should not be used except for special circumstances.
25 Some are so controversial that many healthcare professionals do not use them for
26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

themselves even though they are officially recommended, e.g. the influenza vaccines. We must evaluate carefully each vaccine, one by one, assessing the balance between its benefits and harms, just as we do for other drugs, and then form an opinion about whether we think the vaccine is worth getting or recommending to other people.”

20. I declare under penalty of perjury under the laws of the State of California that the foregoing is true and correct and that this declaration was executed on September 9, 2020 in Denmark.



Peter Gøtzsche

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

EXHIBIT "A"

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Curriculum vitae

for

Peter C. Gøtzsche

last update November 2019
(apart from books and a few other things)

Contents

Personal data	3
Education.....	3
Appointments	3
Pregraduate.....	3
Postgraduate, previous	3
Postgraduate, recent	4
Funding support.....	4
Awards and other academic honours	5
Some recent appearances in documentary films and satires	6
Publications	6
DrMedSci thesis	6
Academic books	6
Travel book	7
Articles in international journals with peer review	7
Articles without peer review	18
Book chapters.....	22
Correspondence, book reviews and similar.....	23
Secondary publications in Danish	34
Teaching	35
Pregraduate courses.....	35
Postgraduate courses	35
Lectures	38
Research mentorships.....	50
Scientific assignments	52
General	52
Editorial work.....	53
Chairman at congresses and meetings.....	54
Advisory Board member at international congresses.....	55
Expert witness in court cases	55
Management experience.....	55

Personal data

Peter Christian Gøtzsche, Kløvervang 39, 2970 Hørsholm, Denmark
 MD, DrMedSci, MSc (biology and chemistry), fil. mag.
 Director, Institute for Scientific Freedom, Copenhagen
 Visiting Professor, Institute of Health & Society, University of Newcastle, England

Email: pcg@scientificfreedom.dk
 Mobile: +45 53 64 20 66
 Websites: scientificfreedom.dk and deadlymedicines.dk.
 Twitter: [@PGtzsche1](https://twitter.com/PGtzsche1)

Date of birth: 26 November 1949
 Family relation: Married, 2 children
 Citizenship: Danish

Education

1968 Student exam, Næstved Gymnasium. Marks: 9.0.
 1970 First part of biology, University of Copenhagen. Marks: ug-.
 1970-73 Studies at the universities of Uppsala and Lund.
 1973 MSc in biology and chemistry, University of Lund.
 1974 MSc in biology and chemistry, University of Copenhagen.
 Special subject in entomology. Marks: 10.
 1984 MD, University of Copenhagen. Marks: 10.0.
 1987 Diploma Course in Tropical Medicine, Copenhagen (2 months; passed).
 1990 Thesis, University of Copenhagen.
 1995 Specialist in internal medicine.

Appointments

Pregraduate

01.04.75 - 31.03.77 Drug representative and product manager, Astra Group A/S.
 01.04.77 - 31.08.83 Chief of medical department, Astra-Syntex A/S.

Postgraduate, previous

		months
01.06.84 - 30.09.84	Registrar, Bispebjerg Hospital, Med Dept C	4
01.10.84 - 31.12.85	Registrar, Herlev Hospital, Surgical Dept	12
01.06.85 - 31.08.85	Registrar, Herlev Hospital, Med Dept F	3
01.01.86 - 31.08.86	Registrar, Rigshospitalet, Dept of Infect Dis	8
01.09.86 - 30.09.87	Registrar, Hvidovre Hospital, Dept of Hepatology	13
01.09.87 - 31.05.95	Chief, Nordic coordination office for AIDS trials, Rigshospitalet	93
01.09.88 - 31.01.90	Junior Lecturer, Theory of Medicine, University of Copenhagen	17
01.02.89 - 28.02.90	Registrar, Herlev Hospital, Med Dept C	11
01.03.90 - 28.02.91	Registrar, Rigshospitalet, Med Dept A	12
01.03.91 - 31.08.91	Registrar, Rigshospitalet, Med Dept L	6
01.09.91 - 29.02.92	Registrar, Rigshospitalet, Dept of Infect Dis	6
01.03.92 - 30.06.93	Senior registrar, Hvidovre Hospital, Dept of Rheumatology	16
01.09.92 - 30.06.93	Lecturer, internal medicine, Hvidovre Hospital	10
01.07.93 - 31.08.95	Senior registrar, Rigshospitalet, Dept of Infect Dis	12
01.10.93 - 31.05.97	Senior House Medical Officer, Rigshospitalet	45
01.03.92 - 31.12.98	Editor, Bibliotek for Læger	82
01.02.90 - 31.03.10	Lecturer, Theory of Medicine, University of Copenhagen	242

Postgraduate, recent

01.10.93 - 30.04.19 Director, The Nordic Cochrane Centre
 01.06.97 - 30.04.19 Chief physician, Rigshospitalet
 01.04.10 - 30.04.19 Professor, Clinical Research Design and Analysis, University of Copenhagen

Funding support

1987 Danish Medical Research Council
 1988 Danish Medical Research Council
 1989 Danish Medical Research Council
 1990 Danish Medical Research Council
 1990 Danish Arthritis Foundation
 1992 Medical Society in Copenhagen
 1992 Fund for progress in Medical Science
 1992 Danish Arthritis Foundation
 1992 Fonden til Lægevidenskabens Fremme
 1992 Todelegatet
 1993 Rigshospitalet
 1993 Research Foundation for Greater Copenhagen, Faroe Islands and Greenland.
 1993 Ministry of Health
 1994 Rigshospitalet
 1994 European Union, BIOMED I
 1995 European Union, BIOMED II
 1995 Nordic Council of Ministers
 1995 Rigshospitalet
 1995 Copenhagen Hospital Foundation
 1996 Danish Medical Research Council
 1996 Nordic Council of Ministers
 1996 Apothecary Foundation
 1997 Fonden ”En god start i livet”
 1997 Nordic Council of Ministers
 1997 Sygekassernes Helsefond
 1997 Research Fund, Leo Pharmaceuticals
 1998 State Institute for Medical Health Technology Assessment
 1998 European Union, BIOMED 2
 1998 Nordic Council of Ministers
 1998 Danish Medical Research Council
 1999 Nordic Council of Ministers
 1999 Danish Ministry of Health
 2000 Nordic Council of Ministers
 2000 Ministry of Health
 2000 Mindelegat (Mrs. Kay Lynæs)
 2001 Nordic Council of Ministers
 2001 Mindelegat (Mrs. Kay Lynæs)
 2002 Mindelegat (Mrs. Kay Lynæs)
 2002 Nordic Council of Ministers
 2003 Danish Medical Research Council
 2003 Danish Ministry of Health
 2003 Rigshospitalet
 2003 Nordic Council of Ministers
 2004 Nordic Council of Ministers
 2005 Nordic Council of Ministers
 2006 Nordic Council of Ministers
 2006 IMK Charitable Fund
 2007 Danish Medical Research Council
 2007 The Cancer Foundation

2008	Nordic Council of Ministers
2008	Sygekassernes Helsefond
2008	Rigshospitalet
2008	Danish Medical Research Council
2009	Rigshospitalet
2009	Capital Region of Denmark
2009	Agnes and Poul Friis' Foundation
2010	Augustinus Foundation
2010	Oticon Foundation
2010	Rigshospitalet
2010	Lundbeck Foundation
2010	Kontorchef Gerhard Brønsted's Travel Grant
2010	Tryg Foundation
2010	University of Copenhagen
2010	Sygekassernes Helsefond
2010	Julie von Müllen's Foundation
2010	The Free Research Councils
2011	The Cochrane Collaboration
2011	Rigshospitalet
2012	Rigshospitalet
2012	Tryg Foundation
2012	Sygekassernes Helsefond
2012	The Cochrane Collaboration
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2014	Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2015	University of Copenhagen, PhD stipend

Awards and other academic honours

1992	Farmer from Stenløse, Peder Laurids Pedersen's donation.
1993	Co-founder of the Cochrane Collaboration
1997	Award of the year from the foundation "A good start in life".
1999	Henrik R. Wulff's prize from Danish Society for Theory in Medicine
2001	Skrabanek Foundation Prize, Trinity College, Dublin.
2001	Niels A. Lassen's prize.
2003	Queen Ingrid's Lecture, Åbenrå Hospital.
2004	Harry Boström Lecture, Swedish Society for Internal Medicine, Annual Meeting.
2006	Top-ten peer reviewer for British Medical Journal for the year 2006.
2007	Winner of the 2007 Society of Medical Writers' Academic Writing Award (for: Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. <i>BMJ</i> 2006;332:538-41).
2009	Michael Berger Award, Düsseldorf.
2012	Winner of the annual Prescrire Prize for medical and pharmaceutical books (for: Gøtzsche PC. <i>Mammography screening: truth, lies and controversy</i> . London: Radcliffe Publishing; 2012:1-388).
2014	Winner of the Annual LAP Award (psychiatry award), Denmark.
2014	Co-founder and member of the Board of the Council for Evidence-based Psychiatry, London.
2014	Winner of the British Medical Association's Annual Book Award in the category Basis of Medicine for <i>Deadly Medicines and Organised Crime: How big pharma has corrupted health care</i> .
2014	Award from the International Society of Ethical Psychology and Psychiatry for "intellectual honesty and bravery in tackling the biomedical-industrial complex."
2015	Honourable Award, Consul General Ernst Carlsen's Foundation.
2015	Book of the Year, US Tributaries Radio, for <i>Deadly Psychiatry and Organised Denial</i> .
2015	Top ten finalist for the award "Dane of the year," nominated by psychiatric patients.
2016	HealthWatch Award, London
2016	Protector for Stemmehørernetværket (Hearing Voices Network)
2016	Co-founder and member of the Board, International Institute for Psychiatric Drug Withdrawal.
2017	Elected member of the Cochrane Governing Board, with the most votes of the 11 candidates.
2017	Honored Guests Award in Ethical Human Sciences and Services. Breggin: <i>Psychiatric Drug Facts</i> .
2018	Member of the Advisory Council of International Center for the Study of Patient-Oriented Psychiatry.

- 2018 Member of the Advisory Council of the Center for the Study of Empathic Therapy, Education & Living.
- 2020 Award from the Danish Patient Association for being the bravest doctor in the last decade.

Some recent appearances in documentary films and satires

1. The Daily Show, New York. 2014; Sept 16.
2. Frank Wittig Frank.Wittig@swr.de Südwestrundfunk
3. Lægemiddelindustrien, NRK1, 2014.
4. Danmark på piller. Tre dokumentarer i DR TV 2014.
5. TV fra en anden planet, kanal 1, juni 2015. <http://kanal-1.dk/tv-fra-en-anden-planet/>.
6. Crazywise, 2016.
7. ”Lykkepillen”. [Dokumentarfilm om Silje Marie Strandberg](#). 2017.
8. [Cause of death: unknown](#). Documentary film about filmmaker’s sister, Renate Hoel. 2017.
9. [Diagnosing psychiatry](#). Documentary film about Peter Gøtzsche. 2018.
10. Speed Demons: Dying For Attention. 2018.
11. sera@westernmassrlc.org
12. The drug industry. sejuicer@gmail.com. Russia 1
13. Michael Siewierski, New Roots Films. info@foodchoicesmovie.com 2018 launch.
14. [Medicating normal](#). Periscope Moving Pictures. 2019.

Publications

My scientific works have been cited about 50,000 times. My H-index is 67 according to Web of Science, September 2018, which means that 67 papers have been cited at least 67 times.

DrMedSci thesis

Bias in double-blind trials. Dan Med Bull 1990;37:329-36. Defended 10 May 1990 at the University of Copenhagen, Faculty for Health Sciences. Examiners: Professor, DrMedSci Ib Lorenzen and chief physician, DrMedSci Henrik R. Wulff.

Academic books

- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 4. udgave. København: Munksgaard; 1997.
- Wulff HR, Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 3rd edition. Oxford: Blackwell Scientific; 2000. Translated into Swedish, Spanish and Polish.
- Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 5. udgave. København: Munksgaard Danmark; 2006.
- Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. Chichester: Wiley; 2007.
- Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.
- Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013. Translated into 15 languages.
- Gøtzsche PC. Dødelig medicin og organiseret kriminalitet: Hvordan medicinalindustrien har korrumpet sundhedsvæsenet. København: People's Press; 2013.
- Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People’s Press; 2015. Translated into many languages.
- Gøtzsche PC. Dødelig psykiatri og organiseret fornægtelse. København: People’s Press; 2015.
- Gøtzsche PC. Overlevelse i en overmedicineret verden: Find selv evidensen. København: People’s Press; 2018.
- Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself. Copenhagen: People’s Press; 2019.
- Gøtzsche PC. Death of a whistleblower and Cochrane's moral collapse. Copenhagen: People’s Press; 2019.
- Gøtzsche PC. Vaccines: truth, lies and controversy. Copenhagen: People’s Press; 2020.

Gøtzsche PC. Mental health survival kit and withdrawal from psychiatric drugs. Copenhagen: Institute for Scientific Freedom; 2020.

Gøtzsche PC. Mentalt overlevelsesskit og udtræning af psykofarmaka. København: Institute for Scientific Freedom; 2020.

Travel book

Gøtzsche PC. På safari i Kenya. København: Samlerens forlag; 1985.

Articles in international journals with peer review

Total number of citations: about 50,000; H-index: 67 (Web of Science, September 2018).

1. Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. *Pharmatherapeutica* 1984;3:535-41.
2. Sindet-Pedersen S, Petersen JK, Gøtzsche PC. Incidence of pain conditions in dental practice in a Danish county. *Community Dent Oral Epidemiol* 1985;13:244-6.
3. Geisler C, Gøtzsche PC, Hansen SS, Juul K, Plesner AM, Nissen NI. Naproxen has greater antipyretic effect on fever related to Hodgkin's disease than to other tumours or to infection. *Scand J Haematol* 1985;35:325-8.
4. Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. *Int J Oral Maxillofac Surg* 1986;15:389-94.
5. Gøtzsche PC, Hvidberg EF, Juul P. Rational choice of dose: insufficient background knowledge? *Ration Drug Ther* 1986;20:1-7.
6. Gøtzsche PC. Reference bias in reports of drug trials. *BMJ* 1987;295:654-6.
7. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine/pyrimethamine. *BMJ* 1988;296:820-2.
8. Gøtzsche PC, Hørding M. Condoms to prevent HIV transmission do not imply truly safe sex. *Scand J Infect Dis* 1988;20:233-4.
9. Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. *Scand J Rheumatol* 1988;17:11-6.
10. Gøtzsche PC, Bygbjerg IC, Olesen B, Møller LH, Salim YS, Faber V. Yield of diagnostic tests of opportunistic infections in AIDS: a survey of 33 patients. *Scand J Infect Dis* 1988;20:395-402.
11. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. *Cephalalgia* 1989;9:29-32.
12. Gøtzsche PC. Patients' preference in indomethacin trials: an overview. *Lancet* 1989;i:88-91.
13. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. *Controlled Clin Trials* 1989;10:31-56 (amendment:356).
14. Gøtzsche PC. Multiple publication in reports of drug trials. *Eur J Clin Pharmacol* 1989;36:429-32.
15. Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. *Dan Med Bull* 1989;36:395-9.
16. Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. *Dan Med Bull* 1989;36:493-5.
17. Hørding M, Gøtzsche PC, Bygbjerg I, Pedersen M, Faber V, Berg K. Lack of immunomodulating effect of disulfiram in HIV positive patients. *Internat J Immunopharmacol* 1990;12:145-7.
18. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K. Opportunistic infections and malignancies in 231 Danish AIDS patients. *AIDS* 1990;4:233-8.
19. Jørgensen A, Shao J, Maselle S, Yangi E, Thomsen A, Matunda S, Bygbjerg I, Gøtzsche P, Svendsen J, Skinhøj P, Faber V. Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. *Scand J Infect Dis* 1990;22:283-5.
20. Jørgensen AF, Mwakyusa D, Cegielski P, Gøtzsche P, Hørding M, Lallinger G, Mbaga I, Pallangyo K, Richter C, Shao J, Bygbjerg I, Skinhøj P, Faber V. The effect of fusidic acid on Tanzanian patients with AIDS. *AIDS* 1990;4:1037-8.
21. Jørgensen AF, Jensen VG, Shao JF, Maselle S, Mbaga IM, Mwakyusa DH, Gøtzsche PC, Richter C, Pallangyo K, Cegielski P, Lallinger G, Bygbjerg I, Skinhøj P, Faber V. Beta-2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. *AIDS* 1990;4:1168-9.

22. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. *J Clin Epidemiol* 1990;43:1313-8.
23. Hørding M, Gøtzsche PC, Christensen LD, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. *Biomed Pharmacother* 1990;44:475-8.
24. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K, Nielsen JO. Trends in survival of Danish AIDS patients from 1981 to 1989. *AIDS* 1990;4:1111-6.
25. Gøtzsche PC, Kelbæk H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, Lyngsøe J, Mathiesen ER. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. *Scand J Clin Lab Invest* 1991;51:93-7.
26. Gøtzsche PC. Patients' views on the least acceptable increase in survival with zidovudine treatment. *Scand J Infect Dis* 1991;23:509-10.
27. Gjørup IE, Gøtzsche PC, Baden H, Andersen B. Surgical treatment of morbid obesity: a survey of overall outcome 1968-89. *Dan Med Bull* 1991;38:405-7.
28. Nielsen C, Nielsen CM, Petersen JL, Gøtzsche PC, Pedersen C, Arendrup M, Vestergaard BF. Isolation of HIV from cultures of purified CD4+ lymphocytes. *J Virol Methods* 1991;35:15-25.
29. Gøtzsche PC, Lange B. Comparison of search strategies for recalling double-blind trials from MEDLINE. *Dan Med Bull* 1991;38:476-8.
30. Nordic Medical Research Councils' HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. *BMJ* 1992;304:13-7 (manuscript and scientific coordinator: PC Gøtzsche).
31. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. *J Clin Epidemiol* 1992;45:587-94.
32. Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. *Antiviral Res* 1992;18:303-16.
33. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. *Scand J Infect Dis* 1992;24:563-5.
34. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs. *J Clin Epidemiol* 1993;46:319-21.
35. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. *BMJ* 1993;306:1093-6.
36. Gøtzsche PC. Zidovudine in HIV infection. *Ann Med* 1993;25:213-4.
37. Rasmussen MH, Andersen T, Breum L, Hilsted J, Gøtzsche PC. Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. *Int J Obes* 1993;17:323-7.
38. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. *Scand J Rheumatol* 1993;22:255-60.
39. Gøtzsche PC. Is there logic in the placebo? *Lancet* 1994;344:925-6.
40. Gøtzsche PC. Steroids and peptic ulcer: an end to the controversy? *J Intern Med* 1994;236:599-601.
41. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. *JAMA* 1994;272:1926-31 (member of writing committee).
42. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. *BMJ* 1995;310:1495-8.
43. Ullum H, Gøtzsche PC, Victor J, Dickmeiss E, Skinhøj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. *J Exp Med* 1995;182:789-99.
44. Mulward S, Gøtzsche PC. Sample size of randomized double-blind trials 1976-1991. *Dan Med Bull* 1996;43:96-8.
45. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. *Int J Technol Ass Health Care* 1996;12:238-46.
46. Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. *Scand J Rheumatol* 1996;25:194-9.
47. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV seropositive subjects. *J AIDS* 1996;13:93-9.
48. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. *Controlled Clin Trials* 1996;17:285-90.
49. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia (Cochrane Review). In: *The Cochrane Library, Issue 2*. Oxford: Update Software; 1997. Updated quarterly.
50. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library, Issue 3*. Oxford: Update Software; 1997. Updated quarterly.

51. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1997. Updated quarterly.
52. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. *Eur J Clin Pharmacol* 1997;51:389-93.
53. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. *BMJ* 1997;314:1238-44.
54. Gerstoft J, Melander H, Bruun JN, Pedersen C, Gøtzsche PC, Berglund O, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. *Scand J Infect Dis* 1997;29:121-8.
55. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor- α and interleukin-1 β in human immunodeficiency virus-seropositive subjects. *J Infect Dis* 1997;175:1507-10.
56. Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Klarlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. *AIDS Res Hum Retroviruses* 1997;13:1039-46.
57. Hammarquist C, Burr ML, Gøtzsche PC. House dust mites and control measures in the management of asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1998. Updated quarterly.
58. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 1998. Updated quarterly.
59. Gøtzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal, anti-inflammatory drugs in rheumatoid arthritis. *BMJ* 1998;316:811-8.
60. Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for *Plasmodium falciparum* malaria: comparing a retrospective and a prospective study. *Trop Med Int Health* 1998; 3:83-8.
61. Gøtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. *BMJ* 1998;317:1105-10.
62. Hróbjartsson A, Gøtzsche PC, Gluud C. The controlled trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. *BMJ* 1998;317:1243-5.
63. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. *Pharmacogenetics* 1998;8:473-9.
64. Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. *Am J Clin Nutr* 1999;69:1117-22.
65. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. *JAMA* 1999;282:1752-9.
66. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 1999;2:430-6.
67. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *Lancet* 2000;355:129-34.
68. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. *BMJ* 2000;320:1058-61.
69. Gøtzsche PC. Do patients with osteoarthritis get the clinical research they need? *Ann Rheum Dis* 2000;59:407-8.
70. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2000;3:521-8 (updated).
71. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be crucially important for patients. *BMJ* 2000;321:585-6.
72. Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
73. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
74. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
75. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2000. (updated).

76. Olesen V, Engell L, Jensen KL, Gøtzsche PC. Randomised clinical trials in the Scandinavian Journal of Rheumatology. *Scand J Rheumatol* 2000;29:349-51.
77. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: *The Cochrane Library*, Issue 3. Oxford: Update Software; 2001. (updated).
78. Gøtzsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. *Ann Rheum Dis* 2001;60:349-52.
79. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. *Ann Intern Med* 2001;134:663-94.
80. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med* 2001;344:1594-602.
81. Gøtzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). In: *The Cochrane Library*, Issue 3. Oxford: Update Software; 2001. (updated).
82. Olsen O, Middleton P, Ezzo J, Gøtzsche PC, Hadhazy V, Herxheimer A, et al. Quality of Cochrane reviews: assessment of sample from 1998. *BMJ* 2001;323:829-32.
83. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;5:800-7 (updated).
84. Hróbjartsson A, Gøtzsche PC. Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review. *Adv Mind-Body Med* 2001;17:312-8.
85. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. *Lancet* 2001;358:1340-2.
86. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. *Lancet* 2001 (<http://image.thelancet.com/extras/fullreport.pdf>).
87. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography (Cochrane Review). In: *The Cochrane Library*, Issue 4. Oxford: Update Software, 2001.
88. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;6:894-901 (updated).
89. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2002. Oxford: Update Software (updated).
90. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2002. Oxford: Update Software. (updated).
91. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2002. Oxford: Update Software. (updated).
92. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2002. Oxford: Update Software. (updated).
93. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;7:1063-70.
94. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagan A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. *JAMA* 2002;287:2769-71.
95. Gøtzsche PC. Medicalisation of risk factors. *BMJ* 2002;324:890-1.
96. McDonald S, Lefebvre C, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rütther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. *Evaluation & The Health Profession* 2002;25:65-76.
97. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;8:1203-11 (updated).
98. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2003;9:1292-300.
99. Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2003. Oxford: Update Software.
100. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: *The Cochrane Library*, Issue 2, 2003. Oxford: Update Software.
101. Gøtzsche PC. The debate on breast cancer screening with mammography is important. *J Am Coll Radiol* 2004;1:8-14.

102. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis (Cochrane Review). In: *The Cochrane Library*, Issue 1, 2004. Chichester: John Wiley & Sons, Ltd.
103. Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. *BMJ* 2004;328:148-51.
104. Gøtzsche PC. On the benefits and harms of screening for breast cancer. *Int J Epidemiol* 2004;33:56-64.
105. Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to *Pseudomonas aeruginosa* in cystic fibrosis patients: A marker of therapeutic success?—A 30-year Cohort study of survival in Danish CF patients after onset of chronic *P. aeruginosa* lung infection. *Pediatr Pulmonol* 2004;37:427-32.
106. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004;291:2457-65.
107. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. *Clin Infect Dis* 2004;39:38-46.
108. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;11:1551-9 (updated).
109. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd (updated).
110. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. *J Intern Med* 2004;256:91-100.
111. Gøtzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. *The Cochrane Database of Systematic Reviews* 2004, Issue 4. Art. No.: CD001187.
112. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: An extension of the CONSORT statement. *Ann Intern Med* 2004;141:781-8.
113. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;12:1702-10 (updated).
114. Schmidt LM, Gøtzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. *J Fam Pract* 2005;54:334-8.
115. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. *BMJ* 2005;330:1049-52.
116. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;13:1525-32 (updated).
117. Karmisholt K, Gyntelberg F, Gøtzsche PC. Physical activity for primary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:86-9.
118. Karmisholt K, Gøtzsche PC. Physical activity for secondary prevention of disease: systematic reviews of randomised clinical trials. *Dan Med Bull* 2005;52:90-4.
119. Gøtzsche PC. Research integrity and pharmaceutical industry sponsorship: trial registration, transparency and less reliance on industry trials are essential. *Med J Aust* 2005;182:549-50.
120. Gluud LL, Sørensen TIA, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepato-biliary randomized clinical trials. *Am J Gastroenterol* 2005;100:2431-5.
121. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. *N Engl J Med* 2005;353:2811-2.
122. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;14:1498-1505 (updated).
123. Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. *The Cochrane Database of Systematic Reviews* 2006, Issue 1. Art. No.: CD004707.
124. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. *Trials* 2006;7:3.
125. Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. *BMJ* 2006;332:538-41.
126. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. *JAMA* 2006;295:1171-3.
127. Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. *J Clin Epidemiol* 2006;59:336-8.
128. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. *JAMA* 2006;295:1645-6.

129. Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with *Pseudomonas aeruginosa* in people with cystic fibrosis. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001399 (updated).
130. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. *BMJ* 2006;333:231-4.
131. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. *BMC Medical Research Methodology* 2006;6:40.
132. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. *BMJ* 2006;333:782-5.
133. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD001877.
134. Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004684.
135. Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. *Dan Med Bull* 2006;53:438-40.
136. Gøtzsche PC, Mæhlen J, Zahl P-H. What is publication? *Lancet* 2006;368:1854-5.
137. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. *PLoS Med* 2007; 4(1):e19.
138. Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. *JAMA* 2007; 298(4):430-7.
139. Hrobjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. *J Clin Psychol* 2007; 63(4):373-7.
140. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. *BMC Med* 2007; 5:12.
141. Pildal J, Hrobjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol* 2007; 36(4):847-57.
142. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18(6):805-35.
143. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med* 2007; 4(10):e297.
144. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Ann Intern Med* 2007; 147(8):W163-94.
145. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007; 370(9596):1453-7.
146. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology* 2007; 18(6):800-4.
147. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ* 2007; 85(11):867-72.
148. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Prev Med* 2007; 45(4):247-51.
149. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335(7624):806-8.
150. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *PLoS Med* 2007; 4(10):e296.
151. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; 147(8):573-7.

152. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. *Arch Intern Med* 2007; 167(21):2289-95.
153. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. *Allergy* 2008 Jun;63(6):646-59.
154. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. *BMC Med Res Methodol* 2008 Apr 21;8:22.
155. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2008; (2):CD001187.
156. Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. *Cochrane Database Syst Rev* 2008; (3):CD000193.
157. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2008; (4):CD001399.
158. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008 Apr;61(4):344-9.
159. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; Iniciativa STROBE. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. *Gac Sanit* 2008 Mar-Apr;22(2):144-50.
160. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. *Rev Esp Salud Publica* 2008; 82(3):251-9.
161. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. *Internist (Berl)* 2008; 49(6):688-93.
162. Zahl PH, Jørgensen KJ, Maehlen J, Gøtzsche PC. Biases in estimates of overdiagnosis due to mammography screening. *Lancet Oncol* 2008 Mar;9(3):199-201.
163. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. *BMC Med Res Methodol* 2008; 8:60.
164. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. *BMJ* 2008;337:1404-7.
165. Madsen MV, Gøtzsche PC, Hrobjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. *BMJ* 2008;338:330-3.
166. Gøtzsche PC. Readers as research detectives. *Trials* 2009;10:2.
167. Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. *BMJ* 2009;338:446-8.
168. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. *BMC Medical Research Methodology* 2009, 9:1.
169. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? *PLoS Med* 2009;6(2):e23.
170. Jørgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gøtzsche PC. Informed choice requires information about both benefits and harms. *J Med Ethics* 2009;35(4):268-9.
171. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; Iniciativa STROBE. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. *Gac Sanit.* 2009 Mar-Apr;23(2):158.
172. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009;339:b2587.
173. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009 Aug 18;151(4):W65-94.
174. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med* 2009 Jul 21;6(7):e1000100.

175. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62(10):e1-34.
176. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009 Jul 21;339:b2700.
177. Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. *BMJ* 2009 Aug 13;339:b3128.
178. Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. *J Clin Epidemiol*. 2009 Sep;62(9):967-73.
179. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. *Cochrane Database of Systematic Reviews* 2009, Issue 4. Art. No.: CD001877.
180. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. *J Negat Results Biomed* 2009 Jun 10;8:7.
181. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. *BMC Women's Health* 2009;9:36.
182. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review of the NHS Breast Screening Programme. *J R Soc Med* 2010;103:14-20.
183. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *Cochrane Database of Systematic Reviews* 2010, Issue 1. Art. No.: CD003974.
184. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. *BMJ* 2010;340:c1241.
185. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. *Pol Arch Med Wewn* 2010;120:89-94.
186. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Obstet Gynecol* 2010 May;115(5):1063-70.
- a. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *PLoS Med* 2010 Mar 24;7(3):e1000251.
187. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):834-40.
188. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* 2010 Jun 1;152(11):726-32.
189. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC Med* 2010 Mar 24;8:18.
190. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Trials* 2010 Mar 24;11:32.
191. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c332.
192. Gøtzsche PC, Berg S. Sleep apnoea: from person to patient, and back again. *BMJ* 2010 Mar 30;340:c360.
193. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010 Mar 23;340:c869.
194. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010 Aug;63(8):e1-37.
195. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version)]. *Zhong Xi Yi Jie He Xue Bao* 2010;8(8):701-41.
196. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41.
197. Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. *Eur J Clin Pharmacol* 2010 Apr;66(4):341-7.
198. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev* 2010;(7):CD007851.

199. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. *Dan Med Bull* 2010;57(9):A4175.
200. Lundh A, Barbateskovic M, Hrobjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. *PLoS Med* 2010;7(10):e1000354.
201. Gøtzsche PC, Delamothe T, Godlee F, Lundh A. Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. *BMJ* 2010 Aug 10;341:c3926.
202. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. *BMJ* 2010;341:c3920.
203. la Cour JL, Brok J, Gøtzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. *BMJ* 2010;341:c3653.
204. Lundh A, Gøtzsche PC. Sponsorship of medical textbooks by drug or device companies. *CMEJ* 2011;1:e10-7.
205. Gøtzsche PC. Time to stop mammography screening? *CMAJ* 2011;183:1957-8.
206. Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. *BMJ* 2011;342:d2686.
207. Gøtzsche PC, Jørgensen KJ. The Breast Screening Programme and misinforming the public. *J R Soc Med* 2011;104(9):361-9.
208. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. *J R Soc Med* 2011;104(1):41-2.
209. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. *Dan Med Bull* 2011;58(3):A4246.
210. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
211. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011;260(3):621-7.
212. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. *Lancet* 2011;378(9808):1995-6.
213. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. *Int J Risk Saf Med* 2011;23(2):125-32.
214. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011;11:22.
215. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
216. Tendal B, Nuesch E, Higgins JP, Juni P, Gøtzsche PC. Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. *BMJ* 2011;343:d4829.
217. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. *Lancet Oncol* 2011;12(12):1118-24.
218. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. *Trials* 2011;12(1):249.
219. Gøtzsche PC, Jørgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. *Cancer Causes Control* 2012;23:15-21.
220. Gøtzsche PC. Strengthening and opening up health research by sharing our raw data. *Circ Cardiovasc Qual Outcomes* 2012;5:236-7.
221. Grønhøj Larsen C, Jørgensen KJ, Gøtzsche PC. Regular health checks: cross-sectional survey. *PLoS One* 2012;7:e33694.
222. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;10:28-55.
223. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. *Addict* 2012;107:900-8.
224. Lundh A, Krogsbøll LT, Gøtzsche PC. Sponsor's participation in conduct and reporting of industry trials: a descriptive study. *Trials* 2012;13:146.
225. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. *PLoS One* 2012;7:e41174.
226. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. *BMJ* 2012;345:e8522.
227. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Sys Rev* 2012;(10):CD009009.

228. Gøtzsche PC, Ioannidis JPA. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? *BMJ (Online)* 2012;345:e7031.
229. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. *BMJ (Online)* 2012;345:e7191.
230. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. *BMJ* 2012;345:e8462.
231. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. *Ann Intern Med* 2013;158:200-7.
232. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I et al. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med* 2013;10:e1001419.
233. Bindslev JBB, Schroll J, Gøtzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. *BMC Med Ethics* 2013;14:19.
234. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ (Online)* 2013;346:e7586.
235. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. *Cochrane Database Syst Rev* 2013;(6):CD001877.
236. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *JAMA* 2013;309:2489-90.
237. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? *Int J Risk Saf Med* 2013;25:155-68.
238. Rasmussen K, Jørgensen KJ, Gøtzsche PC. Citations of scientific results and conflicts of interest: the case of mammography screening. *Evidence - Based Medicine (English Edition)*. 2013;18:83-9.
239. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. *BMJ (Online)* 2013;346:f2231.
240. Wolfe N, Gøtzsche PC, Bero LA. Strategies for obtaining unpublished drug trial data: a qualitative interview study. *Syst Rev* 2013;2:31.
241. Zahl P-H, Juhl Jørgensen K, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. *Br J Cancer* 2013;109:2014-9.
242. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Ghersi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. *Lancet* 2014;383:257-66.
243. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? *BMJ* 2014 ;348:g171.
244. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. *BMJ* 2014;348:g3555.
245. Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ* 2014;348:g3510.
246. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. *J R Soc Med* 2014;107:256-7.
247. Gøtzsche PC. Why I think antidepressants cause more harm than good. *Lancet Psychiatry* 2014;1:104-6.
248. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. *Cochrane Database Syst Rev* 2014;(9):CD002033.
249. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. *Cochrane Database Syst Rev* 2014;(9):CD000026.
250. Gøtzsche PC. "Human guinea pig" asks for animal studies. *BMJ (Online)* 2014;349:g6714.
251. Gøtzsche PC. Our prescription drugs kill us in large numbers. *Polskie Archiwum Medycyny Wewnętrznej* 2014;124:628-34.
252. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. *Cochrane Database Syst Rev* 2014;(9):CD000239.
253. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2014;(9):CD000969.
254. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2014;(2):CD004707.

255. Jørgensen AW, Lundstrøm LH, Wetterslev J, Astrup A, Gøtzsche PC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. *PLoS One* 2014;9:e111964.
256. Vandembroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12:1500-24.
257. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandembroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *Int J Surg* 2014;12:1495-99.
258. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. *J Gen Intern Med* 2014;29:1283-6.
259. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than good? *BMJ* 2015;350:h2435.
260. Gøtzsche PC. Mammography screening is harmful and should be abandoned. *J R Soc Med* 2015;108:341-5.
261. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777-84.
262. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev* 2015;(8):CD001399.
263. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. *Cochrane Database Syst Rev* 2015;(1):CD010007.
264. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
265. Rasmussen KM, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. *J R Soc Med* 2015;108:101-7.
266. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Sys Rev* 2016;(9):CD007851.
267. Johansson M, Brodersen J, Gøtzsche PC, Juhl Jørgensen K. Screening for reducing morbidity and mortality in malignant melanoma (Protocol). *Cochrane Database Sys Rev* 2016;(9):CD012352.
268. Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. *J R Soc Med* 2016;109:381-92.
269. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. "Adaptive pathways" to drug authorisation: adapting to industry? *BMJ* 2016;354:i4437.
270. Jørgensen KJ, Gøtzsche PC. Breast cancer: Updated screening guidelines - much ado about small improvements. *Nat Rev Clin Oncol* 2016;13:139-40.
271. Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. *PLoS Med* 2016;13:e1002101.
272. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ* 2016;352:i65.
273. Simonsen AL, Danborg PB, Gøtzsche PC. Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies. *Int J Risk Saf Med* 2016;28:1-12.
274. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. *CMAJ* 2017;189:E194-203.
275. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. *Ann Intern Med* 2017;166:313-23.
276. Danborg PB, Simonsen AL, Gøtzsche PC. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. *Int J Risk Saf Med* 2017;29(1-2):107-24.
277. Sharma T, Gøtzsche PC, Kuss O. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. *J Clin Epidemiol* 2017;91:129-36.
278. Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC, Jørgensen KJ. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. *Evid Based Med* 2017;22:143-7.
279. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. *J R Soc Med* 2017;110:404-10.
280. Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. *BMJ* 2018;363:k3654.
281. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. *BMJ Evid Based Med* 2018;23:165-8.

282. Marquardsen M, Ogden M, Gøtzsche PC. Redactions in protocols for drug trials: what industry sponsors concealed. *J R Soc Med* 2018;111:136-41.
283. Jørgensen L, Gøtzsche PC, Jefferson T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. *Syst Rev* 2018;7:8.
284. Gøtzsche PC. Patients not patents: Drug research and development as a public enterprise. *Eur J Clin Invest* 2018;48(2):e12875.
285. Gøtzsche PC. A totally new system is needed for drug research and development. *Eur J Clin Invest* 2018;48(2):e12883.
286. Jørgensen L, Doshi P, Gøtzsche PC, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. *BMJ* 2018;362:k3694.
287. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. *Cochrane Database Syst Rev* 2019;1:CD009009.
288. Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood disorders: A systematic review. *Int J Risk Saf Med* 2019;30(3):155-166.
289. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. *Int J Risk Saf Med* 2019 Sep 14. doi: 10.3233/JRS-195063. [Epub ahead of print].
290. Danborg PB, Valdersdorf M, Gøtzsche PC. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review. *Int J Risk Saf Med* 2019;30(2):59-71.
291. Gøtzsche PC. What is the moral collapse in the Cochrane Collaboration about? *Ind J Med Ethics* 2019 Oct-Dec;4(4) NS:303-9.
292. Gøtzsche PC. Cochrane authors on drug industry payroll should not be allowed. *BMJ Evid Based Med* 2019 Apr 11.
293. Gøtzsche PC. Institute for Scientific Freedom. *BMJ Evid Based Med* 2019 Aug;24(4):123-4.
294. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. *Cochrane Database Syst Rev* 2019 Jun 3;6:CD012352.
295. Jørgensen L, Gøtzsche PC, Jefferson T. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination. *BMJ Sex Reprod Health* 2019 Sep 18. pii: bmjsrh-2018-200245. doi: 10.1136/bmj-srh-2018-200245. [Epub ahead of print].
296. Paludan-Müller AS, Ogden MC, Marquardsen M, Vive J, Jørgensen KJ, Gøtzsche PC. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. *BMJ Open* 2019;9:e026661.
297. Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients' rights and the law not respected by Appeals Board in Denmark. *Clin Neuropsychiatry* 2019;16:229-33.
298. Sharma T, Guski LS, Freund N, Meng DM, Gøtzsche PC. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. *Int J Risk Saf Med* 2019;30:217-32.

Articles without peer review

1. Gøtzsche PC. Vandtæggers respirationsforhold (Heteroptera, Hydrocorisae). Special subject, University of Copenhagen, Faculty for Natural Sciences, 1974, 83 pp.
2. Gøtzsche PC, Marinelli K, Gylding-Sabroe JP, Larsen N-E, Sørensen K. Bioavailability of naproxen tablets and suppositories in steady state. *Scand J Rheumatol* 1983;suppl 50:1-9.
3. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1983;145:3902-4.
4. Gøtzsche PC, Karlsen FØ, Andersen B. Dosis-respons bias. *Nord Med* 1986;101:24-5.
5. Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, Rønholt EB, Tranberg FH. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. *Ugeskr Læger* 1986;148:1266-8.
6. Gøtzsche PC. Vurdering af kliniske lægemiddelundersøgelser. *Ugeskr Læger* 1986;148:2417-20.
7. Ørnkov F, Gøtzsche PC. Lodtrækningsprincippet. Et forsøg på en medicinsk-etisk analyse. *Ugeskr Læger* 1988;150:897-900.
8. Gøtzsche PC. Oversigtsartikler og meta-analyser (leder). *Ugeskr Læger* 1988;150:1765-6.
9. Olesen B, Gøtzsche PC, Bygbjerg IC, Møller LH, Faber V. Hospitalsomkostninger ved diagnostik og behandling af AIDS-patienter. De første 33 patienter på Rigshospitalet. *Ugeskr Læger* 1988;150:2250-2.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Artikeltype og forsøgsdesign. *Ugeskr Læger* 1989;151:218-20.

11. Gøtzsche PC, Forrest M, Hermann GG, Jørgensen PE, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Analyse og tolkning af forsøgsresultater. Ugeskr Læger 1989;151:220-2.
12. Gøtzsche PC. Medicinske studenters holdning til lodtrækning og selvvalg ved brystkræftkirurgi og forslag om et nyt design. Ugeskr Læger 1989;151:2719-21.
13. Mandrup-Poulsen T, Gøtzsche PC, Ott P, Pedersen BK, Sørensen JB. Dansk intern medicin i en brydningstid på tærsklen til det 21. århundrede. Bibliotek for Læger 1991;183:69-82.
14. Gøtzsche PC. Biasproblemer i kort- og langtidsdobbelblindforsøg og forslag til forbedringer. Månedsskr Prakt Lægegern 1992;70:159-64.
15. Gøtzsche PC. Metaanalyser: metodologiske og forskningsetiske overvejelser. Bibliotek for Læger 1993;185:17-29.
16. Gøtzsche PC. Det Nordiske Cochrane Center: samarbejde om systematiske oversigter over behandlingers effekter. Nord Med 1994;109:244-5.
17. Gøtzsche PC. Meta-analyser og kvalitetssikring. Journal 1994;2:16-7.
18. Gøtzsche PC. Er placebobegrebet logisk? Bibl Læger 1995;187:71-8.
19. Rigshospitalets Forskningspolitik, 1994, 16 pp.
20. Gøtzsche PC. Supplement til Rigshospitalets Forskningspolitik, 1994, 40 pp.
21. Gøtzsche PC. Kontrollerede kliniske forsøgs troværdighed - randomiseringsproblemet. Ugeskr Læger 1995;157:597-8.
22. Gøtzsche PC, Krog JW, Moustgaard R. Bibliometrisk analyse af dansk sundhedsvidenskabelig forskning 1988-1992. Ugeskr Læger 1995;157:5075-81.
23. Gøtzsche PC. Patientbehandling og sikkerhed - Cochrane-databasernes betydning. Ugeskr Læger 1995;157:6247.
24. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. København: Det Ethiske Råd; 1996:1-32.
25. Gøtzsche PC. Det Nordiske Cochrane Center og Netværk: Nordisk samarbejde om systematiske oversigter over behandlingers effekter. Social- og Hälsovårdsnytt i Norden 1996;13:10-11.
26. Gøtzsche PC. Anvendte procedurer skal være videnskabeligt dokumenterede. Lægen 1996;14:10-2.
27. Hallas J, Gøtzsche PC. Det Nordiske Cochrane Center og Netværk - et samarbejde om systematiske oversigter over behandlingseffekter. Farmakoepi-Nyt 1996;nov:4-5.
28. Olsen O, Gøtzsche PC. Nødvendigheden af elektronisk opdaterede metaanalyser: Doppler-ultralyd i obstetrikken som eksempel. Ugeskr Læger 1997;159:27-8.
29. Gøtzsche PC. Fibigers forsøg om serumbehandling af difteri. Bibl Læger 1997;189:143-6.
30. Gøtzsche PC, Jensen KL, Hammarquist C. Randomiserede kliniske forsøg i Ugeskrift for Læger 1948-1995. Ugeskr Læger 1997;159:4762-5.
31. Gøtzsche PC. Cochrane-samarbejdets betydning for evidensbaseret medicin. Ugeskr Læger 1997;159:6721-4.
32. Gøtzsche PC. Hjælp til et evidensbaseret sundhedsvæsen. Social- & Hälsovårdsnytt i Norden 1998;2:12-13 og www.shn.dk/2-98/cochrane.htm.
33. Gøtzsche PC. Randomisering og blinding i sundhedsvidenskabelig forskning. Bibl Læger 1998;190:369-80.
34. Gøtzsche PC. Lus i skindpelsen. Ugeskr Læger 1998;160:7610-1.
35. Gøtzsche PC. Det Nordiske Cochrane Center: Status efter 5 år og fremtidsperspektiver. Ugeskr Læger 1999;161:932-4.
36. Olsen O, Gøtzsche PC. Der er noget galt i mammografistudierne! Ingen støtte til konklusionen at brystkræftscreening har gavnlig effekt. Läkartidningen 2000;97:286-7.
37. Gøtzsche PC. Cochranesamarbetets betydelse för evidensbaserad medicin. Läkartidningen 2000;97:3180-2.
38. Wille-Jørgensen PA, Gøtzsche PC. Evidensbaseret kirurgi. Ugeskr Læger 2001;163:737-40.
39. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
40. Pedersen T, Gluud CN, Gøtzsche PC, Matzen P, Wille-Jørgensen P. Hvad er evidensbaseret medicin? Ugeskr Læger 2001;163:3769-72.
41. Gøtzsche PC, Olsen O. Screening for mammacancer - to år efter. Ugeskr Læger 2002;164:204-6.
42. Gøtzsche PC, Jørgensen KJ. Screening for brystkræft - et tveægget sværd. Ugeskr Læger 2005;167:1312-4.
43. Gøtzsche PC. Uafhængig klinisk interventionsforskning er meget påkrævet. Ugeskr Læger 2005;167:1491-4.
44. Gøtzsche PC. COX-2-hæmmere og andre nonsteroidale antiinflammatoriske stoffer - hvad er fremtiden? Ugeskr Læger 2006;168:1972-3.

45. Gøtzsche PC. Paracetamol har samme effekt som nonsteroid antiinflammatoriske stoffer ved akutte skader i bevægeapparatet. Ugeskr Læger 2006;168:1981-2.
46. Gøtzsche PC. [Freedom of expression and editorial independence: Four firings and a Kafkaian process]. Ugeskr Læger 2008 Apr 28;170(18):1537-8.
47. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. Månedsskr Prakt Lægegern 2008;86 (maj):551-7.
48. Gøtzsche PC. Kasuistiske meddelelser: fortsat en hovedkilde til forvirring, men nu på patientgruppeniveau. Bibl Læger 2009;201:87-91.
49. Gøtzsche PC, Johansen HK, Haahr MT, Altman DG, Chan A-W. Videnskabelig uredelighed. Ugeskr Læger 2009;171:1206-9.
50. Gøtzsche PC. Atter fri adgang til Cochrane-biblioteket for alle danskere. Ugeskr Læger 2009;171:932-3.
51. Gøtzsche PC, Hartling O, Nielsen M, Jørgensen KJ, Brodersen J. Invitation til brystkræftscreening: propaganda eller information? Ugeskr Læger 2009;171:1963.
52. Gøtzsche PC, Lundh A. Industrisponsoreret efteruddannelse hører ikke hjemme i et evidensbaseret sundhedsvæsen. Ugeskr Læger 2009;171:2228-9.
53. Gøtzsche PC, Jørgensen KJ. [Honest information about mammography screening, please!]. Lakartidningen. 2009;106(44):2860-1.
54. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. Ugeskr Læger 2009;171:3727.
55. Jørgensen AW, Gøtzsche PC. [Insufficient access to research data not acceptable]. Ugeskr Læger 2010 May 24;172(21):1585.
56. Gøtzsche PC. Lovforslaget om kliniske forsøg viger uden om de allerstørste problemer. Ugeskr Læger 2011;173(11):840.
57. Gøtzsche PC. Hvorfor fejlinformerer Sundhedsstyrelsen om mammografiscreening? Videnskab.dk 2011; <http://videnskab.dk/krop-sundhed/hvorfor-fejlinformerer-sundhedsstyrelsen-om-mammografiscreening>.
58. Gøtzsche PC. Medicinalindustriens forskningsfusk og de købte læger. 2011; <http://videnskab.dk/kultur-samfund/medicinalindustriens-forskningsfusk-og-de-kobte-laeger>.
59. Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. Videnskab dk 2011; <http://videnskab.dk/krop-sundhed/abent-brev-til-lundbeck-om-antidepressiva-og-selv-mord>.
60. Gøtzsche PC, Tendal B, Clarke M. Review production in The Cochrane Collaboration - where is it happening and why? Cochrane Database Syst Rev 2011;Suppl 1:16-9.
61. Gøtzsche PC. We need access to all data from all clinical trials. Cochrane Database Syst Rev 2011;12:ED000035.
62. Gøtzsche PC. Hvorfor så snævre grænser for omfang i Ugeskriftet? Ugeskr Læger 2012;174:297.
63. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for breast cancer with mammography. The Nordic Cochrane Centre 2012. Available from: <http://nordic.cochrane.org/>
64. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for brystkræft med mammografi. The Nordic Cochrane Centre 2012. Available from: <http://nordic.cochrane.org/>
65. Jørgensen KJ, Gøtzsche PC. [Mortality in breast cancer is decreasing - but not because of screening. Time to abolish the mammography screening]. Lakartidningen 2012;109:690-2.
66. Jørgensen KJ, Gøtzsche PC. Rintasyöpäkuolleisuus vähenee, muttei seulonnan ansiosta. Suomen Lääkärilehti 2012;11:856-8.
67. Gøtzsche PC. Mammografiscreening gør raske kvinder syge. Fokus på Kræft og sygepleje 2012;2:18-20.
68. Gøtzsche PC. Lægers råd om medicin er ikke sunde. Politikens kronik 2012 Nov 29.
69. Gøtzsche PC. Vores lykkepille-epidemi er dybt skadelig. Berlingskes kronik 2012 Dec 16.
70. Gøtzsche PC. Overdiagnostik og overmedicinering i børnepsykiatrien. Pædagogisk Psykologisk Tidsskrift 2013;50:95-100.
71. Gøtzsche PC. Bør bekendtgørelsen om videnskabelig uredelighed revideres endnu en gang? Ugeskr Læger 2013;175:2512-3.
72. Gøtzsche PC. Alvorlige skadevirkninger af HPV-vaccinen. HPV-magasinet 2016;1:18-9.
73. Gøtzsche PC. De mange usynlige medicindødsfald: Et chokerende højt antal mennesker dør på grund af den medicin, de tager. Men ofte er de dødsfald usynlige før lægen. Løsningen er at bruge mindre medicin. Ugeskr Læger 2016;10:990-1.
74. Gøtzsche PC, Lund K. Tvangsmedisinering må forbys. Kritisk Juss 2016;2:118-57.
75. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Laegeforen 2017;137:11-2.
76. Gøtzsche PC. Hvad er der kommet ud af kræftindsatserne? Dagens Medicin 2017;2:8-9.

77. Gøtzsche PC. Chemical or Psychological Psychotherapy? 2017; Jan 29. www.madinamerica.com/.
78. Gøtzsche PC. Editorial Misconduct: Finnish Medical Journal Rejects Paper on Suicide Risk. 2017; Feb 22. www.madinamerica.com/.
79. Gøtzsche PC. Vi kan og bør undvære antidepressiv medicin: kritik af Sundhedsstyrelsen. www.deadlymedicines.dk.
80. Gøtzsche PC. DSAM-formand på afveje om antidepressiva. Dagens Medicin 2017; 3. marts.
81. Gøtzsche PC. Svar til: DepressionsForeningen: Medicin bliver ofte det eneste mulige valg. <http://videnskab.dk/> 2017; 8. marts.
82. Gøtzsche PC. Medikamentfri behandling. Dagens Medicin 2017; 10. marts.
83. Gøtzsche PC. Antidepressiva bör inte användas till barn och ungdomar. Läkartidningen 2017; 12. marts.
84. Gøtzsche PC. Antidepressiva skader mere end de gavner. Dagens Medicin 2017; 15. marts.
85. Gøtzsche PC. Norske Renate Hoel døde pludseligt og uventet i juli 2005, 34 år gammel. Ugeskr Læger 2017; 23. marts.
86. Toft B, Gøtzsche PC. Psykofarmakaepidemien kan bekæmpes. Information 2017; 3. april.
87. Jørgensen KJ, Gøtzsche PC, Jørgensen T. Tilstrækkelig evidens til at undlade tjek. Dagens Medicin 2017; 7:23.
88. Gøtzsche PC. Private virksomheder skal også kunne undersøges for videnskabelig uredelighed. Ugeskr Læger 2017; 179:633.
89. Gøtzsche PC. Røgfrit Danmark. 2017; 28. april. www.deadlymedicines.dk.
90. Gøtzsche PC. Kræftens Bekæmpelse vildleder. Dagens Medicin 2017; 17. marts.
91. Gøtzsche PC. Ingen pålitlig evidens viser at lækemedel kan forebygge selvmord. Läkartidningen 2017; 1. maj.
92. Gøtzsche PC. Medicin mod Alzheimer virker ikke. Ugeskr Læger 2017; 8. maj.
93. Gøtzsche PC. Måske kan du blive medicinfri. Kronik. Jyllands-Posten 2017; 13. maj.
94. Gøtzsche PC. Skal angst behandles med piller? Angstavisen 2017; nr. 57, juni:4-6.
95. Gøtzsche PC. Depressionspiller gør større skade end gavn. Politiken 2017; 25. juni.
96. Gøtzsche PC. Hun fik den sidste kemo på vej til kapellet. Kronik. Politiken 2017; 2. juli.
97. Gøtzsche PC. Antidepressants increase the risk of suicide, violence and homicide at all ages. BMJ 2017; Sept 3. <http://www.bmj.com/content/358/bmj.j3697/rr-4>.
98. Gøtzsche PC. Psychiatry Ignores an Elephant in the Room. 2017; Sept 21. www.madinamerica.com/.
99. Gøtzsche PC. Din overvægt er en selvskabt plage - derfor skal du selv betale. Berlingske 2017; 12. aug.
100. Gøtzsche PC. What is it like being on the Governing Board? 2017; Sept 27. <http://community.cochrane.org/news/what-it-being-governing-board>.
101. Gøtzsche P. Medicinfri psykiatri. <http://tidsskriftet.no/comment-view/11179>. 2017 (ingen dato).
102. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Hvordan skal man trappe ud af psykofarmaka? Kronik. Jyllands-Posten 2017; 10. okt.
103. Danborg PB, Simonsen AL, Hróbjartsson A, Gøtzsche PC. Long-term changes in observed behaviour after exposure to psychiatric drugs: a systematic review of animal studies. Nordic Cochrane Centre 2017; Nov 14. <http://nordic.cochrane.org/>.
104. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Learning About Psychiatric Drug Withdrawal. 2017; Nov 16. <https://www.madinamerica.com/>.
105. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 1. 2017; Dec 4. <https://breggin.com/>.
106. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Udtrapning af psykofarmaka: En opfordring til de praktiserende læger. Practicus 2017; 17. dec:48-50.
107. Jørgensen KJ, Gøtzsche PC. Lægemedelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017; 179:2336-7.
108. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Lægeforen 2017; 137:11-2.
109. Jørgensen KJ, Gøtzsche PC. Lægemedelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017; 179:2336-7.
110. Jørgensen KJ, Gøtzsche PC. Lægemedelstyrelsens nonchalante holdning til kræftmedicin og interessekonflikter. Ugeskr Læger 2018; 180:170-1.
111. Jørgensen KJ, Gøtzsche PC. Uhæderlighed og interessekonflikter er to forskellige ting, Henrik Ullum. Ugeskr Læger 2018; 180:172.
112. Jørgensen KJ, Gøtzsche PC. Arbejder Lægemedelstyrelsen for patienterne? Politikens Kronik 2018; 5 febr.
113. Jørgensen KJ, Gøtzsche PC. Interessekonflikter er allerede diskvalificerende. Heldigvis. Ugeskr Læger 2018; 180:268.

114. Boesen K, Simonsen AL, Danborg PB, Jørgensen KJ, Gøtzsche PC. Lægemedellannoncer i Ugeskrift for Læger bør ikke forekomme. Ugeskr Læger 2018;180:1596-7.
115. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias: Response to the Cochrane editors. BMJ Evidence-Based Medicine. 2018; 17 September.
116. Gøtzsche PC. Moralsk ledelseskriser i Cochrane-samarbejdet. Politikens Kronik 2018; 27. sept.
117. Gøtzsche PC. Cochrane—no longer a Collaboration. <https://blogs.bmj.com/bmj/2018/11/08/peter-c-gotzsche-cochrane-no-longer-a-collaboration/>. 2018; 8 Nov.
118. Gøtzsche PC. It's Unlikely That 'Antidepressants' Have a True Effect on Depression. <https://www.madinamerica.com/2018/01/antidepressants-effect-depression/>. 2018; 8 Jan.
119. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 2.
120. Gøtzsche PC. <https://breggin.com/psychiatrists-roadblock-psychiatric-drug-withdrawal-initiatives-part-2/>. 2018 (not dated).
121. Gøtzsche PC. Endnu et tragisk selvmord på depressionspiller. Jyllands-Postens Kronik 2018; 3. feb.
122. Gøtzsche PC. Rewarding the Companies That Cheated the Most in Antidepressant Trials. March 7, 2018 <https://www.madinamerica.com/2018/03/rewarding-companies-cheated-most-antidepressant-trials/>. 2018; 7 March.
123. Gøtzsche PC. Forbruget af depressionspiller er næsten halveret hos børn og unge i Danmark. <http://www.deadlymedicines.dk/forbruget-af-depressionspiller-er-naesten-halveret-hos-born-og-unge-i-danmark/>. 2018; 1 maj.
124. Gøtzsche PC. Usage of depression pills almost halved among children in Denmark. <https://www.madinamerica.com/2018/05/usage-depression-pills-almost-halved-among-children-denmark/>. 2018; 4 May.
125. Davies J, Read J, Hengartner MP, Cosci F, Fava G, Chouinard G, van Os J, Nardi A, Gøtzsche P, Groot P, Offidani E, Timimi S, Moncrieff J, Spada M, Guy A. Clinical guidelines on antidepressant withdrawal urgently need updating. BMJ 2019 May 20;365:l2238.
126. Gøtzsche PC. The harmful myth about the chemical imbalance causing psychiatric disorders. CrossFit 2019 June 28.
127. Gøtzsche PC. "Trust me, I'm a doctor". CrossFit 2019 June 16.
128. Gøtzsche PC. Expert Report. Effect of DTP Vaccines on Mortality in Children in Low-Income Countries. 2019 June 19.
129. Gøtzsche PC. Forced drugging with antipsychotics is against the law: decision in Norway. Mad in America 2019 May 4. <https://www.madinamerica.com/2019/05/forced-drugging-antipsychotics-against-law/>
130. Gøtzsche PC. Institutional corruption in the Cochrane Collaboration. Mad in America 2019 Feb 14.
131. Gøtzsche PC. Norsk ombudsmand har afgjort, at tvangsmedicinering ikke kan begrundes. Psykiatriavisen 2019 Jan 27.
132. Gøtzsche PC. The depression pill epidemic. CrossFit 2019 June 4.
133. Gøtzsche PC. Why we're establishing an Institute for Scientific Freedom. Mad in America 2018 Dec 30.
134. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. Fem læger, psykologer og farmaceuter: Skru ned for psykofarmaka. Piller er ikke løsningen. Politikens kronik 2019 Sept 8.
135. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. The epidemic of psychiatric drug usage – taper off the pills. Deadly Medicines 2019 Oct 22.
136. Gøtzsche PC. Surviving psychiatry: a typical case of serious psychiatric drug harms. Mad in America 2020 Jan 7.

Book chapters

1. Gøtzsche PC. Problemer og muligheder ved lægemiddelundersøgelser ved reumatoid artrit. I: Jarner D, Friis J, eds. Dansk Reumatologisk Selskab: postgraduat kursus om arthritis rheumatoides. København: Astra, 1992:18-30.
2. The Cochrane Collaboration Handbook. Sackett D, Chalmers I, Silagy C, Gøtzsche PC, Dickersin K, Oxman A, eds. 1994.
3. Gøtzsche PC. Clinical practice should reflect clinical science. In: Gordon C, Christensen JP, eds. Health Telematics for Clinical Guidelines and Protocols. Amsterdam: IOS Press, 1995:17-25.
4. Gøtzsche PC. Meta-analyses: assets and limitations. In: Rose C, Larsen S, Hansen O, Bergh J, Andersen J, eds. Recent advances in breast cancer. Colloquium, Scandinavian Breast Group, Hindsgavl, Oct 11-14. Bristol-Myers Squibb, 1996:139-45.

5. Kleijnen J, Gøtzsche PC, Kunz RH, Oxman A, Chalmers I. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. *Non-random reflections on health services research: on the 25 anniversary of Archie Cochrane's Effectiveness and Efficiency*. London: BMJ Books, 1997:231-49.
6. Gøtzsche PC. Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? I: *Evidensbaseret sundhedsvæsen. Rapport fra II symposium om evidensbaseret sundhedsvæsen*. København: Institut for Sundhedsvæsen, DSI rapport 98.04, 1998:119-25.
7. Gøtzsche PC. Metaanalyse - begreber og metoder. I: Andersen D, Almind G, Bock E, Havsteen B, Hørder M, Riis P. *Sundhedsvidenskabelig forskning*, 5. udg. København: FADL's Forlag, 1999:303-14.
8. Gøtzsche PC. Eettisiä näkökulmia systemaattisiin kirjallisuuskatsauksiin. Helsinki: Stakes, FinOHTAn raportti 11, 1999:19-24.
9. Gøtzsche PC, red. *Introduktion til forskning*. http://www.dadlnet.dk/dok/?/2videnskab/bibliotekforlaeger/frz_forskning.htm, april 2000.
10. Gøtzsche PC. Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. I: MTV, sundhedstjenesteforskning og klinisk praksis. Rapport fra et symposium om evidensbaseret sundhedsvæsen. København: Statens Institut for Medicinsk Teknologivurdering, 2000. p. 38-44.
11. Johansen HK, Gøtzsche PC. Lægemedelindustrien og ytringsfriheden. I: Høiby (red): *Råb op og sig stop*. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
12. Gøtzsche PC. Screeningsindustrien og ytringsfriheden. I: Høiby (red): *Råb op og sig stop*. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
13. Gøtzsche PC. Assessment bias. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, eds. *Encyclopedia of statistical sciences*, 2nd ed. Hoboken, New Jersey: John Wiley & Sons, 2006;vol 1:237-40.
14. Also published in: *Wiley Encyclopedia of Clinical Trials*, 2007. DOI: 10.1002/9780471462422.eoct062.
15. Gøtzsche PC. Commercial interests versus common goods. In: Lötjönen S, von Troil H, eds. *Bioethics, Politics and Business*. Copenhagen: Nordic Council of Ministers, TemaNord 2008:125-32. ISBN 978-92-893-1728-3.
16. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*, 17. udg. København: Nyt Nordisk Forlag, 2009, kap. 75. ISBN 978-87-17-03933-9.
17. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Informerat samtykke ved mammografiscreening. I: Brodersen J, Hovelius B, Hvas L, eds. *Skapar vården ohälsa? Allmänmedicinske reflektioner*. Lund: Studentlitteratur AB, 2009:167-75.
18. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. I: Brodersen J, Hovelius B, Hvas L, eds. *Kan sundhedsvæsenet skabe usundhed? Refleksioner fra almen praksis*. København: Månedsskrift for Praktisk Lægegerning, 2009:153-162.
19. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. *Medicinsk Kompendium*. 18. udg. København: Nyt Nordisk Forlag; 2013, kap. 73.
20. Gøtzsche PC. Overdiagnostik og overbehandling i psykiatrien. I: Brinkmann S and Petersen, eds. *Diagnoser*. Aarhus: Klim; 2015:kapitel 7.
21. Gøtzsche PC. Psychopharmacology is not evidence-based medicine. In: Davies J, ed. *The Sedated Society*. London: Palgrave Macmillan; 2017:23-50.
22. Gøtzsche PC, Lund K. Intet kunnskapsgrundlag for tvangsmedisinering. In: Kolstad A, Kogstad R, eds. *Medikalisering av psykosociale problemer*. Oslo: Abstrakt Forlag; 2019: 175-210.

Correspondence, book reviews and similar

1. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. *Ugeskr Læger* 1984;146:207.
2. Gøtzsche PC. Turnusordningen - eller hvordan tre måneder bliver til ingenting. *Ugeskr Læger* 1984;146:2765.
3. Gøtzsche PC, Karlsen FØ. Buprenorfin og morfin. *Ugeskr Læger* 1985;147:1786.
4. Gøtzsche PC, Bygbjerg IC. Leverbiopsi ved AIDS? *Ugeskr Læger* 1988;150:173-4.
5. Gøtzsche PC. Enalapril, atenolol, and hydrochlorothiazide in hypertension. *Lancet* 1986;iii:38-9.
6. Gøtzsche PC, Karlsen FØ. Lodtrækningsprincippet. *Ugeskr Læger* 1988;150:1899-1990.
7. Gøtzsche PC, Hørding M. Kondomers sikkerhed. *Ugeskr Læger* 1988;150:1000.
8. Gøtzsche PC, Hørding M. Kondomers sikkerhed. *Ugeskr Læger* 1988;150:1697.
9. Gøtzsche PC. Ditiocarb in HIV infection. *Lancet* 1988;Oct 29:1024.

10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. (U)videnskabeligt bogholderi. Ugeskr Læger 1989;151:901.
11. Gøtzsche PC. Forskningsmetodologisk lærestykke 2. Ugeskr Læger 1989;151:319.
12. Gøtzsche PC. Forskningsmetodologiske lærestykker 4. Vurdering af korrelationer. Ugeskr Læger 1989;151:456-7.
13. Gøtzsche PC (book review). Duodenal ulcer. Analyses of 293 randomized trials. Stat Med 1990;9:1225-6.
14. Rosenberg R, Gøtzsche PC. Urigtig påstand om naturmedicin. Ugeskr Læger 1991;153:3027.
15. Gøtzsche PC (boganmeldelse). Schou I, ed. Good clinical practice. Kvalitetskrav til klinisk undersøgelse. Ugeskr Læger 1991;153:3636.
16. Gøtzsche PC. P-piller giver ikke brystkræft. Ugeskr Læger 1992;154:1437.
17. Gøtzsche PC. Kommentar (til artikel om placebo). Ugeskr Læger 1992;154:2452.
18. Gøtzsche PC. Placeboeffekt? Ugeskr Læger 1992;154:3006.
19. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine and weight loss. BMJ 1993;307:446-7.
20. Gøtzsche PC. Trials of homeopathy. Lancet 1993;June 12:1533.
21. Gøtzsche PC. Zidovudine dosage. BMJ 1993;307:682-3.
22. Gøtzsche PC. Randomiseret undersøgelse af oxytocin? Ugeskr Læger 1994;156:201.
23. Gøtzsche PC (boganmeldelse). Skrabanek P, McCormick J. Follies and fallacies in medicine, anden udgave. Ugeskr Læger 1994;156:7386.
24. Gøtzsche PC. Metaanalyse af magnesiumbehandling af myokardieinfarkt. Ugeskr Læger 1995;157:2727-8.
25. Gøtzsche PC (book review). Xenotransplantation. J Med Ethics 1995:190-1.
26. Gøtzsche PC (boganmeldelse). Chalmers I, Altman DG, eds. Systematic reviews. Ugeskr Læger 1995;157:4364-5.
27. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering? Ugeskr Læger 1996;158:6291-2.
28. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. Ugeskr Læger 1997;159:68-9.
29. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering II. Ugeskr Læger 1997;159:70-1.
30. Gøtzsche PC, Johansen HK. Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. BMJ 1997;315:489.
31. Johansen HK, Gøtzsche PC. Meta-analysis of prophylactic or empirical antifungal therapy in cancer with neutropenia. Topics Supp Care Oncol 1997;26:9-10.
32. Johansen HK, Gøtzsche PC. Use of odds ratio in calculation of number needed to treat was inappropriate. BMJ 1997;315:879.
33. Gøtzsche PC. Screening for colorectal cancer. Lancet 1997;349:356.
34. Gøtzsche PC. Greenhalgh T: How to read a paper: the basics of evidence based medicine (boganmeldelse). Ugeskr Læger 1998;160:305-6.
35. Gøtzsche PC. Løgn, forbandet løgn og ... metaanalyse (svar). Ugeskr Læger 1998;160:896-7.
36. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding. Lancet 1998;351:911.
37. Gøtzsche PC, Johansen HK. Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ 1998;316:1606-7.
38. Gøtzsche PC. Statusartikel om antibiotikas effekt ved halsbetændelse. Ugeskr Læger 1998;160:5376.
39. Gøtzsche PC. Hvad er relationen mellem randomiserede forsøg og evidensbaseret medicin? Ugeskr Læger 1999;161:624.
40. Gøtzsche PC. Probability without equations (book review). Stat Med 1999;18:622-3.
41. Gøtzsche PC, Hammarquist C, Burr M. Control of house dust mite in managing asthma. BMJ 1999;318:871.
42. Gøtzsche PC. Var zoneterapiforsøget randomiseret? Ugeskr Læger 1999;161:2224.
43. Gøtzsche PC. Cochranologiens vokseværk. Ugeskr Læger 1999;161:2690-1.
44. Gøtzsche PC. Om Cochrane og brugen af albumin. Ugeskr Læger 1999;161:5552-4.
45. Gøtzsche PC. Skal radikal prostatektomi indføres? Ugeskr Læger 1999;161:3472-3.
46. Gøtzsche PC. Radikal prostatektomi er udokumenteret. Ugeskr Læger 1999;161:5691-2.

47. Gøtzsche PC, Olsen O. Screening mammography re-evaluated. *Lancet* 2000;355:752.
48. Johansen HK, Gøtzsche PC. Improving the conduct and reporting of clinical trials. *JAMA* 2000;283:2789.
49. Gøtzsche PC. "Skarp kritik af mammografiscreening"(svar). *Ugeskr Læger* 2000;162:817.
50. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed. *Läkartidningen* 2000;97:3105-6.
51. Gøtzsche PC, Olsen O. God begrundelse for mammografiscreening. *Ugeskr Læger* 2000;162:4166-7.
52. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. *BMJ* 2000;321:568-9.
53. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed (author's reply). *Läkartidningen* 2000;97:3105.
54. Gøtzsche PC, Olsen O. More on mammography. *Lancet* 2000;356:1276.
55. Gøtzsche PC. Albumin: et vigtigt princip i behandlingen af dekompenaseret leversygdom (svar). *Ugeskr Læger* 2001;163:63-4.
56. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? *Ugeskr Læger* 2001;163:1576.
57. Gøtzsche PC. Er evidensbaseret medicin evidensbaseret? (svar). *Ugeskr Læger* 2001;163:182.
58. Gøtzsche PC, Olsen O. Postoperativ strålebehandling øger mortaliteten hos kvinder, der får diagnosticeret brystkræft ved screening. *Läkartidningen* 2001;98:347.
59. Wille-Jørgensen PA, Gøtzsche PC. Angående evidensbaseret kirurgi (svar). *Ugeskr Læger* 2001;163:1450.
60. Pedersen T, Møller AM, Gøtzsche PC. Albumin, evidens og metaanalyse: kan dommen appelleres (svar)? *Ugeskr Læger* 2001;163:1719-20.
61. Gøtzsche PC. Mortalitet efter humant albumin. *Ugeskr Læger* 2001;163:2260-1.
62. Gøtzsche PC. Debate on screening for breast cancer is not over. *BMJ* 2001;323:693.
63. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? *N Engl J Med* 2001;345:1278-9.
64. Gøtzsche PC. Office of NHS cancer screening programme misrepresents Nordic work in breast screening row. *BMJ* 2001;323:1131.
65. Gøtzsche PC. Cochrane-rapport om mammografiscreening. *Ugeskr Læger* 2001;163:6768.
66. Pildal, Gøtzsche PC. Kritikken er berettiget. *Läkartidningen* 2001;98:5625.
67. Gøtzsche PC. Screening for breast cancer with mammography. *Lancet* 2001;358:2167-8.
68. Gøtzsche PC. Kritik af Cochrane-oversigt om screening med mammografi er uberettiget. *Ugeskr Læger* 2002;164:653-4.
69. Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues *Eur J Cancer* 2001, 37, 2435-2440. *Eur J Cancer* 2002;38:1288.
70. Gøtzsche PC. Update on effects of screening mammography. *Lancet* 2002;360:338-9.
71. Gøtzsche PC. Terlipressin for acute esophageal variceal hemorrhage. Comment on Cochrane Review. In: *The Cochrane Library*, Issue 3. Oxford: Update Software; 2002.
72. Gøtzsche PC. Beyond randomized controlled trials. *Cancer* 2002;94:578.
73. Gøtzsche PC. Mammographic screening: no reliable supporting evidence? *Lancet* 2002;359:706.
74. Gøtzsche PC. Alarmerande att screeningsförsöken inte ger minskad cancerdödlighet. *Läkartidningen* 2002;99:945.
75. Hróbjartsson A, Gøtzsche PC. Placebo og bevisbyrde. *Ugeskr Læger* 2002;164:1525-6.
76. Gøtzsche PC. Misvisende fremstilling af vort arbejde om screening med mammografi. *Läkartidningen* 2002;99:75-6.
77. Gøtzsche PC. Albumin ved dekompenaseret levercirrose. *Ugeskr Læger* 2002;164:1203-4.
78. Gøtzsche PC. Screening mammography: setting the record straight. *Lancet* 2002;359:440-1.
79. Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme. <http://bmj.com/cgi/eletters/325/7361/418#24972>, 26 Aug 2002.
80. Gøtzsche PC. How to swallow one's words with a standard deviation. <http://bmj.com/cgi/eletters/325/7366/682#26186>, 11 Oct 2002.
81. Gøtzsche PC. Grønt lys for udokumenteret behandling. *Ugeskr Læger* 2002;164:3568-9.
82. Gøtzsche PC. WHO og The Lancet: ja til mammografiscreening (svar). *Ugeskr Læger* 2002;164:3082-3.

83. Gøtzsche PC. Invited reponse to "The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche". *J Surg Oncol* 2002;81:162-3.
84. Gøtzsche PC. Placebokirurgi: artroskopisk lavage og débridement ved slidgigt. *Ugeskr Læger* 2002;164:5151.
85. Gøtzsche PC. Kræftens Bekæmpelse, screening og troværdigheden. *Ugeskr Læger* 2003;165:611-2.
86. Gøtzsche PC. Screening mammography and mortality. *Med J Aust* 2003;178:189-90.
87. Gøtzsche PC, Hartling O. Er oplysninger om brystkræftscreening troværdige? *Ugeskr Læger* 2003;165:1068-70.
88. Gøtzsche PC. Uærlighed i lægemiddelafprøvninger koster samfundet dyrt. *Ugeskr Læger* 2003;165:1691-2.
89. Gøtzsche PC. Breast cancer screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention (book review). *Int J Epidemiol* 2003;32:472.
90. Gøtzsche PC. Screening for breast cancer. *Ann Intern Med* 2003;138:769-70.
91. Gøtzsche PC, Hartling O. Svar på debatindlæg "Mister kvinder unødigt brystet, hvor der screenes for brystkræft?". *Ugeskr Læger* 2003;165:2586-7.
92. Gøtzsche PC. Uærlighed i lægemiddelafprøvninger koster samfundet dyrt (svar). *Ugeskr Læger* 2003;165:2673-4.
93. Gøtzsche PC, Hartling O. Svar på "Ingen evidens for at mammografiscreening fører til overbehandling". *Ugeskr Læger* 2003;165:3026-7.
94. Gøtzsche PC. Uærlighed i lægemiddelforskning og Cochrane Centeret (svar). *Ugeskr Læger* 2003;165:3098-9.
95. Gøtzsche PC. Skadelig screening for kræft. *Politiken* 2003; 1. juni, 3. sektion, s. 9.
96. Gøtzsche PC. Mammographic screening for breast cancer. *N Engl J Med* 2003;349:611.
97. Gøtzsche PC. Mortality reduction by breast-cancer screening. *Lancet* 2003;362:246.
98. Gøtzsche PC. Mammographic service screening and mortality. *Lancet* 2003;362:329-30.
99. Gøtzsche PC. Hvornår er noget skadeligt? *Politiken* 2003; 31. august, 3. sektion, s. 9.
100. Hróbjartsson A, Gøtzsche PC. Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. *Pain* 2003;104:714-5.
101. Gøtzsche PC. "Behandlingen er veldokumenteret". *Politiken* 2003; 5. oktober, 3. sektion, s. 9.
102. Gøtzsche PC. Medicinalindustrien har alt for let spil. *Politiken* 2003; 23. november, 3. sektion, s. 9.
103. Gøtzsche PC. Ikke-evidensbaseret kommentar om nytten af madrasbetræk ved astma med husstøvmideallergi. *Ugeskr Læger* 2003;165:4234-5.
104. Gøtzsche PC, Johansen HK, Burr M. Are encasings effective in asthma caused by house dust mite allergens (letter)? *J Allergy Clin Immunol* 2003;112:220.
105. Gøtzsche PC. Martin Bland and Janet Peacock, *Statistical questions in evidence-based medicine* (book review). *Stat Med* 2003;22:2817-20.
106. Gøtzsche PC. Hendes Majestæt Dronning Ingrid XI Festforelæsning, 2003. *SØLK* 2003;27(9):16-20.
107. Gøtzsche PC. Ondt i ryggen og muskelrelaksantia (reply). *Ugeskr Læger* 2004;166:1034.
108. Jørgensen KJ, Gøtzsche PC. Websites on screening for breast cancer (authors' reply). *BMJ* 2004;328:769-70.
109. Gøtzsche PC. Vær forsigtig med videnskabelig uredelighed. *Politiken* 2004; 25. januar, 3. sektion, s. 9.
110. Gøtzsche PC, Vestergård B. Åbent bibliotek om virkninger og bivirkninger. *Politiken* 2004; 9. maj, 3. sektion, s. 9.
111. Gøtzsche PC. What to conclude when treatments are harmful. *CoRect News, Newsletter, The Cochrane Colorectal Cancer Group* 2004;8:2-4.
112. Hróbjartsson A, Gøtzsche PC. Tesen om the powerless placebo. *Ugeskr Læger* 2004;166:2693-4.
113. Jørgensen KJ, Gøtzsche PC. Overfortolkning af inkonklusivt populationsstudie om brystkræft. *Ugeskr Læger* 2004;166:2822.
114. Gøtzsche PC. Kreativ markedsføring af margarine og medicin. *Politiken* 2004; 15. aug., 3. sektion, s. 9.
115. Gøtzsche P. Niels Finsen's treatment for lupus vulgaris. *James Lind Library* (www.jameslindlibrary.org). © Peter Gøtzsche, 2004.
116. Gøtzsche PC. Re: Trends in the treatment of ductal carcinoma *in situ* of the breast. *J Natl Cancer Inst* 2004;96:1257.

117. Gøtzsche PC, Jørgensen KJ. Mammografiscreening uden overdiagnostik (reply). Ugeskr Læger 2004;166:3737-8.
118. Gøtzsche PC, Møller A, Pedersen T. Albumin eller fysiologisk saltvand til volumendepleterede intensivpatienter? Ugeskr Læger 2004;166:3835.
119. Gøtzsche PC, Hróbjartsson A. Undocumented editorial on placebos. <http://bmj.bmjournals.com/cgi/eletters/329/7472/927>, 2004.
120. Gøtzsche PC. Reply: What to conclude when treatments are harmful (reply). CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8(2):4.
121. Gøtzsche PC. Misleading quotations and other errors persist in rejoinder on breast cancer screening. Int J Epidemiol 2004;33:1404.
122. Gøtzsche PC. Does exercise training lower mortality in patients with chronic heart failure? <http://bmj.bmjournals.com/cgi/eletters/328/7433/189>, 2005.
123. Gøtzsche PC, Jørgensen KJ, Thornton H. Benefits and harms of breast cancer screening. <http://bmj.bmjournals.com/cgi/eletters/330/7485/220>, 2005.
124. Gøtzsche PC, Jørgensen KJ, Hartling O. Mammografiscreening - igen. Ugeskr Læger 2005;167:783-4.
125. Gøtzsche PC, Wille-Jørgensen P. Ghost authorship in evidence-based medicine. <http://bmj.bmjournals.com/cgi/eletters/330/7484/163>, 2005.
126. Gøtzsche PC, Jørgensen KJ. Outcomes of screening mammography: information to support informed choices. <http://bmj.bmjournals.com/cgi/eletters/bmj.38398.469479.8Fv1>, 2005.
127. Gøtzsche PC. Reporting bias: any consequences for Methods and Results sections in Cochrane Reviews? Cochrane News 2005;33:1+8. Also published in: The Cochrane Collaboration Methods Groups Newsletter 2005;9:5.
128. Gøtzsche PC. Screening for brystkræft. Ugeskr Læger 2005;167:1871.
129. Gøtzsche PC, Jørgensen KJ, Thornton H. Presentation of benefits and harms needs to be balanced. BMJ 2005;330:1024.
130. Pedersen T, Møller AM, Gøtzsche PC. Human albumin in critically ill patients. Crit Care Med 2005;33:1183.
131. Gøtzsche PC. Klinisk interventionsforskning: to ledere og et indlæg. Ugeskr Læger 2005;167:2308-9.
132. Gøtzsche PC, Jørgensen KJ. Information needs to support informed choices. BMJ 2005;331:350-1.
133. Gøtzsche PC. Uafhængig klinisk interventionsforskning - eller evidence biased medicine? Ugeskr Læger 2005;167:2916-7.
134. Gøtzsche PC. ALLHAT - epokegørende? Ugeskr Læger 2005;167:3422-3.
135. Gøtzsche PC. The mammography controversy (book review). Lancet 2005;366:1519-20.
136. Gøtzsche PC, Johansen HK. Misleading statements in industry-sponsored meta-analysis of itraconazole. J Clin Oncol 2005;23:9428-9.
137. Gøtzsche PC. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005; 15 Oct: DOI 10.1002/ijc.21632 (and 2006;118:2648).
138. Gøtzsche PC. Screening and breast cancer. N Engl J Med 2006;354:768.
139. Gøtzsche PC. Ramifications of screening for breast cancer: overdiagnosis in the Malmö trial was considerably underestimated. BMJ 2006;332:727.
140. Haug C, Gøtzsche PC, Schroeder TV. Clinical trials report card (reply). N Engl J Med 2006;354:1429.
141. Gøtzsche PC, Jørgensen KJ. Estimate of harm/benefit ratio of mammography screening was five times too optimistic. <http://bmj.bmjournals.com/cgi/eletters/332/7543/691>, 2006.
142. Hróbjartsson A, Gøtzsche PC. Follow-up commentary. J Clin Epidemiol 2006;59:340-1.
143. Gøtzsche PC. Disclosures should not be delayed. WHO International Clinical Trials Registry Platform (ICTRP) 2006, March 31 (http://www.who.int/ictrp/006-Peter_Gøtzsche_31March06.pdf)
144. Gøtzsche PC. No double standards in research, please. <http://bmj.bmjournals.com/cgi/eletters/333/7564/374>, 2006.
145. Gøtzsche PC, Jørgensen KJ. Mammografiscreening - ideologi kontra videnskab (svar). Ugeskr Læger 2006;168:2263-5.
146. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur. Ugeskr Læger 2006;168:3635.
147. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur 2. Ugeskr Læger 2006;168:4331-2.

148. Hróbjartsson A, Gøtzsche PC. Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? *Am J Hypertens* 2006;19:655.
149. Gøtzsche PC, Hróbjartsson, Marić K, Tendal B. Comment on Cochrane review CD004878. *Cochrane Database of Systematic Reviews* 2007.
150. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews and other meta-analyses, authors' reply. <http://bmj.bmjournals.com/cgi/eletters/333/7572/782>, 2006.
151. Gøtzsche PC. Mammography screening leads to an increase in mastectomies, not a decrease. <http://www.annals.org/cgi/eletters/146/7/511>, 2007.
152. Gøtzsche PC. Comment on: A Martí-Carvajal, G Salanti, AF Cardona. Human recombinant activated protein C for severe sepsis. *Cochrane Database of Systematic Reviews* 2007, Issue 3. Art. No.: CD004388.
153. Gøtzsche P, Hróbjartsson A, Johansen HK, Altman DG, Chan AW. Criticism is unwarranted: Please read our paper again. September 12, 2007. <http://medicine.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pmed.0040019#r1759>, 2007.
154. Gøtzsche PC. Asthma guidelines on house dust mites are not evidence-based. *Lancet* 2008; 370(9605):2100-1.
155. Gøtzsche PC. Mammographic screening from age 40 years. *Lancet* 2007; 369(9563):737-8.
156. Gøtzsche PC, Bjarnason NH. COX-2 inhibitor. *Rheumatology (Oxford)* 2007; 46(10):1623-4.
157. Gøtzsche PC, Maehlen J, Zahl PH. Undeclared motives in withdrawing a publication. *Lancet* 2007; 369(9574):1690.
158. Gøtzsche PC. Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). *Int J Nurs Stud* 2008; 45(9):1398.
159. Gøtzsche PC. [Non-useful cancer survival statistics following the Danish Cancer Control Plan]. *Ugeskr Laeger* 2008; 170(43):3442.
160. Gøtzsche PC. Osteoarthritis of the knee: Topical NSAIDs have unknown effectiveness. *BMJ* 2008; 336(7640):344.
161. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Comment on review of intercessory prayer for the alleviation of ill health (Roberts L, Ahmed I, Hall S. Intercessory prayer for the alleviation of ill health). *Cochrane Database of Systematic Reviews* 2009, Issue 2. Art. No.: CD000368.
162. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Estimate of breast screening benefit was 6 times too large. http://www.bmj.com/cgi/eletters/338/jan27_2/b86. 2009.
163. Gøtzsche PC, Jørgensen KJ. Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong. http://www.bmj.com/cgi/eletters/338/jan27_2/b86#212985. 2009.
164. Gøtzsche P. Are new drugs for schizophrenia better than old ones? *Lancet* 2009;373:1248.
165. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening. *Br J Cancer* 2009;100(1):219.
166. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. *J Clin Oncol* 2009;27(4):639-40.
167. Gøtzsche PC. Quackery, chiropractic and alternative medicine. *BMJ* 2009: http://www.bmj.com/cgi/eletters/339/jul08_4/b2766.
168. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Svar til Lif. *Ugeskr Læger* 2009;171:1308.
169. Hróbjartsson A, Gøtzsche PC. Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low. *BMJ rapid responses* (17 March); 2009.
170. Hróbjartsson A, Gøtzsche PC. Authors' reply: The quality of the acupuncture interventions was considered in our systematic review. *BMJ rapid responses* (5 October); 2009.
171. Hróbjartsson A, Gøtzsche PC. Effect of acupuncture and placebo acupuncture. *BMJ rapid responses* (3 March); 2009.
172. Hróbjartsson A, Gøtzsche PC. Reply to Linde. *FACT* 2009;14:105.
173. Gøtzsche PC, Johansen HK. Authors' reply on 'House dust mite control measures for asthma'. *Allergy* 2009;64:190.
174. Jørgensen KJ, Brodersen J, Nielsen M, Hartling OJ, Gøtzsche PC. Fall in breast cancer deaths. A cause for celebration, and caution. *BMJ*. 2009 May 27;338:b2126.

175. Jørgensen KJ, Gøtzsche PC. Fundamental mistakes in estimate of lives saved by breast screening. *BMJ* 2009; http://www.bmj.com/cgi/eletters/339/jul21_2/b2922.
176. Jørgensen KJ, Gøtzsche PC. Fundamental errors in estimate of lives saved by screening. *BMJ* 2009 Aug 25;339:b3359.
177. Jørgensen KJ, Gøtzsche PC. It is time for a new paradigm for overdiagnosis with screening mammography. http://www.bmj.com/cgi/eletters/339/jul09_1/b2587.
178. Jørgensen KJ, Gøtzsche PC. Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows. http://www.bmj.com/cgi/eletters/339/aug25_1/b3359#220390.
179. Jørgensen KJ, Gøtzsche PC. Overdiagnosis with breast screening was seriously underestimated. http://www.annals.org/content/151/10/727.full/reply#annintmed_el_120127. 2009, 20 Nov.
180. Gøtzsche PC, Johansen HK. Alpha1-antitrypsin deficiency. *N Engl J Med*. 2009;361(21):2101-2.
181. Gøtzsche PC, Jørgensen KJ. [Overdiagnosis with mammography screening is a serious problem]. *Lakartidningen*. 2009;106(47):3180.
182. Jørgensen KJ, Gøtzsche PC. No visible effect of mammography screening in Denmark. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
183. Jørgensen KJ, Gøtzsche PC. Mammography screening hasn't lived up to expectations. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
184. Gøtzsche PC. Overdiagnosis with mammography screening is around 25-50%, not 10%. http://www.bmj.com/cgi/eletters/340/jun24_1/c3106.
185. Gøtzsche P. Depression severity and effect of antidepressant medications. *JAMA* 2010 Apr 28;303(16):1597.
186. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. *Ugeskr Laeger* 2010 Mar 1;172(9):733.
187. Jørgensen KJ, Gøtzsche PC. The background review for the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010 Apr 20;152(8):538-9.
188. Jørgensen KJ, Gøtzsche PC. Where is the effect of mammography screening? *BMJ* 2010. http://www.bmj.com/cgi/eletters/341/aug11_1/c3620.
189. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, et al. Breast cancer awareness month. Still awaiting screening facts. *BMJ* 2010;341:c6152.
190. Gøtzsche PC, Lundh A. [The rheumatologists' conflict of interest and biological medicines]. *Ugeskr Laeger* 2010;172(45):3126.
191. Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. *J Med Screen* 2010;17(3):158-9.
192. Gøtzsche PC. Lessons from the mammography wars. *N Engl J Med* 2010;363(26):2569.
193. Gøtzsche PC, Jørgensen KJ. Kopans, Smith and Duffy Misrepresent Facts about Mammographic Screening. *Radiology* 2011; http://pubs.rsna.org/doi/suppl/10.1148/radiol.11110716/suppl_file/110716supp.pdf.
194. Gøtzsche PC, Lundh A. Vigtig deklarerer af interessekonflikter. *Dagens Medicin* 2011;13:27.
195. Gøtzsche PC. [Control should be counteracted]. *Ugeskr Laeger* 2011;173(33):1991.
196. Gøtzsche PC. Mammography screening ten years on: reflections on a decade since the 2001 review. *The Cochrane Collaboration* 2011; <http://www.cochrane.org/news/blog/mammography-screening-ten-years-reflections-decade-2001-review>.
197. Gøtzsche PC. Stop medicinudgifternes himmelflugt. *Politiken* 5 marts 2011. <http://politiken.dk/debat/kroniker/ECE1214179/stop-medicinudgifternes-himmelflugt/>
198. Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. *BMJ* 2011;343:d4203.
199. Gøtzsche PC. Unreliable studies are quoted instead of reliable ones. *CMAJ* 2011;183:1957-8.
200. Jørgensen KJ, Gøtzsche PC. Elementary flaws in the FH01 study. *Lancet Oncol* 2011;12(3):215-6.
201. Jørgensen KJ, Gøtzsche PC. The proposed review will not be independent without NICE. *BMJ* 2011;343:d7533.
202. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Leibovici's non-study must be excluded from the Cochrane review. <http://www.cochranefeedback.com/cf/cda/citation.do?id=10133#10133> 2011;
203. Jørgensen KJ, Zahl PH, Gøtzsche PC. More on screening mammography. *N Engl J Med* 2011;364(3):284-6.

204. Krogsboll LT, Jørgensen KJ, Gøtzsche PC. [Should the population be offered general health screenings?]. *Ugeskr Laeger* 2011;173(23):1671.
205. Lunde IM, Gøtzsche PC. [Transparency, reliability and conflict of interest]. *Ugeskr Laeger* 2011;173(33):1989.
206. Gøtzsche PC. Psykiaterne har ukritisk accepteret ssri-præparaterne. *Dagens Medicin* 2011; <http://www.dagensmedicin.dk/opinion/debat/psykiaterne-har-ukritisk-accepteret-ssri-præparaterne/>.
207. Gøtzsche PC. RE: Peter Gøtzsche burde anerkende det vigtige forskningssamarbejde, der foregår mellem læger og medicinalindustrien. *Ugeskr Laeger* 2011;173(8):599-600.
208. Gøtzsche PC. Selektiv rapportering er et stort problem. *Ugeskr Laeger* 2011;173(15):1154.
209. Gøtzsche PC. Vigtig debat om gavnlige og skadelige virkninger. *Dagens Medicin* 2011;14:29.
210. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
211. Gøtzsche PC, Jørgensen KJ. RE: RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. *BMJ* 2011;343:d7017.
212. Gøtzsche PC. Cancer specific mortality is biased in breast screening trials. *BMJ* 2011;343:d6395.
213. Gøtzsche PC. Total mortality should be the primary outcome in cancer screening trials. *BMJ* 2011;(343):d6397.
214. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. RE: Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011;343:d4692.
215. Gøtzsche PC. Kopans' arguments are untruthful. 2011 Aug 18. Available at: www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dwom%26pag%3ddis%26ItemID%3d96204 (accessed 1 Sept).
216. Gøtzsche PC. Etisk analyse på automatpilot. *Dagens Medicin* 2012; <http://www.dagensmedicin.dk/blog/kristians-blog/blog-etisk-analyse-pa-automatpilot/>.
217. Jørgensen KJ, Gøtzsche PG. Breast Cancer Screening. An independent review is under way. *BMJ* 2012; 24 April. <http://www.bmj.com/content/343/bmj.d6843?tab=responses>
<http://www.bmj.com/content/343/bmj.d6843/rapid-responses>.
218. Jørgensen KJ, Keen JD, Zahl PH, Gøtzsche PC. The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. *Radiology* 2012;262:729-30.
219. Gøtzsche PC. Why does the BMJ support donations of pulse oximeters when they have no effect? *BMJ* 2012;344:e409.
220. Gøtzsche PC, Jørgensen KJ. Effect of population-based screening on breast cancer mortality. *Lancet* 2012;379:1297.
221. Jørgensen KJ, Gøtzsche PC. Mammografiscreening redder ikke liv. *Dagens Medicin* 2012;28 Sept.
222. Gøtzsche PC. Screening for tvangstanker, depression og ADHD?. *Ugeskr Læger* 2013;175:77.
223. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ* 2013;346:f398.
224. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013;368:677-8.
225. Gøtzsche PC. The EMA should continue its new openness policy despite current lawsuits. <http://www.bmj.com/content/346/bmj.f2961?tab=responses> 2013;21 June.
226. Gøtzsche PC, Maund E. Re: Restoring invisible and abandoned trials: a call for people to publish the findings. <http://www.bmj.com/content/346/bmj.f2865/rr/650915> 2013;21 June.
227. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. *BMJ* (Online) 2013;347:f7569.
228. Gøtzsche PC. Developing a new drug costs less than \$100m, not \$900m. *BMJ* 2013;346:f398.
229. Gøtzsche PC. Roche continues to drag its feet on access to Tamiflu data. *BMJ* (Online) 2013;346:f3001.
230. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. *N Engl J Med* 2013;368:677-8.
231. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. *Int J Cancer* 2013;132:1725-6.

232. Krogsbøll L, Juhl Jørgensen K, Gøtzsche PC. Social ulighed i sundhed. Ugeskr Læger 2013;175:74-5.
233. Zahl P-H, Suhrke P, Jørgensen KJ. Overdiagnosis of breast cancer in Norway: what have the authors adjusted for? Int J Cancer 2013;133:2754-5.
234. Gøtzsche PC. Nye cancermidler er ikke bedre end gamle. Ugeskr Læger 2013;175:2138.
235. Gøtzsche PC. Screening for tvangstanker, depression og ADHD? Ugeskr Læger 2013;175:77.
236. Gøtzsche PC. Tvivlsomt om lokalt appliceret NSAID har nogen effekt. Ugeskr Læger 2013;175:377-8.
237. Gøtzsche PC. Vildledning fra Kræftens Bekæmpelse om mammografiscreening. Ugeskr Læger 2013;175:1056.
238. Gøtzsche PC. Vores forskning om lægemiddelindustrien er veldokumenteret. Ugeskr Læger 2013;175:3048.
239. Gøtzsche PC. Der er ikke effekt af drotrecogin alfa ved svær sepsis. Ugeskr Læger 2013;175:903-4.
240. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. Lancet 2013;381:799.
241. Krogsbøll LT, Jørgensen KJ. Helbredstjek - igen. Ugeskr Læger 2013;175:532.
242. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Universal health checks should be abandoned. BMJ (Online) 2013;347:f5227.
243. Gøtzsche PC. Mammography screening increases non-breast cancer mortality. Trials 2013;14:368.
244. Gøtzsche PC. The drug industry is similarly harmful as the tobacco industry. BMJ 2013;347:f5193.
245. Gøtzsche PC. Treatment of urinary incontinence with antimuscarinic drugs is pointless. BMJ 2013;347:f5170.
246. Gøtzsche PC. "I don't want the truth, I want something I can tell Parliament!" BMJ 2013;347:f5222.
247. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Health check check. The Times 2013;Aug 20:25.
248. Gøtzsche PC. Incorrect statements by Novo Nordisk. BMJ 2013;347:f4386.
249. Gøtzsche PC. SSRI kan føre til selvmord. Dagens Medicin 2013;3Maj .
250. Gøtzsche PC. Whistleblowere skal beskyttes. Berlingske 2013;5Aug:21.
251. Gøtzsche PC. GlaxoSmithKline and Roche won't disclose their results. BMJ 2013;346:f819.
252. Gøtzsche PC. Comment on risk of bias tool. www.thecochranelibrary.com/details/editorial/5655441.2014;10 Jan.
253. Gøtzsche PC. Medicinalindustriens mange løgne. Jyllands-Postens kronik 2014;4 Jan..
254. Gøtzsche PC. Psykiatri på afveje. Politiken, kronik, 2014;6 Jan.
255. Gøtzsche PC. Lykkepille-epidemien: skyd ikke budbringeren, men se budskabet. www.epracticus.dk/flx/debat/?FID=2&MID=30 ?. 2014;13 Jan.
256. Gøtzsche PC. Toneangivende psykiatere er fortsat på afveje. Politiken, kronik, 2014;21 Jan .
257. Gøtzsche PC. Brug psykofarmaka mindre og bedre. Weekendavisen 2014;31 Jan.
258. Gøtzsche PC. Vi skal bruge mindre psykofarmaka. Ugeskriftet.dk 2014;6 Feb .
259. Gøtzsche PC. Om statistik og bias. Ugeskr Læger 2014;176:273.
260. Gøtzsche PC. Unwarranted criticism of "Psychiatry Gone Astray". davidhealy.org/get-real-peter-gotzsche-responds/ 2014;17 Feb .
261. Gøtzsche PC. Vildledende forskning og markedsføring. Ugeskr Læger 2014;176:373.
262. Gøtzsche PC. Fejlцитeringer om psykiatri. Berlingske 2014;23 Feb.
263. Gøtzsche PC. Fup eller fakta om dødelig medicin. Dagens Medicin 2014;28 Feb .
264. Gøtzsche PC. Screening virker ikke. Jyllands-Posten 2014;8 Mar.
265. Gøtzsche PC. Screening af gravide for depression. Månedsskr Almen Praksis 2014;326-8.
266. Auken M, Gøtzsche PC. Kun via EU sikrer vi åbenhed i medicinalindustrien. Information 2014;5 April.
267. Auken M, Gøtzsche PC. Hyklerisk medicinalindustri. Information 2014;9 April.
268. Gøtzsche PC. Misvisende oplysninger om Cochrane. Altinget 2014;8 April.
269. Gøtzsche PC. Lægger ikke luft til mig. Politiken 2014;9 April.
270. Gøtzsche PC. Cochrane-fjeren, der blev til fem høns. Dagens Medicin 2014;11 April.
271. Gøtzsche PC. Antidepressiv medicin bør undgås til børn og unge. OCD-nyt 2014;1-14:7.
272. Gøtzsche PC. Nyhed om Cochrane var misvisende. <http://ugeskriftet.dk/nyhed/cochrane-laegger-afstand-til-goetzsche#comment-354>. 2014;8 Apr.

273. Gøtzsche PC. Adverse effects of statins are very common. 2014;21 May .
www.bmj.com/content/348/bmj.g3306/rr/698864.
274. Gøtzsche PC. Sundhedstjek: Den politiserende Sundhedsstyrelse. Dagens Medicin 2014;10 Okt.
275. Bewley S, Rose L, Gøtzsche P, Blennerhassett M, Colquhoun D, Pryke M, et al. Time to halt an out of control trial with ineffective oversight. B M J (Online) 2014;349:g5601.
276. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. B M J (Online) 2014;349:g4790.
277. Gøtzsche PC. Muscular adverse effects are common with statins. BMJ (Online) 2014;348:g3724.
278. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. General health checks don't work. BMJ (Online) 2014;348:g3680.
279. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. J R Soc Med 2014;107:256-7.
280. Gøtzsche PC. Study of study of changes in antidepressant use after FDA warnings is not reliable. BMJ (Online) 2014;349:g5623.
281. Gøtzsche PC, Jørgensen KJ, Zahl P-H. Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. JACR 2014;11:1098.
282. Gøtzsche PC. Przepisywane leki przyczyną zgonu rzeszy pacjentów. Pol Arch Med Wewn 2014;124:750-6.
283. Gøtzsche PC. Antidepressiva bør ikke bruges til børn og unge. Ugeskr Læger 2015;18 Maj.
284. Gøtzsche PC. Atomoxetin til ADHD er værre end sit rygte. Ugeskr Læger 2015;177:1301-2.
285. Gøtzsche PC. Author's reply to Tovey and colleagues. BMJ 2015;350:h2955.
286. Gøtzsche PC. Comment on "Our prescription drugs kill us in large numbers". Author's reply. Pol Arch Med Wewn 2015;125:106-7.
287. Gøtzsche PC. Correction to "Author's reply to Tovey and colleagues". BMJ 2015;350:h3138.
288. Gøtzsche PC. Days tomme postulater om psykiatrien. Berlingske Tidende 2015;12 Sep;16.
289. Gøtzsche PC. Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin 2015;9 Okt;16:1.
290. Gøtzsche PC. Hvor stor en rolle spiller antipsykotika i overdødeligheden ved skizofreni? Ugeskr Læger 2015;177:895-6.
291. Gøtzsche PC. Psychiatric drugs should not be used in demented people. BMJ 2015;350:h369.
292. Gøtzsche PC. Psykiateren prøver at skyde budbringeren. Dagens Medicin 2015;9 Okt;16:1.
293. Gøtzsche PC. RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
294. Gøtzsche PC. Re: Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
295. Gøtzsche PC. Re; Does long term use of psychiatric drugs cause more harm than good?: Maudsley debate and guild interests. BMJ 2015;351:h2435.
296. Gøtzsche PC. Screening doesn't reduce the occurrence of advanced cancers. BMJ 2015;350:h867.
297. Gøtzsche PC. Svar: Børn behandlet med stimulanser udvikler ofte hjerneatrofi. Ugeskr Læger 2015;4 Nov .
298. Gøtzsche PC. Svar: Dokumentation for, at antidepressiva forårsager selvmord. Ugeskr Læger 2015;177:1649.
299. Gøtzsche PC. Svar: Selvmord forårsaget af antidepressiva skal frem i lyset. Ugeskr Læger 2015;177:1303.
300. Gøtzsche PC. Svar: Tavshedspligt, akademisk dannelse, lægelig pli. Ugeskr Læger 2015;18 Jun.
301. Gøtzsche PC. Tre psykiatrisprofessorer på afveje. Politiken 2015;4 Sep.
302. Gøtzsche PC. Tvang i psykiatrien bør forbydes. Politiken 2015;5 Aug.
303. Gøtzsche PC. Usandheder i psykiaterformands boganmeldelse. Ugeskr Læger 2015;7 Okt 7.
304. Jørgensen KL, Gøtzsche PC. Helbredstjek til lavtuddannede er skadeligt. Ugeskr Læger 2015;11 Feb.
305. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Influence of mammography screening on use of mastectomies in Denmark. Acta Oncol 2015;133:54.
306. Gøtzsche PC. SVAR: Begrebet interessekonflikter bør ikke udvandes (svar på Kronik: Interessekonflikter – mere end ussel mammon). Ugeskr Læger 2016;19:1840.

307. Boesen K, Gøtzsche PC, Juhl Jørgensen K. Re: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. *Cochrane Database Sys Rev* 2016;(1):CD005041.
308. Boesen K, Gøtzsche PC. Quality of life of adult patients with attention-deficit/hyperactivity disorder taking methylphenidate. *Arch Gen Psychiatry* 2016;73:533-4.
309. Gøtzsche PC. Abolishing forced treatment in psychiatry is an ethical imperative [Online] 2016 [Citeret 2016 jun. 17] <https://www.madinamerica.com/2016/06/abolishing-forced-treatment-in-psychiatry-is-an-ethical-imperative/>
310. Gøtzsche PC. Antidepressants are addictive and increase the risk of relapse. *BMJ* 2016;352:i574.
311. Gøtzsche PC. Antidepressants increase the risk of suicide and violence at all ages [Online] 2016 [Citeret 2016 nov. 16] <https://www.madinamerica.com/2016/11/antidepressants-increase-risk-suicide-violence-ages/>
312. Gøtzsche PC. Author's reply to Dubicka and colleagues and Stone. *BMJ* 2016;352:i915.
313. Gøtzsche PC. Bliv hjemme, næste gang du får en invitation til brystkræftscreening. *Politiken* 2016;31 Maj:1.
314. Gøtzsche PC. Bred afvisning af mere tvang på bosteder. *Ugeskr Læger* 2016;13 Sep:9.
315. Gøtzsche PC. Fakta om sundhedstjek er mørkelagt (kronik). *Politiken* 2016;14 Jan.
316. Gøtzsche PC. Forced admission and treatment in psychiatry are violations of basic human rights and must be abolished. Lecture in Anchorage 2 June 2016. <http://psychrights.org/education/GoetzscheJune2016/160602PeterGoetzscheAnchorageTalkTranscript.htm>.
317. Gøtzsche PC. Forårsager benzodiazepiner demens? *Ugeskr Læger* 2016;178:693.
318. Gøtzsche PC. Hvad er der kommet ud af vore indsatser mod kræft?: Hvad har fremskridtet på kræftområdet så været i virkeligheden? Med enkelte undtagelser ikke ret meget. *Dagens Medicin* 2016;6 Dec .
319. Gøtzsche PC. Medicin og screening mod demens virker ikke: Sundhedsministeren ønsker tidlig opsporing af demens. Men det kan gøre mere skade end gavn. *Ugeskr Læger* 2016;178:1291.
320. Gøtzsche PC. Polyfarmaci med antipsykotika øger dødeligheden: Studier, der viser, at antipsykotika med polyfarmaci ikke medfører øget dødelighed, er fejlbehæftede, mener Peter Gøtzsche. *Ugeskr Læger* 2016;178:397.
321. Gøtzsche PC. Praktiserende læger er guld værd (kronik). *Jyllands-Posten* 2016;9 Nov .
322. Gøtzsche PC Prescription drugs are the third leading cause of death [Online] 2016 [Citeret 2016 jun. 16] <http://blogs.bmj.com/bmj/2016/06/16/peter-c-gotzsche-prescription-drugs-are-the-third-leading-cause-of-death/>
323. Gøtzsche PC. Psykofarmaka øger risikoen for vold: Noget bør laves om i retspsykiatrien. *Ugeskr Læger* 2016;178:2039.
324. Gøtzsche PC. Seks ting der er værd at vide om masseskyderier. *Videnskab.dk* 2016;1 Jun.
325. Gøtzsche PC. Tvangslovene i psykiatrien skal afskaffes. *Psykologernes Fagmagasin* 2016;17 Mar.
326. Gøtzsche PC Tvangsbehandling med elektrochok bør forbydes [Online] 2016 [Citeret 2016 mar. 12] Tilgængelig fra: URL:<http://www.deadlymedicines.dk/tvangsbehandling-med-elektrochok-bor-forbydes/>
327. Gøtzsche PC. Unblinding in SSRI trials due to side effects is an important source of bias. *Br J Psychiatry* 2016;208.
328. Jørgensen KJ, Gøtzsche PC. Breast Cancer Screening: Benefit or Harm? *JAMA* 2016;315:1402.
329. Gøtzsche PC. Antidepressiva øger risikoen for selvmord og vold i alle aldre. *Medicinsk Tidsskrift* 2016; 20 Nov:506.
330. Gøtzsche PC. Patients should have free and immediate access to all information related to clinical trials. *BMJ* 2017;356:j1221.
331. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl P-H. Breast Cancer Screening in Denmark. *Ann Intern Med* 2017;167:524.
332. Gøtzsche PC. Hyllning till en enastående psykiatriker. Forord til: Breggin PR. Att sluta med psykofarmaka. Stockholm: Karneval Förlag, 2018.
333. Gøtzsche PC. What is it like being on the Governing Board? <http://community.cochrane.org/news/what-it-being-governing-board>. 2017; 27 Sept.
334. Gøtzsche PC. Akupunktur virker ikke. Det er ikke dokumenteret, at akupunktur har nogen klinisk relevant effekt på noget som helst. *Dagens Medicin* 2018; 7 feb.
335. Gøtzsche PC. Nej, jeg står ikke bag 'uhyrlige påstande'. *Politiken* 2018; 30. april.
336. Gøtzsche PC. Psychiatry is a disaster area in healthcare that we need to focus on. <http://www.bmj.com/content/360/bmj.k9/rr-15>. 2018; 10 Jan.

337. Gøtzsche PC. Skærpet tilsyn med psykiatere kan være nødvendigt. *Dagens Medicin* 2018; 9. feb.
338. Gøtzsche PC. Selvmordene forårsaget af depressionspiller vil fortsætte – man bør simpelthen undgå dem. *Jyllands-Posten* 2018; 11. feb.
339. Gøtzsche PC. Om depression, videnskabelig debat og Cochrane. *Jyllands-Posten* 2018; 20. feb.
340. Gøtzsche PC. Cipriani review does not add anything. *Council for Evidence-based Psychiatry*. 2018; 22 Feb.
341. Gøtzsche PC. Learning to live with hearing voices – an authoritative statement lacks documentation. *BMJ* 2018;361:k2018.
342. Gøtzsche PC. Comment on: “My OCD story: evidence-based medicine to the rescue!” *Evidently Cochrane* 2019 May 29.
343. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Esketamine for depression? No thanks, please. *BMJ* 2019 Oct 3.
344. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. *BMJ* 2019 Oct 11.
345. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. *BMJ* 2019 Oct 22.
346. Jørgensen KJ, Gøtzsche PC, Krogsbøll LT. Ønskedrømme til en høj pris. *Dagens Medicin* 2019 June 25.
347. Urato AC, Abi-Jaoude E, Abramson J, et al. National Partnership for Maternal Safety: consensus bundle on venous thromboembolism. *Obstet Gynecol* 2019;134:1115-7.
- 348.

Secondary publications in Danish

1. Gøtzsche PC. Reference-bias. *Ugeskr Læger* 1988;150:228-9.
2. Nordic Medical Research Councils' HIV Therapy Group. Dobbeltblind dosis-responsundersøgelse af zidovudin ved AIDS og fremskreden HIV-infektion. *Ugeskr Læger* 1993;155:104-7.
3. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Patientoverlevelse ved zidovudinresistent HIV. *Ugeskr Læger* 1994;156:185-6.
4. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Randomiseret undersøgelse og metaanalyse af somatostatin overfor placebo ved blødende øsofagusvaricer. *Ugeskr Læger* 1996;158:2393-6.
5. Gøtzsche PC. Vigtigheden af et bredt perspektiv på metaanalyse: kan have afgørende betydning for patienterne. *Ugeskr Læger* 2000;162:5601.
6. Gøtzsche PC. Bredt perspektiv på metaanalyse af afgørende betydning for patienten. *Läkartidningen* 2000;97:5882-3.
7. Gøtzsche PC. Bredt perspektiv på metaanalyse - kan have afgørende betydning for patienterne. *Tidsskr Nor Lægeforen* 2000;120:2810-1.
8. Hróbjartsson A, Gøtzsche PC. Hvad er effekten af placebobehandling? *Ugeskr Læger* 2002;164:329-33.
9. Jørgensen KJ, Gøtzsche PC. Information om brystkræftscreening på internetsider er ensidig og mangelfuld - sekundærpublikation. *Ugeskr Læger* 2005;167:174-8.
10. Gøtzsche PC. Forbedret rapportering af skadevirkninger i randomiserede forsøg: udvidelse af CONSORT-vejledningen. *Ugeskr Læger* 2005;167:1520-2.
11. Hróbjartsson A, Chan A-W, Haahr MT, Gøtzsche PC, Altman DG. Selektiv rapportering af effektmål i randomiserede forsøg. Sekundærpublikation. *Ugeskr Læger* 2005;167:3189-91.
12. Haug C, Gøtzsche PC, Schroeder T. Registre og registrering af kliniske forsøg. Sekundærpublikation. *Ugeskr Læger* 2006;168:457-8.
13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Begrænsninger i publikationsrettighederne i industriinitierede kliniske forsøg - sekundærpublikation. *Ugeskr Læger* 2006;168:2467-9.
14. Jørgensen KJ, Gøtzsche PC. Er invitationer til mammografiscreening et rimeligt udgangspunkt for det informerede samtykke? Sekundærpublikation. *Ugeskr Læger* 2006;168:1658-60.
15. Gøtzsche PC. Er relative risici og oddsratioer i resumeer troværdige? Sekundærpublikation. *Ugeskr Læger* 2006;168:2678-80.

Teaching

Pregraduate courses

1988-89	Junior lecturer, Theory of Science, University of Copenhagen.
1990-2012	Lecturer, Theory of Science, University of Copenhagen.
1992-93	Lecturer, internal medicine, Hvidovre Hospital.
1993, 13 May	Course in research methodology, human biology, University of Copenhagen.
1994, 2-3 Feb	Course in research methodology, human biology, University of Copenhagen.
2003, 2 Sept	When is one drug better than another? Denmark's Pharmaceutical University.
2003, 20 Oct	Meta-analyses and their role in systematic reviews. Students in Public Health, Copenhagen.
2015, 15 April	Lectures on Theory of Science for pharmacy students.
2016, 8 Dec	Vore lægemidler er den 3. hyppigste dødsårsag. Farmaceutstuderende, København.
2017, 7 Dec	Kliniske forsøg. Farmaceutstuderende, København.
2018, 30 Apr	Psykiatriske diagnoser og depressionsmedicin. Psykologstuderende, København.
2018, 11 Oct	Kliniske forsøg. Farmaceutstuderende, København.

See also Lectures below, which include many for students.

Postgraduate courses

C: course manager.

1. Controlled clinical trials of drugs, Rigshospitalet, 3-5 Nov 1986.
2. C Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 28 Oct 1987.
3. A-course in research methodology. National Board of Health, 15 Nov 1988.
4. A-course in clinical decision theory. National Board of Health, 17 Apr 1989.
5. C Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 2 Nov 1989.
6. C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1989.
7. C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1990.
8. Course on meta-analyses. Medicom, Copenhagen, 21 May 1990.
9. C Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 10 Nov 1990.
10. PhD course in medical ethics. University of Southern Denmark, 17 May 1991.
11. Course on rheumatoid arthritis. Danish Rheumatological Society, 27 Okt 1991.
12. Course in clinical trials. Apothecary Society, Hillerød, 5 Nov 1991.
13. C Litterature evaluation for pharmacists, Hillerød, 2-4 Dec 1991.
14. Bias. Course in pharmacodynamics. Danish Society for Clinical Pharmacology, 6 Dec 1991.
15. C Rigshospitalet's course in clinical trials. Hillerød, 2-6 Mar 1992.
16. A-course in clinical pharmacology. National Board of Health, 3 Mar 1992.
17. Research methodology for back diseases. Back research group, Copenhagen, 2 Apr 1992.
18. A-course in clinical pharmacology. National Board of Health, 5 May 1992.
19. PhD course in medical ethics. University of Southern Denmark, 8 May 1992.
20. A-course in clinical pharmacology. National Board of Health, 6 Oct 1992.
21. C Rigshospitalet's course in clinical trials. Hillerød, 19-23 Oct 1992.

22. A-course in rheumatology. National Board of Health, 24 Nov 1992.
23. A-course in clinical pharmacology. National Board of Health, 8 Dec 1992.
24. A-course in rheumatology. National Board of Health, 9 Feb 1993.
25. A-course in clinical pharmacology. National Board of Health, 2 Mar 1993.
26. PhD course in medical ethics. University of Southern Denmark, 26 Mar 1993.
27. C Rigshospitalet's course in clinical trials. Hillerød, 31 Mar-2 Apr 1993.
28. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 19-20 Oct 1993.
29. A-course in clinical pharmacology. National Board of Health, 1 Mar 1994.
30. C PhD course in systematic reviews. Panum Institute, 11-12 Apr 1994.
31. C PhD course in systematic reviews. Panum Institute, 13-14 Apr 1994.
32. C Rigshospitalet's course in clinical trials. Hillerød, 18-22 Apr 1994.
33. Rigshospitalet's research policy. Rigshospitalet, 18 Aug 1994.
34. Course in biological psychiatric research. Bispebjerg Hospital, 17 Jan 1995.
35. Scientific dishonesty. University hospitals' Centre for Nursing Research. Rigshospitalet, 23 Feb 1995.
36. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Copenhagen, 27-29 Mar 1995.
37. Post Conference Course in Evidence-based Health Care: critical appraisal of evidence. International Society for Technology Assessment in Health Care, Dalarna, Sweden, 7-10 June 1995.
38. Use of research results. Rigshospitalet's course in quality development, 15 June 1995.
39. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 29-31 Oct 1995.
40. Course in quality development. Rigshospitalet, 13 Dec 1995.
41. C Course on systematic reviews. Panum Institute, 14-15 Dec 1995.
42. Meta-analyses and evaluation of the quality of research. Danish Society for Internal Medicine. Sundby Hospital, 27 Mar 1996.
43. C Workshop on Handsearching. Nordic Cochrane Centre, 16 Apr 1996.
44. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 17 Apr 1996.
45. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 18 Apr 1996.
46. Workshop on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 12-14 May 1996.
47. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 12 Sept 1996.
48. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 13 Sept 1996.
49. Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 4-6 Dec 1996.
50. C Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Göteborg, 17 Dec 1996.
51. The controlled clinical trial and meta-analysis. Danish Society for Internal Medicine. Sundby Hospital, 10 Mar 1997.
52. Meta-analyses and the international Cochrane Collaboration. PhD course in clinical intervention research. MEDIF/MEFA, 13 Mar 1997.
53. Second Nordic Course in Evidence-based Medicine. Oslo, 1-5 June 1997.
54. Minicourse in evidence-based medicine and the Cochrane Library. Rigshospitalet, 5 Nov 1997.
55. C Workshop on Handsearching. Nordic Cochrane Centre, 12 Nov 1997.
56. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 13 Nov 1997.
57. Course in evidence-based medicine. Rigshospitalet, 30 Apr-2 May 1998.

58. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 May 1998.
59. C Workshop on Handsearching. Nordic Cochrane Centre, 9 July 1998.
60. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Helsinki, 21 Sept 1998.
61. Course in evidence-based medicine. Rigshospitalet, 9-12 Nov 1998.
62. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 1 Mar 1999.
63. C Workshop on Handsearching. Nordic Cochrane Centre, 3 Mar 1999.
64. Course in evidence-based medicine. Panum, 14-17 June 1999.
65. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 21 Mar 2000.
66. Workshop on Handsearching. Nordic Cochrane Centre, 22 Mar 2000.
67. C Evidence-based medicine. Ringe Back Centre, 14 Apr 2000.
68. C Evidence-based cardiology. Society for Younger Cardiologists, 15 Apr 2000.
69. Workshop on controversial issues related to clinical trials and systematic reviews. Barcelona, 30 June 2000.
70. Workshop on Handsearching. Nordic Cochrane Centre, 11 Sept 2000.
71. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, 31 Jan 2001.
72. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 Mar 2001.
73. Meta-analyses - use and misuse. Danish Drug Industry Association, 30 May 2001.
74. C Workshop on Cochrane editing. Hotel Marina, 6-8 Sept 2001.
75. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Karrebæksminde, 6 Feb 2002.
76. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 23 Apr 2002.
77. Course in evidence-based medicine. Rigshospitalet, 3-4 og 17-18 June 2002.
78. C Workshop on Cochrane editing. Hotel Marina, 12-14 Sept 2002.
79. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 7 Oct 2002.
80. Meta-analysis and potential and limitations of evidence-based medicine. 6. Lübecker course, Lübeck, 9-10 Oct 2002.
81. PhD course, Panum Institute, 12 Dec 2002.
82. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Tune Landbrugsskole, 29 Jan 2003.
83. Prioritisation and evidence-based medicine. Nordjyllands Amtsråd, Ålborg, 13 Feb 2003.
84. C Workshop on Cochrane editing. Nordic Cochrane Centre, 18-19 Sept 2003.
85. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 6 Oct 2003.
86. C Quality of allocation concealment. 11th Cochrane Colloquium, Barcelona, 28 Oct 2003.
87. PhD course, Panum Institute, 24 Nov 2003.
88. Workshop on research in alternative medicine, Rigshospitalet, 30-31 Mar 2004.
89. Course in evidence-based medicine. Panum Institute, 1-2 og 14-15 June 2004.
90. C PhD course in systematic reviews and meta-analyses. Rolighed, 8-11 Nov 2004.
91. PhD course, Panum Institute, 1 Dec 2004.
92. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, KVL, 24 Aug 2005.
93. Course in infection pathogenesis. Rigshospitalet, 5 Sept 2005.
94. Doctors' Annual Gathering (Lægedage). Copenhagen, 18 Nov 2005.

95. PhD course in planning clinical research. Panum Institute, 21 Feb 2006.
96. PhD course in epidemiology. Køge, 30 Mar 2006.
97. Reporting of harms. GCP units in Denmark, Nyborg, 31 Mar 2006.
98. PhD course. Pharmaceutical University, 13 June 2006.
99. Doctors' Annual Gathering (Lægedage). Copenhagen, 11 Nov 2006.
100. Systematic reviews. Advanced seminar, Madrid, 16-17 Nov 2006.
101. Seminar on peer review and scientific misconduct. Karolinska Institute, Stockholm, 30 Nov 2006.
102. PhD course, Research ethics. Copenhagen Business School, 19 Mar 2007.
103. Course in clinical decision theory. National Board of Health, Copenhagen, 8 May 2007.
104. PhD course, Ethics in science. Faculty of life sciences, Copenhagen, 13 Aug 2007.
105. Evidence-based medicine. WHO, delegation from Uzbekistan, Hillerød, 21 Sept 2007.
106. Course for clinical microbiologists. National Board of Health, Copenhagen, 24 Sept 2007.
107. PhD course, Research ethics. Copenhagen Business School, 31 Oct 2007.
108. PhD course, Research ethics. Copenhagen Business School, 31 Mar 2008.
109. Course in Clinical Pharmacology, National Board of Health, 17 April 2008.
110. PhD course in planning clinical research. University of Copenhagen, 31 May 2008.
111. Workshop: Clinical trials registration & results reporting: The CONSORT guidelines and beyond. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
112. Course in clinical decision theory. National Board of Health, Copenhagen, 7 and 20 May 2007.
113. PhD course in clinical epidemiology. Køge, 9 Oct 2008.
114. Course in clinical decision theory. National Board of Health, Copenhagen, 19 Nov 2008.
115. Course in clinical decision theory. National Board of Health, Copenhagen, 24 Nov 2009.
116. PhD course in planning clinical research. University of Copenhagen, 21 Jan 2010.
117. Course in clinical decision theory. National Board of Health, Copenhagen, 18 May 2010.
118. Course in clinical pharmacology. National Board of Health, Copenhagen, 1 Apr 2011.
119. Forskeruddannelsesnetværket. Korsør, 17 May 2011.
120. PhD course. Herlev, 16 June 2011.
121. Highlights i reumatologien. Korsør, 1 Sept 2011.
122. PhD course, systematic reviews. University of Copenhagen, 26-29 Sept 2011.
123. Lægemiddelinformation – fup eller fakta? DULM-kursus, 20 April 2012.
124. PhD course, Good scientific practice and reporting, University of Copenhagen, 26-28 Sept 2012.
125. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Rigshospitalet, 12 May 2016.
126. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Bispebjerg, 10 Nov 2016.
- 127.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Sydhavnen, 15 Dec 2016.
- 128.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Fredericia, 25 April 2017.
- 129.C Udtræpning af psykofarmaka. Heldagskursus, København, 12 June 2017.
130. Withdrawal of psychiatric drugs, Göteborg, 18-20 Oct 2017.
131. Varför SSRI & liknande antidepressiva bör utgå. Swedish Psychiatrists, Göteborg, 25 Jan 2018.
- 132.C Seminar om udtræpning af psykofarmaka. Nyborg, 16 March.
- 133.C Seminar om udtræpning af psykofarmaka. Nyborg, 16 March. (seminar held twice the same day).
- 134.C Research seminar about depression pills. Copenhagen, 14 June.
135. Power versus rationality: fighting conflicts of interest. Oxford, 19 June 2019.

Lectures

IS: invited speaker; more recent titles have been translated into English, for convenience.

1. IS Steady state pharmacokinetics of naproxen in rheumatoid arthritis. XV congrès international de rhumatologie, Paris, 21-27 June 1981.

2. Dosis-respons forhold ved rheumatoid arthritis. Ribe amts lægekredsforsamling, 5 nov 1982.
3. Klinisk farmakologi af naproxen (Naprosyn). Aftenmøder den 7, 11, 12, 19, 25 og 26 april 1983 på hhv. Store Kro, Fredensborg, Hotel H. C. Andersen, Odense, Hotel Impala, Silkeborg, Mogenstrup kro, Hotel Sheraton, København og Rold Storkro.
4. Månedens forskningsproblem: bedre end sig selv. Staff-meeting, amtssygehuset i Herlev, 24 okt 1985.
5. IS Reference bias. En undersøgelse af litteraturreferencemønstret i offentliggjorte lægemiddelundersøgelser. Dansk Selskab for Klinisk Farmakologi, 27 jan 1987.
6. IS Værdien af mikrobiologiske undersøgelser hos HIV-inficerede patienter. Dansk Selskab for Klinisk Mikrobiologi, 7 dec 1987.
7. Yield of diagnostic investigations of opportunistic infections in 33 AIDS patients. European Conference on Clinical Aspects of HIV Infection, Bruxelles, 10-11 Dec 1987.
8. IS Bias i dobbeltblinde undersøgelser af NSAID's med perspektiver for meta-analyser. Dansk Selskab for Medicinsk Reumatologi, 17 feb 1989.
9. IS Meta-analyse af antirheumatica behandling. Møde om den kontrollerede kliniske undersøgelses metodologi: status og perspektiver. Rigshospitalet, 28 apr 1989.
10. IS Meta-analyse af non-steroide antiinflammatoriske stoffer. Dansk Selskab for Intern Medicin, amtssygehuset i Herlev, 13 okt 1989.
11. IS Hvordan stiller man forsøg op, og hvordan analyserer man resultaterne? Årsmøde i Den Danske Klub for Centralsterilisering og Sygehushygiejne, Hotel Frederik II, Slagelse, 10 nov 1989.
12. IS Valg af NSAID ud fra kliniske studier. Specialistmøde for reumatologer, Novo Nordisk, København, 3 maj 1990.
13. IS Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. 23rd Nordic Congress of Rheumatology, Tampere, 15 June 1990.
14. IS Bias. Fællesundervisning for den medicinske blok, Hvidovre Hospital, 19 sept 1990.
15. IS Bias in NSAID trials. Italian Meeting on Meta-analysis within Hepatology. Erice, Sicilien, 3-5 Dec 1990.
16. IS Meta-analysis of multiple clinical trials: biases revealed by analysis of trials on first- and secondline antirheumatic drugs. 75th Anniversary of the Danish Association for Internal Medicine, København, 24 Jan 1991.
17. IS Muligheder og farer ved meta-analyser. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 13 feb 1991.
18. IS Hvilket NSAID er bedst? Møde arrangeret af medicinsk afdeling C med de praktiserende læger, amtssygehuset i Herlev, 9 apr 1991.
19. IS Præliminære resultater fra AIDSDOSE studiet. Dansk Selskab for Infektionsmedicin, Rigshospitalet, 30 apr 1991.
20. IS Detection of bias problems through the use of meta-analysis with examples from drug trials in rheumatology. Society for Clinical Drug Trials and Society for Medical Statistics, Stockholm, 22 May 1991.
21. IS Meta-analysis of DMARD's: are they effective? DAK's Rheuma Meeting in Tivoli, 23 Aug 1991.
22. IS Dobbelt-blind dosis responsundersøgelse af zidovudin ved AIDS og fremskreden HIV infektion, Statens Sundhedsvidenskabelige Forskningsråd, 12 nov 1991.
23. IS Internationella och nordiska erfarenheter av zidovudinbehandling. XLVIII Läkaresällskapets Riksstämman, Stockholm, 27 nov 1991.
24. Clinimetric problems in arthritis. Seminar on Bias and Controversies in Clinical Research, Rigshospitalet, 28 Feb 1992.
25. IS Problems and opportunities in drug trials with DMARDs. 24th Scandinavian Congress of Rheumatology, Malmö, 1 June 1992.
26. Meta-analysis is more than a combination of odds ratios. 13th International Meeting of International Society for Clinical Biostatistics, København, 18 Aug 1992.
27. IS Faldgruber i den klinisk kontrollerede undersøgelse. Medicinsk Selskab for Fyns Stift, Odense, 2 nov 1992.
28. IS Statistiske og filosofiske aspekter ved score systemer. Reumatologisk symposium, Nyborg, 12 mar 1993.

29. IS Good Clinical Practice. Ph.d.-studerende på Hvidovre Hospital, 30 sept 1993.
30. The Scandinavian Cochrane Centre. Dansk Selskab for Medicinsk Filosofi, Etik og Metode og Dansk Selskab for Medicinsk Prioritering, København, 13 okt 1993.
31. Det etiske grundlag for det danske sundhedsvæsen. Folkeuniversitetet, 9 november 1993.
32. IS NSAID og gastrointestinal tractus. Metodologiske problemer: er der forskelle mellem midlerne af klinisk relevans? Dansk Gastroenterologisk Selskabs E-kursus, København, 11 jan 1994.
33. IS Clinical practice should reflect clinical science. EU meeting, AIMCOM, Bruxelles, 24 Apr 1994.
34. IS Systematic reviews of clinical trials in policy making and health planning. Nordisk konference om kritiske valg i sundhedssektoren, Dansk Sygehus Institut, 26 Apr 1994.
35. IS Bias in statistical reporting: should the data analyst be blinded? Society for Clinical Trials, 15th annual meeting, Houston, Texas, 9 May 1994.
36. IS Meta-analyses in rheumatology. 25th Scandinavian Congress of Rheumatology, Lillehammer, 2 June 1994.
37. IS Cochrane Center på Rigshospitalet - meta-analyser i klinikken. Dansk Medicinsk Selskabs 75-års jubilæumsmøde, København, 26 aug 1994.
38. IS Orientering om Det Nordiske Cochrane Center. GCP-selskabet, Gentofte, 2 feb 1995.
39. IS Forskningen som prioriteringsgrundlag. Dansk Selskab for Medicinsk Prioritering, Svendborg, 28 apr 1995.
40. IS Meta-analysis of continuous data - NSAIDs as an example. Dansk Epidemiologisk Selskab, København, 2 June 1995.
41. IS Philosophy of sciences - in meta-analysis. 4th Nordic Conference for Medical Libraries, København, 24 Aug 1995.
42. IS Det internationale Cochrane-samarbejde. Nordisk medicinaldirektørmøde, Hornbæk, 1 sept 1995.
43. IS Cochrane Collaboration: implementering i *evidence based medicine*. Prioritering i sundhedsvæsenet, Ringkøbing amtskommune, 27 sept 1995.
44. Cochrane centres. 3rd Annual Cochrane Colloquium, Oslo, 6 Oct 1995.
45. IS Meta-analyses: assets and limitations. Recent Advances in Breast Cancer, Scandinavian Breast Cancer Group, Hindsgavl, 13 Oct 1995.
46. IS A randomized trial of withdrawal of slow acting antirheumatic drugs. Dansk Reumatologisk Selskab, København, 20 okt 1995.
47. IS Forskning som grundlag for indførelse af nye behandlingsmetoder. Temadag om prioritering i sundhedsvæsenet. Nordjyllands amt, Rebild, 1 nov 1995.
48. IS What is sound evidence for decision making? Medicine 96, Finnish Medical Association (Duodecim), Helsinki, 10 Jan 1996.
49. IS Cochrane Collaboration and the health care technology assessment. Medicine 96, Finnish Office for Health Care Technology Assessment, Helsinki, 11 Jan 1996.
50. IS Metaanalyse og kvalitetssikring. Dansk Selskab for Medicinsk Onkologi, Helsingør, 19 jan 1996.
51. Cochrane Centret, Rigshospitalet. Staff-meeting, Sundby Hospital, 23 jan 1996.
52. IS Nordic Cochrane Centre. H:S Forskningsråd, København, 12 mar 1996.
53. Cochrane-samarbejdet. Staff-meeting, Sankt Elisabeths Hospital, 9 apr 1996.
54. IS Bibliometrisk analyse af publikationer udgået fra danske intern medicinske afdelinger 1988-92. Dansk Selskab for Intern Medicins konference om forskningens vilkår i intern medicin, Hillerød, 12 apr 1996.
55. IS Hvad ved vi, og hvad gør vi? Temadag om tværfaglige specialeråd, Rigshospitalet, 2 maj 1996.
56. IS The Cochrane Collaboration. Cochrane Hepato-Biliary Group Meeting, Genève, 25 Aug 1996.
57. IS Medicinsk teknologivurdering og lægemidler. MEDIF's direktørseminarium, Hornbæk, 4 sept 1996.
58. Cochrane-samarbejdet. Staff-meeting, Hvidovre Hospital, 17 sept 1996.
59. IS Meta-analyser. Det Medicinske Selskab i København, Domus Medica, 24 sept 1996.
60. IS Debate: Within ten years, all health decisions will be evidence-based. 4th Annual Cochrane Colloquium, Adelaide, 24 Oct 1996.
61. IS Hvad skal diagnosen bruges til? Dansk Selskab for Klinisk Mikrobiologi, Kolding, 8 nov 1996.
62. Omsorg som effektiv behandling? Næstekærlighed, placebo og alternativ medicin. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, Domus Medica, 14 nov 1996.

63. IS MTV - en nødvendighed i sundhedsvæsenet. Dansk Selskab for Sygehusledelse, Kolding, 28 nov 1996.
64. IS Is the Norwegian Minister of Health correct in saying that the Cochrane Collaboration has made a fetish of the randomised controlled trial? Annual Meeting for The Nordic Cochrane Centre and Network, Oslo, 17 Jan 1997.
65. IS Det Nordiske Cochrane Center. H:S Bestyrelse, København, 29 jan 1997.
66. IS Cochrane centeret. Sundhedsministeriet, København, 30 jan 1997.
67. IS Evidensbaseret medicin. Foreningen af Læger i Erhvervslivet, København, 19 mar 1997.
68. IS The Cochrane Collaboration. Svensk Internmedicinsk förenings vårmöte, Umeå, 20 mar 1997.
69. IS Hvilken sundhedsforskning har vi brug for? (paneloplæg). Forskningsudvalgets og Sundhedsudvalgets høring om sundhedsforskning, Folketinget, 2 apr 1997.
70. IS Nordiska Cochrane-centrat i Köpenhamn. Karolinska Institutet och Stockholm läns landsting, 3 apr 1997.
71. IS Beware of surrogate outcome measures. Dansk hypertensionsselskabs årsmøde, Svendborg, 11 Apr 1997.
72. IS The Cochrane Collaboration. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
73. IS Systematic review: somatostatin and octreotide in bleeding oesophageal varices. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
74. IS Quality and relevance of clinical trials. European Headache Federation 5th Summer School. Rungsted, 25 Apr 1997.
75. IS Sammenfattende vurderinger af behandlingsmetoders værdi - metaanalyser. Møde mellem medlemmerne af de regionale videnskabsetiske komiteer og Den Centrale Videnskabsetiske Komité. Kolding, 21 aug 1997.
76. IS "Evidence Based Medicine". Overlægeforeningens Årsmøde. Nyborg Strand, 29 Aug 1997.
77. The Cochrane Collaboration. WHO's European Office, Programme Manager's Meeting. København, 3 Sept 1997.
78. Cochrane-samarbejdet. Lægemeddelstyrelsen. København, 16 sept 1997.
79. IS Rigshospitalets forskningsproduktion i 1994-96. Temadag om budgettering af forsknings- og udviklingsmidler, Rigshospitalet, 23 sept 1997.
80. IS Scopes and topic lists of Review Groups. 5th Annual Cochrane Colloquium, Amsterdam, 9 Oct 1997.
81. IS Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? Institut for Sundhedsvæsen, Symposium, Køge, 24 okt 1997.
82. IS Evidence based medicine - oplæg og diskussion. H:S Sundhedsfaglige råd, Rigshospitalet, 28 okt 1997.
83. IS Vad är - och hur arbetar - Cochrane Collaboration? Regiondag om Evidence Based Medicine, Södra sjukvårdsregionen, Malmö, 21 nov 1997.
84. Cochrane-samarbejdet. Läkemedelsverket, Uppsala, 5 dec 1997.
85. IS Evidence-based medicine: the present and the future. Duodecim, 10th Anniversary Seminar of the Physician's Desk Reference and Database, Helsinki, 28 Jan 1998.
86. IS Ethical aspects in the use of systematic reviews in health care. Workshop on systematic reviews, Stakes & FinOHTA, Helsinki, 30 Jan 1998.
87. IS Præsentation af Cochrane-projektet. Nordisk Ministerråd, Hellerup, 25 mar 1998.
88. IS Getting the message across. 7th European Stroke Conference, Edinburgh, 29 May 1998.
89. IS RCT, status og visioner. Dansk Selskab for Medicinsk Filosofi, Etik og Metode. Festmøde, København, 17 sept 1998.
90. IS Evidensbaseret medicin. Farmaciens Dag, Danmarks Farmaceutiske Selskab, København, 2 okt 1998.
91. IS Demonstrating evidence in action: a case study. 6th Annual Cochrane Colloquium, Baltimore, 25 Oct 1998.
92. IS Bias i randomiserade försök och meta-analyser. Svenska Läkarsällskapets Riksstämman, Göteborg, 24 nov 1998.
93. IS Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. Statens Sundhedsvidenskabelige Forskningsråd og Statens Institut for Medicinsk Teknologivurdering, Middelfart, 11 feb 1999.

94. IS Evidens fra systematiske reviews. Dansk Endokrinologisk Selskab, Domus Medica, 22 feb 1999.
95. IS Overall status of the Cochrane Collaboration. Cochrane Colorectal Cancer Group meeting, København, 19 Mar 1999.
96. Det Nordiske Cochrane Center og evidensbaseret medicin. Folketingets Sundhedsudvalg, 24 mar 1999.
97. IS Evidensbaseret klinisk praksis. Områdeledelsens Stab og Sekretariat, Odense Universitetshospital, 8 apr 1999.
98. IS Hvad kan Cochrane-databasen bruges til? Dansk Kirurgisk Selskabs Forårsmøde, Herlev, 15 apr 1999.
99. Presentation of The Cochrane Collaboration. Exploratory meeting to consider establishing a Russian Branch of The Nordic Cochrane Centre. Hotel Akademicheskaya, Moskva, 7-8 June 1999.
100. IS Mega-trials or meta-analysis? European Society for Paediatric Research, Panum Institutet, 28 June 1999.
101. IS Hvad er rationel farmakoterapi? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 22 okt 1999.
102. IS The Cochrane Collaboration i Norden. SBU, Evidensbaseret sjukvård. Stockholm, 27 jan 2000.
103. IS Hvad vil det sige, at behandlingen er evidensbaseret? Jydsk Medicinsk Selskab, Århus, 5 apr 2000.
104. IS Meta-analyser, systematiske reviews. Kursus i evidensbaseret klinik. Frederiksberg hospital, 9 juni 2000.
105. IS Systematic review of breast cancer screening. Meeting with local minister of health and specialist societies. Barcelona, 29 June 2000.
106. IS History of The Cochrane Collaboration. 8th Cochrane Colloquium, Cape Town, 25 Oct 2000.
107. IS Er det alvorlige mangler ved det vitenskapelige grunnlaget for mammografi-screeningen? Årsmøde i Norsk Patologforening, Oslo, 10 nov 2000.
108. IS Är mammografiscreening värdefull? Svensk förening för radiologisk bröstdiagnostik, Rigshospitalet, 16 nov 2000.
109. IS Systematic review of mass screening for breast cancer with mammography. Dansk Selskab for Medicinsk Onkologi, Panum, 20 Nov 2000.
110. IS Hvornår er ændret klinisk praksis nødvendig? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 23 nov 2000.
111. IS Evidensbaseret medicin. KAS Herlev, 28 nov 2000.
112. IS Fallstudie Mammographie Screening. Bern's Universität, 6 Dec 2000.
113. IS Cochrane Collaboration. SBU, Stockholm, 7 feb 2001.
114. IS Utility of mammographic screening for detection of breast cancer and the measurement of the placebo effect. São Paulo, 23 Feb 2001.
115. IS Screening for breast cancer with mammography: a systematic review. Breast and Cervical Cancer Screening Conference, Bielefeld, 6 Apr 2001.
116. IS Concept and methods in Cochrane reviews. Dansk Selskab for Psykiatrisk Epidemiologi, 20 apr 2001.
117. IS Putting the evidence into breast cancer care - challenges and controversies for the future. National Breast Cancer Coalition's Annual Meeting, Washington, 6 May 2001.
118. IS Ankelligament-metaanalyse. Dansk Fod- og Ankelkirurgisk Selskab, Gjern, 18 aug 2001.
119. Misleading publications of major mammography screening trials in major medical journals. Fourth International Congress on Peer Review in Biomedical Publication, Barcelona, 14 Sept 2001.
120. IS Cochrane reviews - the clinical application of evidence. Skandinavisk Forening af Oral og Maxillofacial Kirurger, 21 Sept 2001.
121. IS Hvilke problemer ved screeningsmetoder er politikere ikke blevet informeret om? Dansk Selskab for Medicinsk Prioritering og Dansk Selskab for Almen Medicin, København, 30 okt 2001.
122. IS Mammografiscreening - undersøgt i en metaanalyse. Dansk Selskab for Almen Medicins Risikogruppe, Silkeborg, 23 nov 2001.
123. IS Metaanalyse. Foredrag efter modtagelse af Niels A Lassen prisen, Bispebjerg Hospital, 7 dec 2001.
124. IS Metaanalyse, styrke og svaghed, metodologiske betragtninger. Gruppen af Yngre Gastroenterologer På Vej, København, 12 dec 2001.
125. IS Metaanalyser - hvad kan og skal de bruges til? Selskabet for Teoretisk og Anvendt Terapi, København, 7 feb 2002.

126. IS The old vs the new review. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
127. IS The importance of the published, peer reviewed protocol. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.
128. IS Problemer ved vurderingen af lægemiddelundersøgelser. Dansk Reumatologisk Selskab, Horsens, 19 apr 2002.
129. IS Conflict of interest. Cochrane Colorectal Cancer Group's Status Meeting, København, 19 Apr 2002.
130. IS Lægers videnskabelige ytringsfrihed, interkollegiale problemer. Dansk Selskab til Sikring af Lægers Ytringsfrihed, København, 3 juni 2002.
131. IS Things to be cautious about when making policy recommendations based on systematic reviews, randomised trials, cohort studies, and expert opinion. Delegates from The Ministry of Health, China, Rigshospitalet, 20 Aug 2002.
132. IS Forskning er ikke fuldstændig objektiv - den kan drejes og vendes, så den passer politisk. Kursus for journalister, København, okt 2002.
133. IS Mammascreeing: a critical analysis. Wenckebach Symposium, Groningen, 5 Nov 2002.
134. IS Dissemination experiences in the Cochrane Collaboration. Nordic Campbell Center inauguration seminar, Helsingør, 13 Nov 2002.
135. IS Hva kan epidemiologer bidra med i deatten om mammografiscreening? Den tiende norske epidemiologikonferansen, Trondheim, 14 nov 2002.
136. IS Unambiguous and comparable results as quality measures in health related research. Is randomisation a necessity to obtain reliable knowledge? How are self-selection and self-conscious efforts handled? Conference arrangeret af Videns- og Forskningscenter for Alternativ Behandling, Århus, 27 Nov 2002.
137. IS Ten years of the Cochrane Collaboration. Seminar for Finnish doctors, Biomedicum, Helsinki, 23 Jan 2003.
138. IS Dronning Ingrid's Festforelæsning. Hvad er vore behandlinger værd? Åbenrå Sygehus, 8 maj 2003.
139. IS Temaeftermiddag. Evidensbaseret forebyggelse og behandling. Ålborg Sygehus, 9 sept 2003.
140. IS Plenary lecture. Pitfalls in evidence based medicine. 4th Congress, European Federation of Internal Medicine, Berlin, 11 Sept 2003.
141. IS Debate. Population based breast cancer screening. ECCO 12, Federation of European Cancer Societies, København, 25 Sept 2003.
141. Evidensbaseret forbrugeroplysning. Konference arrangeret af Forbrugerrådet og Det Nordiske Cochrane Center, Christiansborg, København, 22 okt 2003.
142. IS Plenary lecture. Conflicts of interest. XIth Cochrane Colloquium, Barcelona, 27 Oct 2003.
143. IS Evidensbaseret medicin: eksempler og betydning. Møde om medicinforsøg, arrangeret af Institut for Rationel Farmakoterapi, København, 19 nov 2003.
144. Discrepancies between protocols and publications: Evidence of outcome reporting bias in randomised trials. De Videnskabsetiske komitéer for Københavns og Frederiksbergs kommuner, 11 dec 2003.
145. IS Experiences within the Cochrane Collaboration. WHO workshop on grading of evidence, København, 16 Dec 2003.
146. IS Evidensbaseret medicin. Sosial- og helsedirektoratet, Oslo, 15 jan 2004.
147. IS Why is the practice of evidence-based medicine more difficult than it seems? Læknadager 2004, Reykjavik, 23 Jan 2004.
148. IS Doctor, should I have a mammography? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
149. IS The management of hypertension, should we rely on the good old drugs? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.
150. IS Evidence-based microbiology. Dansk Selskab for Klinisk Mikrobiologi, uddeling af Wyeth-prisen for 2003, København, 27 jan 2004.
151. IS Mammografi-screening, contra. Foreningen af Yngre Gynækologer og Obstetrikere Forårsmøde, Odense, 18 marts 2004.
152. IS Evidensgrundlag. Institut for Rationel Farmakoterapi, møde om kriterier for rationelt valg af lægemidler, Kolding, 30 april 2004.
153. IS Hvad er vore behandlinger værd? Gentofte-Vangede Rotary Klub, 26 aug 2004.

154. IS Empirical evidence for selective reporting of outcomes in randomised trials. Den Centrale Videnskabetiske Komité, København, 27 aug 2004.
155. IS Risikovurdering og formidling omkring screening, og industrisponsoreret forskning. Det Ethiske Råd, København, 16 sept 2004.
156. IS Fortsat udbredelse af mammografiscreening. Nordjyllands amtsråd, Ålborg, 19 nov 2004.
157. IS Harry Boström föreläsningen: Cochrane-samarbetet och evidensbaserad medicin. Riksstämman, Svensk Internmedicinsk Förening, Göteborg 25 nov 2004.
158. IS Nutidens og fremtidens krav om evidens for det lægelige arbejde. Nordjyllands Lægekredsforenings 150 års jubilæum, Ålborg, 26 nov 2004.
159. IS Blinding. Expert Discussion Workshop. Institute of Public Health, Cambridge, 17 maj 2005.
160. Sponsorship, bias and methodology: Cochrane Reviews compared with industry-sponsored meta-analyses of the same drugs. 5th International congress on peer review and biomedical publication, Chicago, 17 Sept 2005.
161. Are relative risks and odds ratios in abstracts believable? 5th International congress on peer review and biomedical publication, Chicago, 18 Sept 2005.
162. IS Medical statistics in practice: Dr Jekyll and Mr Hyde. 10 year celebration, Centre for Statistics in Medicine, Oxford, 20 Sept 2005.
163. IS Introduction to key concepts and principles of evidence-based medicine. Moscow Medical Academy, 13 Oct 2005.
164. Constraints on academic freedom in industry-initiated clinical trials. XIII Cochrane Colloquium, Melbourne, 22-26 Oct 2005.
165. IS Should we believe in epidemiology? Scientific seminar, Royal Veterinary and Agricultural University, Copenhagen, 14 Nov 2005.
166. IS Evidence in health care. Health Administration, Copenhagen County, 28 April 2006.
167. IS Commercial interests versus common goods. Nordic Committee on Bioethics, Malmö, 16 Oct 2006.
168. Far too many excluded studies listed in Cochrane Reviews. XIV Cochrane Colloquium, Dublin, 23-26 Oct 2006.
169. IS Cochrane Library. Ministry of Health, Warszawa, 18 Dec 2006.
170. IS Editorial misconduct. Finnish Medical Association, Helsinki, 25 Jan 2007.
171. IS Evidence-based health care. Institute for Competence Development, Copenhagen, 27 Feb 2007.
172. IS Commercial interests. Institute of Technology, Copenhagen, 14 Mar 2007.
173. IS Screening. Danish Society for Pathology, Copenhagen, 23 Mar 2007.
174. IS Selective reporting. Dutch Cochrane Centre's 12.5-year anniversary, Amsterdam, 18 April 2007.
175. IS Evidence-based health care. Aalborg University Hospital, 26 Sept 2007.
176. IS Bias in drug trials. Eur Assoc Clin Pharmacol, Amsterdam, 29 Aug 2007.
177. IS Commercial influence on clinical research. University of Southern Denmark, 15 Nov 2007.
178. IS Evidence-based medicine. Clinical microbiologists, Copenhagen, 21 Nov 2007.
179. IS Evidence for prevention. National Board of Health, Nyborg, 26 Nov 2007.
180. IS Can we trust clinical research results? Medical Society of Copenhagen, 27 Nov 2007.
181. IS Tainted evidence: drug companies and the power of marketing. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
182. IS Research collaboration. Danish Society for Theory in Medicine, Panum, 21 Apr 2008.
183. IS Mammography screening. Dept of Obstetrics, Rigshospitalet, 15 May 2008.
184. IS The corruption of drug research. Swiss Soc Intern Med, Lausanne, 21 May 2008.
185. IS Credibility of clinical research. Central Ethics Committee, Copenhagen, 13 June 2008.
186. IS The burdens of screening. Euroscience Open Forum, Barcelona, 21 July 2008.
187. IS Unhealthy health care. Distinguished scholar lecture, University of Minneapolis, 9 Sept 2008.
188. IS Unhealthy health care. Visiting scientist, University of Dartmouth, 11 Sept 2008.
189. IS Off-label use of drugs. Danish Pharmaceutical Society, Copenhagen, 29 Oct 2008.
190. IS Bias in drug trials. Danish Society for Psychiatric Epidemiology, Copenhagen, 6 Nov 2008.
191. IS Screening for lung cancer. Symposium, Focus on Lung Cancer, Copenhagen, 17 Nov 2008.

192. IS Screening for lung cancer. Danish Society for Pulmonary Medicine, Kolding, 28 Nov 2008.
193. IS Commercial interests. Institute of Technology, Copenhagen, 17 Dec 2008.
194. IS Screening and ethics. Clinical Ethics Committee, Frederiksberg Hospital, 2 Apr 2009.
195. IS Reflexions on screening. Region Middle Jutland, 15 Apr 2009.
196. IS Is the university trustworthy? LIFE, The Bioscientific Faculty, 6 May 2009.
196. IS Mammography screening. Nordic Congress in General Medicine, Copenhagen, 15 May 2009.
197. IS Opening lecture, Evidence-Based Medicine. 8th Congress of European Federation of Internal Medicine, Istanbul, 27 May 2009.
198. IS Cancer screening. Heinrich-Heine University, Düsseldorf, 17 June 2009.
199. IS Overdiagnosis of breast cancer. Cancer Intervention and Surveillance Modelling Network (CISNET), Rotterdam, 24 June 2009.
200. IS Good quality of drug trials. GCP meeting, Gentofte Hospital, 21 Sept 2009.
201. IS Forskningspolitisk debat, cancer screening. Forskningens dag, Herlev Hospital, 28 Okt 2009.
202. IS Breast screening. Norwegian-Danish Seminar, Oslobåden, 2 Nov 2009.
203. IS Breast screening - the facts. Royal College of Obstetricians, London, 9 Nov 2009.
204. IS Er det dyreste det bedste? Region Sjælland, Sørup Heregård, 1 Dec 2009.
205. IS Randomisering i praksis. Trygfondens Forebyggelsescenter, 14 Jan 2010.
206. IS Mammographie-Screening. Berlin, German Cancer Society, 25 Feb 2010.
207. IS Klinisk relevans, hvad er det? Danish Society for Clinical Pharmacology, 2 Mar 2010.
208. IS Evidence: conflict of interest. Auckland, 22 Mar 2010.
209. IS Lægers interaktioner med medicinalindustrien. Region Nordjylland, 4 May 2010.
210. IS Fungal infections. Rigshospitalet, 12 May 2010.
211. IS Arguments for RCTs. Nordic Gastroenterology Congress, Copenhagen, 11 June 2010.
212. IS Ghostwriting is scientific misconduct. Polish Academy of Sciences, 8 Oct 2010.
213. IS Conflicts of interest. Danish University Antidepressant Group, Nyborg, 5 Nov 2010.
214. IS Bioethics: access to data and mammography screening. EU Parliament, Strassbourg, 24 Nov 2010.
215. IS Hvem har mest gavn af lægens medicinudskrivning? Patientforeningen Danmark, 18 Jan 2011.
216. IS Ethical aspects of public vs private research. Nordic Committee on Bioethics, Helsinki, 1 Nov 2011.
217. IS Strengthening and opening up EU's health research. EU Parliament, Brussels, 30 Nov 2011.
218. IS Medicinalindustrien. EU Parliament, Brussels, Social democrats, 1 Feb 2012.
219. IS Access to data from regulatory authorities. Paris, 19 April 2012.
220. IS European Drug Regulators' meeting. Why we need easy access to all data from all clinical trials and how to accomplish it. Copenhagen, 26 April 2012.
221. IS Why we need to open up health research by sharing our raw data. EU Parliament, Brussels, 6 June 2012.
222. IS Access to medical research data in the EU. HAI Europe, Amsterdam, 12 Oct 2012.
223. IS Rethinking clinical practice. Danish University Antidepressant Group, Nyborg, 9 Nov 2012.
224. IS Open access to all data is a moral obligation towards the patients. EU Parliament, Brussels, 13 Nov 2012.
225. IS Introductory statement. European Medicines Agency, London, 22 Nov 2012.
226. IS Time to stop mammography screening. Selling sickness, Washington DC, 21 Feb 2013.
227. IS Transparency saves lives. EU Parliament, Brussels, 10 Apr 2013.
228. IS Medical data transparency. Ombudsman meeting, EU Parliament, Brussels, 23 Apr 2013.
229. IS Overblik over børn med psykisk sygdom/diagnoser. Sundhedsudvalget, Folketinget, 27 May 2013.
230. IS Gavnige og skadelige virkninger ved medicinering af børn med psykisk sygdom. Sundhedsudvalget, Folketinget, 27 May 2013.
231. IS Mammografiscreening er skadelig og bør stoppes. Dagens Medicin, Folketinget, 31 May 2013.
232. IS What will we do about overdiagnosis? Dartmouth Institute for Health Policy & Clinical Practice, 12 Sept 2013.

233. IS Deadly medicines and organised crime. Johns Hopkins School of Public Health, Baltimore, 13 Sept 2013.
234. IS Deadly medicines and organised crime. Georgetown University, Washington DC, 16 Sept 2013.
235. IS Why drugs are the third leading cause of death. University College, London, 2 Oct 2013.
236. IS Early diagnosis. University College, London, 2 Oct 2013.
237. IS Psykiatri: medicinalindustriens paradis. Dispuk, Helsingør, 3 Oct 2013.
238. IS Working with evidence. Dansk Selskab for Obstetrik og Gynækologi, Roskilde, 7 Oct 2013.
239. IS 12 usandheder om depression til skade for patienterne. Psykovision, København, 7 Nov 2013.
240. IS Deadly medicines and organised crime. Harvard University, Safra Center for Ethics, 5 Dec 2013.
241. IS Deadly medicines and organised crime. McGill University, Montreal, 6 Dec 2013.
242. IS Deadly medicines and organised crime. Quebec University, Quebec, 9 Dec 2013.
241. IS Deadly medicines and organised crime. Ottawa Hospital, 10 Dec 2013.
243. IS Deadly medicines and organised crime. Women's College Hospital, Toronto, 11 Dec 2013.
244. IS Deadly medicines and organised crime. Toronto University, 12 Dec 2013.
- 245 IS Dødelig medicin og organiseret kriminalitet. Patientforeningen Danmark, Rigshospitalet, 14 Jan 2014.
- 246 IS Myter og facts om antidepressiva. Plastikkirurgisk afd., 16 Jan 2014.
- 247 IS Lægers samarbejde med industrien, Overlægeföreningen, Hvidovre Hospital, 23 Jan 2014.
- 248 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 25 Feb 2014.
- 249 IS Dødelig medicin og organiseret kriminalitet. Ølstykke Bibliotek, 27 Feb 2014.
- 250 IS Dødelig medicin og organiseret kriminalitet. JP Læserarrangement, 4 Mar 2014.
- 251 IS Psykofarmaka. Psykologisk Studenterforum, Århus Universitet, 4 Mar 2014.
- 252 IS Dødelig medicin og organiseret kriminalitet. Enhedslisten, Region Hovedstaden, 6 Mar 2014.
- 253 IS Psykofarmaka og andre lægemidler. Plan & Handling, Socialt-Lægeligt Seminar, Valby, 10 Mar 2014.
- 254 IS General health checks in adults. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 255 IS Why mammography screening should be stopped. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
- 256 IS Dødelig medicin og organiseret kriminalitet. Gentofte Bibliotek, 18 Mar 2014.
- 257 IS Why are prescription drugs the third leading cause of death? Panama City, 2 Apr 2014.
- 258 Health checks, what were the reactions? Nordic Cochrane Centre, 8 Apr 2014.
- 259 IS Set all data free. Young Investigators Network, Faculty Club, Panum, 10 Apr 2014.
- 260 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 22 Apr 2014.
- 261 IS Why the use of psychiatric drugs may be doing more harm than good. House of Lords, UK, 30 Apr 2014.
- 262 IS This is not a symptom. South London Gallery, 30 Apr 2014.
- 263 IS Hvorfor er lægemidler den 3. hyppigste dødsårsag? Studenterforeningen, København, 2 May 2014.
- 264 IS Good scientific practice. Institute for Public Health, Copenhagen, 7 May 2014.
- 265 IS Dødelig medicin og organiseret kriminalitet. Praktiserende læger, Hotel Hesselet, 9 May 2014.
- 266 IS Psykiatri. Sundhedspolitisk Netværk, Ingeniørforeningen, 12 May 2014.
- 267 IS Psykiatri på afveje. Psykovision, Bethesda, København, 14 May 2014.
- 268 IS Interessekonflikter i lægeverdenen. Panum Instituttet, 19 May 2014.
- 269 IS Lægers relation til medicinalindustrien. Roskilde Sygehus, 21 May 2014.
- 270 IS Psychiatric drugs: does the way we use them cause more harm than good? Distinguished seminars in neuroscience and pharmacology. Panum Institute, 28 May 2014.
- 271 IS Håndtering af kommercielle interesser. Københavns Universitet, 10 June 2014.
- 272 IS Psychiatric drugs: does the way we use them cause more harm than good? Amsterdam, 13 June 2014.
- 273 IS Psykiatri på afveje. Stemmerørnetværket, Christiansborg, 17 June 2014.
- 274 IS Academia and industry. Annual Nobel Laureate meeting, Lindau, 3 July 2014.
- 275 IS Overdiagnosis and overtreatment in psychiatry. Finnish Psychological Association, Helsinki, 1 Sept 2014.
- 276 IS Deadly medicines and organised crime. Helsinki University, 2 Sept 2014.

- 277 IS Medicamentos que matan y crimen organizado. Barcelona, Institut d'Estudis Catalans, 8 Sept 2014.
- 278 IS Medicamentos que matan y crimen organizado. Madrid, Organización de Consumidores y Usuarios (OCU), 9 Sept 2014.
- 279 IS Psykofarmaka-debat. Århus Universitet, 11 Sept 2014.
- 280 IS What are the true benefits and harms of our drugs? Jagiellonian University, Krakow, 7 Oct 2014.
- 281 IS Cochrane reviews and their importance for evidence-based medicine. Jagiellonian University, Krakow, 7 Oct 2014.
- 282 IS Deadly medicines and organised crime. Maynooth University, Dublin, 8 Oct 2014.
- 283 IS Deadly medicines and organised crime. Stillorgan Park Hotel, Dublin, 8 Oct 2014.
- 284 IS Danmark på lykkepiller. Herstedøster Forsamlingshus, 21 Oct 2014.
- 285 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Carlsberg, 23 Oct 2014.
- 286 IS Danskernes mentale sundhed. Folkeuniversitetet, Panum, 3 Nov 2014.
- 287 IS Kliniske forsøg. Pharmaschool, Copenhagen, 5 Nov 2014.
- 288 IS Dødelig medicin og organiseret kriminalitet. Lægeforeningen Syddanmark, Kolding, 5 Nov 2014.
- 289 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Århus, 5 Nov 2014.
- 290 IS Mammography screening: why it hasn't lived up to expectations. Santa Rosa, California, 8 Nov 2014.
- 291 IS Why very few patients benefit from the drugs they take and why many are killed by them. Santa Rosa, California, 9 Nov 2014.
- 292 IS Why very few patients benefit from the drugs they take and why many are killed by them. Stanford Medical School, 11 Nov 2014.
- 293 IS Why very few patients benefit from the drugs they take and why many are killed by them. University of British Columbia, Vancouver, 11 Nov 2014.
- 294 IS Mammography screening: why it hasn't lived up to expectations. University of British Columbia, Vancouver, 12 Nov 2014.
- 295 IS How to reduce big pharma's influence on guidelines. Kaiser Permanente, Los Angeles, 13 Nov 2014.
- 296 IS Transforming mad science, reimagining mental health care. International Society of Ethical Psychology and Psychiatry, Los Angeles, 15 Nov 2014.
- 297 IS Medisinering av psyken – mer skade enn gagn? Cinemateket, Oslo, 25 Nov 2014.
- 298 IS Global Health. Univ. of Copenhagen, 6 Jan 2015.
- 299 IS Depression. Young Psychiatrists, Rigshospitalet, 19 Jan 2015.
- 300 IS Psychiatry. Nurses, Silkeborg 20 Jan 2015.
- 301 IS Selective publication. Joanna Briggs Institute, Adelaide, 9 Feb 2015.
- 302 IS Drugs. Grand round. Royal Adelaide Hospital, Adelaide, 10 Feb 2015.
- 303 IS Psychiatry. Univ. of Adelaide, Adelaide, 10 Feb 2015.
- 304 IS Drug crimes. Alfred Hospital, Melbourne, 11 Feb 2015.
- 305 IS Psychiatry. State Library of Victoria, Melbourne, 11 Feb 2015.
- 306 IS Mammography screening. Alfred Hospital, Melbourne, 12 Feb 2015.
- 307 IS Drug crimes. Grand round. Royal Melbourne Hospital, Melbourne, 12 Feb 2015.
- 308 IS Antidepressants. Garvan Institute, Sydney, 12 Feb 2015.
- 309 IS Drug crimes. Concord Hospital Clinical School, Sydney, 13 Feb 2015.
- 310 IS Mammography screening. Dougherty Community Centre, Sydney, 13 Feb 2015.
- 311 IS Psychiatric drugs. University of Sydney Law School, Sydney, 14 Feb 2015.
- 312 IS Drug crimes. Grand round. Princess Alexandra Hospital, Brisbane, 16 Feb 2015.
- 313 IS Drug crimes. RACGP College House, Brisbane, 16 Feb 2015.
- 314 IS Drug crimes. Univ. of Queensland Medical School, Brisbane, 17 Feb 2015.
- 315 IS Psychiatry. Lady Cilento Children's Hospital, Brisbane, 18 Feb 2015.
- 316 IS Psychiatry. Adina Apartment Hotel, Brisbane, 18 Feb 2015.
- 317 IS Drug crimes. Grand round. Gold Coast University Hospital, 19 Feb 2015.
- 318 IS Lægemedler. Medicinsk Studenterforskning, Nyborg, 12 Mar 2015.

- 319 IS Depression. Rigshospitalet, 16 Apr 2015.
- 320 IS Psychiatric drugs. Lansing, Michigan, 17 Apr 2015.
- 321 IS Antidepressiva. Ålborg Sygehus, 21 Apr 2015.
- 322 IS Drugs. Danish National Board of Health, 27 Apr 2015.
- 323 IS The Maudsley Debate. London, 13 May 2015.
- 324 IS Drugs. Robert-Bosch-Stiftung, Berlin 22 May 2015.
- 325 IS Psychiatry. General Practitioners Annual Meeting, Bergen 27 May 2015.
- 326 IS Lægemedler. Læger fra Lolland, 29 May 2015.
- 327 IS Regulatory data. Int Soc Drug Bull, Pamplona, 29 June 2015.
- 328 IS Overdiagnosis and overtreatment. Int Soc Drug Bull, Pamplona, 30 June 2015.
- 329 IS Psykofarmaka. Dansk Psykologforening, København, 12 Sep 2015.
- 330 IS Antidepressants. Int Meeting, Copenhagen, 16 Sep 2015.
- 331 IS Forced treatment. Int Meeting, Copenhagen, 16 Sep 2015.
- 332 IS Antidepressants. Univ. of Roehampton, London, 18 Sept 2015.
- 333 IS Drugs. Katowice, 19 Sept 2015.
- 334 IS Mammography screening. Cochrane Colloquium, Wien, 3 Oct 2015.
- 335 IS Drugs. Oslo 20 years Anniversary Seminar, 19 Oct 2015.
- 336 IS Tvangsmedicinering. Litteraturhuset, Oslo, 19 Oct 2015.
- 337 IS Lægemedler. Guldborgsund Bibliotekerne, Nykøbing F, 21 Oct 2015.
- 338 IS Psykofarmaka. Benzorådgivningen, Middelfart, 23 Oct 2015.
- 339 IS Psykofarmaka. Enhedslisten, København, 23 Oct 2015.
- 340 IS Lægemedler. Norsk Studenterforening, Tromsø, 30 Oct 2015.
- 341 IS Psykofarmaka. Dansk Psykologforening, København, 7 Nov 2015.
- 342 IS Drugs. Medical Centre in Leiden, 11 Nov 2015.
- 342 IS Drugs. Arminius, Rotterdam, 12 Nov 2015.
- 343 IS Lægemedler. FOF Hvalsø, 23 Nov 2015.
- 344 IS Cancer screening. Gemeinschaftskrankenhaus Havehöhe, Berlin, 25 Nov 2015.
- 345 IS Psykofarmaka. Dansk Socialrådgiverforening, Fredericia, 30 Nov 2015.
- 346 IS Deadly medicines. Roma, Italy, 1 Dec 2015.
- 347 IS Deadly medicines. Univ. of Verona, 2 Dec 2015.
- 348 IS Deadly medicines. Gruppo Abele, Torino, 3 Dec 2015.
- 349 IS Deadly medicines. Alba, 3 Dec 2015.
- 350 IS Psykofarmaka. LAP, København, 18 Dec 2015.
- 351 IS Global Health. Univ. of Copenhagen, 6 Jan 2016.
- 352 IS Psykofarmaka. Hvidovre og Glostrup Psykiatri, 7 Jan 2016.
- 353 IS Psykofarmaka. Bedre Psykiatri, Odense, 14 Jan 2016.
- 354 IS Läkemedel. Stockholm läns landstings läkemedelskomité, 20 Jan 2016.
- 355 IS Psykofarmaka. Socialmedicinsk Enhed, Frederiksberg Hospital, 22 Jan 2016.
- 356 IS Vore overmedicinerede ældre. Assens Ældreråd, 26 Jan 2016.
- 357 IS Vore overmedicinerede ældre. School of Culture and Society, Karup, 11 Feb 2016.
- 358 IS Dødelig medicin og organiseret kriminalitet, LOF Slagelse, 29 Feb 2016.
- 359 IS Receptpligtig medicin – den tredjehyppigste dødsårsag, Tåstrup Bibliotek, 29 Feb 2016.
- 360 IS Antidepressants Do More Harm Than Good, Tampa, Florida, Adlerian Society, 4 March 2016.
- 361 IS Mammography screening, European Breast Cancer Meeting, Amsterdam, 9 March 2016.
- 362 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 15 March 2016.
- 363 IS Drugs: the Dutch Medicines vision. Dutch Parliament, 29 March 2016.
- 364 IS Medicinsk behandling af psykiske sygdomme. Danske Regioner, Aarhus, 6 April 2016.
- 365 IS Psykofarmaka gør langt større skade end gavn. Aarhus Universitet, Aarhus, 6 April 2016.

- 366 IS Fup og fakta om antidepressiv medicin. Folkeuniversitetet i Aalborg, 7 April 2016.
- 367 IS Dødelig psykiatri. Sind på Frederiksberg, 10 May 2016.
- 368 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 17 May 2016.
- 369 IS Without data sharing, there is no science, only marketing. Krakow University, 20 May 2016.
- 370 IS Den psykiatriske epidemi. National Neurokonference, Middelfart, 26 May 2016.
- 371 IS Dødelig biologisk psykiatri. Dansk Retspsykologisk Selskab, 30 May 2016.
- 372 IS Forced Psychiatric Treatment Must Be Abolished. Anchorage, 2 June 2016.
- 373 IS Prescription drugs are the third leading cause of death. Evidence Live, Oxford, 21 June 2016.
- 374 IS Mortality and drugs (top-3). 50th Anniversary of the Geneesmiddelenbulletin, Leiden, 30 June 2016.
- 375 IS What is wrong with research and treatment in psychiatry? 50th Anniversary, Leiden, 30 June 2016.
- 376 IS Hvorfor så få har gavn af psykofarmaka? Social- og Sundhedsskolen. Middelfart, 30 Aug 2016.
- 377 IS Varning för psykofarmaka! Stockholm, ABF-huset, 5 Sept 2016.
- 378 IS Deadly psychiatry. Spanish Association for Mental Health, Madrid, 19 Sept 2016.
- 379 IS Deadly psychiatry. Alibri Llibreria, Barcelona, 20 Sept 2016.
- 380 IS Varning för psykofarmaka! Bokmässan, Göteborg, 23 Sept 2016.
- 381 IS Why is it controversial to tell the truth about health care? HealthWatch Award, London, 20 Oct 2016.
- 382 IS Mammography screening. Cochrane Colloquium, Seoul, 25 Oct 2016.
- 383 IS Why so few patients benefit from the drugs they take. 21th WONCA, Rio de Janeiro, 3 Nov 2016.
- 384 IS Varning för psykofarmaka! Stockholm, ABF-huset, 22 Nov 2016.
- 385 IS Hvorfor er udtrapning af psykofarmaka så vigtigt? Høring i Folketinget, 13 Dec 2016.
- 386 IS Deadly psychiatry. De Balie, Amsterdam, 19 Dec 2016.
- 387 IS Myter, misforståelser og skader i psykiatrien. Pædagogisk Psykiatrisk Vejledning, Greve, 4 Jan 2017.
- 388 IS Psychiatric drugs. Sherbrooke, education for doctors, 20 Jan 2017.
- 389 IS Myten om den biologiske psykiatri. Christiansborg, 3 March 2017.
- 390 IS Prescription drugs are the third leading cause of death. University of Helsinki, 9 March 2017.
- 391 IS Forskning; med eller uden industri. Medicinsk Studenterforskning, Nyborg, 17 March 2017.
- 392 IS Psykofarmaka. Diplomuuddannelsen for socialarbejdere, Faxe Ladeplads, 23 March 2017.
- 392 IS Dödlig psykiatri och organiserad förnekelse. ISPS, Stockholm, 31 March 2017.
- 393 IS Vi kan leve uden antipsykotika. Stemmeværket, Odense Rådhus, 27 April 2017.
- 394 IS Psykofarmaka slår mange ihjel og forkrøbler langt flere. Slagelse Kommune, 3 May 2017.
- 395 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, København, 22 Aug 2017.
- 396 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, Vejle, 28 Aug 2017.
- 397 IS Overdiagnostik og overbehandling i psykiatrien. Bedre Psykiatri, Odense, 31 Aug 2017.
- 398 IS Myter om psykofarmaka? København, 26 Sept 2017.
- 399 IS Myter, misforståelser og skader i psykiatrien. Socialpædagoger, Kolding, 2 Oct 2017.
- 400 IS Den biologiske psykiatri bygger på en række misforståelser og myter. SIND, Aalborg, 10 Oct 2017.
- 401 IS International Institute for Psychiatric Drug Withdrawal. World Congress in Psychiatry, Berlin, 11 Oct.
- 402 IS Psychiatric drugs are the third leading cause of death. World Congress in Psychiatry, Berlin, 11 Oct.
- 403 IS Psykofarmaka. Neurologisk afd., Herlev Sygehus, 1 Oct.
- 404 IS How to survive in an over-medicated world. Columbus, Ohio, 11 Nov.
- 405 IS Harmful drugs you should know about. Columbus, Ohio, 12 Nov.
- 406 IS Afhængighed af og udtrapning af psykofarmaka. BBH, Klinisk Farmakologisk afd., 1 Dec.
- 407 IS Mental health in crisis. Sydney, 24 Feb 2018.
- 408 IS Mental health in crisis. Christchurch, 26 Feb 2018.
- 409 IS Mental health in crisis. Wellington, 27 Feb 2018.
- 410 IS Mental health in crisis. Hamilton, 28 Feb 2018.
- 411 IS Mental health in crisis. Auckland, 2 March 2018.
- 412 IS Psykofarmaka bør undgås, især til børn og unge. FADD, Slangerup, 7 March.

- 413 IS How to survive in an overtreated world. Public health course, Madrid, 10 March.
- 414 IS Why you should usually avoid cancer screening. Cambridge University, 5 April.
- 415 IS Depressionspiller gør mer skada än nytta. Stockholm, 13 April.
- 416 IS Complaint to the European Ombudsman and maladministration at EMA. Dublin 21 April via Skype.
- 417 IS Benefits and harms of depression pills. Copenhagen, 14 June.
- 418 IS Heroes of Science: Survival of a Whistleblower. Berlin, Max Planck Institute, 27 June.
- 419 IS Why the current usage of psychiatric drugs does far more harm than good. Berlin, Charité, 28 June.
- 420 IS Why systematic reviews of published drug trials lead to too much medicine. Helsinki, 17 Aug.
- 421 IS Overlevelse i en overmedicineret verden. Hillerød, 27 Sept.
- 422 IS Hvordan overlever man i en overmedicineret verden? Odense, Seniorhøjskolen, 3 Oct.
- 423 IS Why did we get a Cochrane Collaboration and what is it like today? Rigshospitalet, 12 Oct.
- 424 IS Chemical and physical interventions for house dust mites: why not? Rigshospitalet, 12 Oct.
- 425 IS Survival in an overtreated world: Look up the evidence yourself. Univ. of Groningen, 22 Oct.
- 426 IS Survival in an overtreated world: Look up the evidence yourself. Patiëntenfederatie, Utrecht, 23 Oct.
- 427 IS Survival in an overtreated world: Look up the evidence yourself. De Balie, Amsterdam, 23 Oct.
- 428 IS Survival in an overtreated world: Look up the evidence yourself. Ministry of Health, den Haag, 24 Oct.
- 429 IS Psykofarmaka gør større skade end gavn. Thisted, 31 Oct.
- 430 IS We need a revolution in psychiatry, the only medical specialty that does more harm than good. Berlin, Charité Hospital, 27 Nov.
- 431 IS Open science for better health-care for all. Bruxelles, EU Parliament, 29 Nov.
- 432 Death of a whistleblower: scientific censorship in action. Copenhagen, 9 Mar 2019.
- 433 IS Evidensbasert medisin. Trondheim, 20 Mar.
- 434 IS Myter, misforståelser og skader i psykiatrien. København, 13 May.
- 435 IS Death of a whistleblower and Cochrane's moral collapse. Santa Cruz, California, 9 June.
- 436 IS Mammography screening should be stopped. Barcelona, 15 June.
- 437 IS Death of a whistleblower and Cochrane's moral collapse. Madison, Wisconsin, 30 July.
- 438 IS Critical thinking about psychiatric drugs. Tromsø, 5 Sept.
- 439 IS Myter, misforståelser og skader i psykiatrien. Århus, 3 Oct.
- 440 IS The Cochrane affair and conflicts of interest. Paris, 11 Oct.
- 441 IS Hvordan overlever man i en overmedicineret verden? Esbjerg, 30 Oct.
- 442 IS Breast cancer screening: state of the art. Porto, 4 Nov.
- 443 IS General health checks: state of the art. Porto, 5 Nov.

Research mentorships

PhD and other degrees

- 1992 - 1994 Pia Therkildsen. Clinical research behaviour in Denmark. Main tutor. PhD not finished.
- 1993 - 1994 Flemming Ørnkov. Drug treatment. Main tutor. PhD not finished (emigration).
- 1996 - 2001 Asbjørn Hróbjartsson. The placebo concept. Main tutor. PhD defended 8 June 2001 at the University of Copenhagen.
- 2001 - 2004 Jan Peter Kösters (German doctor). Breast cancer screening. Main tutor. Doktors der Medizin defended 17 Sept 2004 at the University of Hamburg.
- 2000 - 2004 Lise Lotte Kjærgaard. The randomised clinical trial. PhD, changed to DrMedSci, defended 19 Aug 2005 at the University of Copenhagen.
- 2001 - 2005 Bodil Als-Nielsen. Hepatic encephalopathy. PhD defended 13 May 2005 at the University of Copenhagen.
- 2001 - 2005 Julie Pildal. Bias in systematic reviews. Main tutor. PhD defended 6 Sept 2005 at the University of Copenhagen.
- 2004 - 2013 Karsten Juhl Jørgensen. Screening for breast cancer. Main tutor. PhD changed to DrMedSci, defended 11 Jan 2013 at the University of Copenhagen.

2008 - 2009	Marija Barbateskovic. Impact factors and sponsorship. Main tutor. Candidate in science. Marks 12 (top on new scale)
2007 - 2010	Britta Tendal. Standardised mean difference in meta-analysis. Main tutor. PhD defended 26 Aug 2010 at the University of Copenhagen.
2007 - 2011	Anders W. Jørgensen. Robustness of results and conclusions in systematic reviews, trials and abstracts. Main tutor. PhD defended 16 Nov 2011 at the University of Copenhagen.
2007 - 2013	Margrethe Nielsen. Selective serotonin reuptake inhibitors. Main tutor. PhD defended 19 April 2013 at the University of Copenhagen.
2008 - 2013	Andreas Lundh. Conflicts of interest in biomedical publishing. Main tutor. PhD defended 25 April 2013 at the University of Copenhagen.
2010 - 2015	Lasse Teis Krogsbøll. Health checks. Main tutor. PhD defended.
2011 - 2015	Jepe Schroll. Coding of harms in randomised trials. Main tutor. PhD defended.
2011 - 2016	Emma Maund. Harms of Selective serotonin reuptake inhibitors. Main tutor. PhD defended.
2012 - 2016	Michelle Ogdén. Are randomised trials ethical? Main tutor. Stopped 2016.
2012 - 2018	Tarang Sharma. Suicidality and violence on SSRIs. Main tutor. PhD defended.
2016 - 2018	Kristine Rasmussen. Conflicts of interest. Main tutor. PhD defended.
2014 - 2018	Pia Danborg. Psychiatric animal studies. Main tutor.
2016 - 2018	Camilla Hansen. Conflicts of interest. Tutor.
2016 - 2019	Lars Jørgensen. HPV vaccines. Main tutor. PhD defended.
2016 -	Anders Sørensen. Psychiatry. Main tutor.
2016 -	Marie Bohlbro. Psychiatry. Main tutor.
2017 -	Kim Boesen. ADHD drugs. Main tutor.

Training students in research

2003	Troels Wienecke. OSVAL II, marks 9, ref. 153 in reference list above.
2003	Karsten Juhl Jørgensen. OSVAL II, marks 10, ref. 154 in reference list above.
2003	Mette Haahr, scholar student, ref. 157 in reference list above.
2003	Lasse Schmidt. OSVAL II, marks 10, ref. 169 in reference list above.
2003	Katrine Karmisholt, scholar student, ref. 172 og 173 in reference list above.
2004	Anne Due, OSVAL II, marks 10, ref. 189 in reference list above.
2004	Anders Jørgensen, OSVAL II, marks 10, ref. 190 in reference list above.
2005	Anders Klahn, OSVAL II, marks 10, ref. 198 in reference list above.
2006	Britta Tendal, scholar student, ref. 196 in reference list above.
2006	Katja Maric, scholar student, ref. 196 in reference list above.
2007	Matias Vested Madsen, OSVAL II, marks 9, ref. 215 in reference list above.
2007	Lasse Krogsbøll, OSVAL II, marks 10, ref. 221 in reference list above.
2007	Jørgen Jacob Eschen, OSVAL II, marks 11. No journal manuscript.
2009	Marija Barbateskovic, manuscript under preparation.
2009	Jepe Lerche Hansen, manuscript under revision.
2009	Jepe Schroll, manuscript under revision.
2010	Ann-Sofia Skou Thomsen, OSVAL II, marks 12
2010	Frida Samuelsson, OSVAL II, marks 12
2010	Christian Grønhøj Larsen, OSVAL II, marks 12
2010	Nino Ortner, OSVAL II, marks 12 (Hróbjartsson tutor)
2011	Kristine Rasmussen, special subject, marks 12
2011	Anine Skibsted, special subject, marks 12
2011	Jon Egelund Jensen, special subject, marks 10
2012	Julie Bindslev, special subject, marks 12
2012	Marie Damkjær Hansen, special subject, marks 10 (Hróbjartsson tutor)
2014	Mikkel Marquardsen, special subject, marks 12
2014	Andreas Bielefeldt, special subject, marks 12
2014	Jakob Jensen, special subject, marks 7
2014	Louise Jensen
2014	Nana Freund, no special subject
2014	Asmus Mortensen, special subject, marks 10
2015	Asger Paludan-Müller, bachelor subject, marks 12
2015	Kim Boesen, special subject, marks 12
2015	Anders Simonsen, special subject, marks 12

Expert, Medical Research Council's Statistical Aid Service

- 1991 Nick Rasmussen. Randomised trial, steroids in periarthrosis.
- 1991 Holger Sørensen. Randomised trial, haloperidol vs. oxazepam.
- 1991 Arne Gam. Meta-analysis, soft laser treatment.
- 1992 Søren Eiskjær. Meta-analysis, osteosynthesis methods in collum fracture.
- 1993 Arne Gam. Meta-analysis, ultrasound in musculoskeletal disorders.
- 1993 Hanne Olesen. Meta-analysis, oxygen deficit by anaerobic training.
- 1993 Kim Brøsen. Meta-analysis, genetic polymorphism and disease risk.
- 1993 Anita Rønn. Randomised trial, Maloprim vs. placebo in malaria.
- 1993 Mette Bitsch-Christensen. Immune therapy of children with allergy.
- 1993 Anne-Lise Christensen. Comparison of methods to diagnose pneumonia.
- 1993 Anne-Cathrine Halvorsen. Diagnostic methods in bleeding disorders.
- 1993 Michael Hansen. Biochemical markers for bone formation and resorption.
- 1994 Robin Bohlen. Treatment of fibromyalgia based on psychomotoric theory.
- 1994 Helle Rask. Randomised trial, volume expansion in surgery.
- 1995 Allan Ibsen Sørensen. Meta-analysis of endoscopic carpal tunnel dissection.
- 1996 Hanne Sørensen. Randomised trial, physiotherapy in back pain.
- 1997 Judith Kongsted. Healing in breast cancer.
- 1998 Poul Sindberg Eriksen. Risks after laser conisation of cervix uteri.
- 1998 Niels Petri. Orthodontic treatment of sleep apnoea.
- 2000 Hanne Sørensen. Training for back pain.
- 2002 Lars Højgaard-Rasmussen. Asthma and osteopathy.
- 2002 Mette Pedersen. Vocal cord nodules: non-surgery vs. surgery.
- 2004 Thorkil Christensen. Randomised trial, herbal cream for pain.

Scientific assignments

General

Previously

- 1988 - 1990 Secretary, Danish Society for Theory in Medicine.
- 1990 Examiner, prize report in medicine, University of Copenhagen.
- 1990 Member of WHO's expert group in Bukarest, evaluation of AIDS trial in children.
- 1991 Member of drug committee's quality group, Rigshospitalet.
- 1992 Member of Ministry of Education's group in Latvia, research evaluation.
- 1991 - 1998 Expert, Medical Research Council's Statistical Aid Service.
- 1992 - 1996 Chairman, Danish Society for Theory in Medicine.
- 1993 - 2005 Examiner, PhD applications, Rigshospitalet.
- 1993 - 2005 Member of Research Council, Rigshospitalet.
- 1993 - 2010 Member of Drug Committee, Rigshospitalet.
- 1995 Member of HS's working group on clinical databases.
- 1998 Examiner, PhD thesis (Rasmus Licht).
- 1998 Chairman and examiner, PhD thesis (Palle Valentiner-Brandt).
- 1998 Member of ad hoc committee, Office for Scientific Integrity.
- 1998 - 2005 Expert, Medical Research Council's Statistical Aid Service for East Denmark.
- 1999 Member of ad hoc committee, Office for Scientific Integrity.
- 2001 Member of ad hoc committee, Office for Scientific Integrity.
- 2008 Examiner of case of suspected scientific misconduct in Iran for The Oxford Health Alliance.
- 2008 Examiner of case of suspected scientific misconduct in Norway.
- 2011 Examiner, PhD thesis (Bendt Johansen), University of Southern Denmark
- 2013 Chairman, assessment of candidates for a professorship, University of Copenhagen
- 2014 Chairman and examiner, PhD thesis (Robert Eriksson), University of Copenhagen
- 2015 Chairman and examiner, PhD thesis (Bruno Heleno), University of Copenhagen

Currently

- 1993 - Member CONSORT (Consolidated Standards of Reporting Trials), see www.consort-statement.org.
- 2004 - Member of STROBE (Developing Standards of Reporting for Observational Studies in Epidemiology), see www.strobe-statement.org.
- 2005 - Member of PRISMA (Quality of reporting of meta-analyses), see <http://www.prisma-statement.org/>.
- 2005 - Member of SPIRIT (Standard Protocol Items for Randomised Trials), see www.spirit-statement.org/.

Editorial work

- 1992 - 1998 Editor, Bibliotek for Læger.
- 1995 - 2002 Member of Editorial Board, British Medical Journal.
- 1995 - Member of Editorial Advisory Board, Scandinavian Journal of Rheumatology.
- 1995 - Member of Editorial Advisory Board, The Cochrane Collaboration.
- 1997 - 2014 Editor, Cochrane Methodology Review Group
- 1997 - Member of Advisory Board, Clinical Evidence, BMJ Publishing.
- 2000 - Editorial advisor, BioMedCentral (supports PubMedCentral, USA).
- 2000 - 2010 Member of Scientific Board, Ugeskrift for Læger
- 2004 - Member of Editorial Board, BioMedCentral Medical Research Methodology
- 2004 - Member of BMJ Knowledge Advisory Board
- 2007 - Academic editor, PLoS Medicine

Performed peer reviews for:

- Acta Neuropsychiatrica
- Annals of Internal Medicine
- BioMed Central Medical Research Methodology
- BioMed Central Family Practice
- BioMed Central Infectious Diseases
- Bibliotek for Læger
- BMJ
- BMJ Open
- Breast Cancer Research and Treatment
- Canadian Medical Association Journal
- Cancers
- Clinical Evidence
- Clinical Trials
- Clinical Trials and Meta-analysis
- Cochrane Airways Group
- Cochrane Anaesthesia Group
- Cochrane Gynaecological Cancer Group
- Cochrane Hepato-Biliary Group
- Cochrane Infectious Diseases Group
- Cochrane Musculoskeletal Group
- Cochrane Musculoskeletal Injuries Group
- Cochrane Oral Health Group
- Controlled Clinical Trials
- Danish Medical Bulletin
- European Journal of Neurology
- Hong Kong Government Research Council
- International Journal of Cancer
- International Journal of Epidemiology
- International Journal of Technology Assessment in Health Care
- JAMA
- Journal of Clinical Epidemiology
- Journal of Medical Ethics
- Lancet
- La revue Précrire
- Medical Journal of Australia

Medical Research Council, UK
 Medicine, Philosophy and Health Care
 Nature Reviews Nephrology
 New England Journal of Medicine
 PLoS Medicine
 Politik
 Pharmacogenetics
 PharmacoEconomics
 Radiotherapy and Oncology
 Scandinavian Journal of Gastroenterology
 Scandinavian Journal of Medicine and Science in Sports
 Scandinavian Journal of Rheumatology
 Scandinavian Journal of Social Medicine
 Science
 Statens beredning för medicinsk utvärdering
 Statistics in Medicine
 Tobacco Control
 Ugeskrift for Læger
 Vetenskapsrådet, Sverige
 Women's Health

Chairman at congresses and meetings

1. Seminar on Bias and Controversies in Clinical Research. Rigshospitalet, 28 Feb 1992.
2. Pharmacotherapy I - methodological aspects. 25th Scand Congr Rheumatol, Lillehammer, 2 June 1994.
3. Reviews of data on continuous scales. Workshop, 2nd Cochrane Colloq, Hamilton, Canada, 1 Oct 1994.
4. Reviews and Syntheses. 11th Meeting, International Society of Technology Assessment in Health Care, Stockholm, 6 June 1995.
5. Cochrane Hepato-biliary Review Group Meeting. European Association for the Study of the Liver, København, 19 Aug 1995.
6. Cochrane Tuberculosis Review Group Meeting. International Union against Tuberculosis and Lung Disease, Paris, 9 Sept 1995.
7. Scientific presentations. 3rd Annual Cochrane Colloquium, Oslo, 4-8 Oct 1995.
8. Cochrane Depression/Neurosis Review Group Meeting. 3rd Annual Cochrane Colloq, Oslo, 8 Oct 1995.
9. Cochrane Placebo Methods Working Group Meeting. 4th Annual Cochrane Colloq, Adelaide, 21 Oct 1996.
10. Cochrane Colorectal Cancer Group Pre-exploratory Meeting. Cochrane Cancer Network Meeting, Bruxelles, 1 Feb 1997.
11. Cochrane Colorectal Cancer Group Exploratory Meeting. København, 12-13 Sept 1997.
12. 50 years of clinical trials: past, present and future. BMA/BMJ, London, 29-30 Oct 1998. Conference chair and chair of session: Quality and relevance of randomised controlled trials.
13. Evidence based medicine: How do we implement research results effectively? Annual meeting for the Nordic Cochrane Centre and Network, Rigshospitalet, 28 Jan 1999.
14. Exploratory meeting for the Cochrane Anaesthesia Group. 7th Annual Meeting of the European Society of Anaesthesiologists, Amsterdam, 29-30 May 1999.
15. Medical Editors. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 8-10 Apr 2002.
16. Scientific presentations. 15th Annual Cochrane Colloquium, São Paulo, 23-27 Oct 2007.
17. Influenza symposium. Rigshospitalet, 23 Sept 2008.
18. Scientific presentations. 16th Annual Cochrane Colloquium, Freiburg, 3-7 Oct 2008.
19. International Cochrane Symposium: EBM and Cochrane reviews. Rigshospitalet, 22 April 2009.
20. Investigating bias. 19th Cochrane Colloquium, Madrid, 21 Oct 2011.
21. Nordic Cochrane Centre's 25th Anniversary Research Symposium. Rigshospitalet, 12 Oct 2018.
22. Institute for Scientific Freedom, inaugural symposium. Copenhagen, 9 March 2019.

Advisory Board member at international congresses

- 2nd Cochrane Colloquium, Hamilton, Ontario, 1-4 Oct 1994.
- 3rd Cochrane Colloquium, Oslo, 4-8 Oct 1995.
- 4th Cochrane Colloquium, Adelaide, Australia, 20-24 Oct 1996.
- 7th Cochrane Colloquium, Rome, Italien, 5-9 Oct 1999.
- 8th Cochrane Colloquium, Cape Town, Sydafrika, 25-29 Oct 2000.
- 9th Cochrane Colloquium, Lyon, 9-13 Oct 2001.
- 11th Cochrane Colloquium, Barcelona, 26-31 Oct 2003.
- 12th Cochrane Colloquium, Ottawa, 2-6 Oct 2004.
- 5th Congress on Peer Review and Biomedical Publication, Chicago, 15-17 Sept 2005.
- 15th Cochrane Colloquium, São Paulo, 23-27 Oct, 2007, Scientific Program Committee.
- 6th Congress on Peer Review and Biomedical Publication, Vancouver, 10-12 Sept 2009.
- 7th Congress on Peer Review and Biomedical Publication, Chicago, 8-10 Sept 2013.
- Psychiatric drugs do more harm than good. Copenhagen, 16 Sept 2015.
- 8th Congress on Peer Review and Biomedical Publication, Chicago, 10-12 Sept 2017.

Expert witness in court cases

- 2014 Danish High Court, double homicide attempt on methylphenidate.
- 2014 Norwegian High Court, forced treatment with olanzapine.
- 2015 Norwegian High Court, Patient Harms Council, oseltamivir for influenza.
- 2016 Dutch High Court, double homicide case on paroxetine.
- 2016 Alaska High Court, forced retention and medication of a psychiatric patient.
- 2019 New York, effects of the DTP vaccine on mortality.
- 2019 Montreal, harms caused by psychiatric drugst.
- 2019 Los Angeles, harms of the HPV vaccine.

Management experience

- 1977 - 1983 Founder and head, medical department, Astra-Syntex.
- 1987 - 1995 Founder and head, Nordic coordination office for AIDS trials, Rigshospitalet.
- 1993 Co-founder of the Cochrane Collaboration
- 1993 - 2019 Founder and head, The Nordic Cochrane Centre (39 people employed in 2014, incl. those in Copenhagen Trial Unit).
- 1993 - 1996 Member of the Steering Group, the Cochrane Collaboration.
- 1996 - 2001 Founder and head, Cochrane Placebo Methods Group.
- 2002 SHL leadership course.
- 2018 - 2019 Member of the Cochrane Governing Board.